



CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.
Manufacturer of Condoms

Dated: August 28, 2026

To,
Corporate Service Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East),
Mumbai – 400051

Symbol: ANONDITA ISIN: INE0VTV01012

Subject: Proposed Rights Issue of the Fully Paid-up Equity Shares of Anondita Medicare Limited (“the Company”).

Dear Sir/Madam,

This is in continuation to our earlier announcements dated August 27, 2026, wherein the Company has proposed a Rights Issue of 9,58,000 fully paid-up Equity Shares of the Face Value of ₹10/- each for an aggregate amount not exceeding ₹91,01,00,000/- (Rupees Ninety-One Crore One Lakh Only) on rights basis to the eligible shareholders of the Company in the ratio of 97 (Ninety-Seven) Rights Equity Shares for every 1,831 (One Thousand Eight Hundred Thirty-One) fully paid-up Equity Shares held by eligible shareholders as on the Record Date, i.e., Wednesday, September 02, 2026.

Further, the Board of Directors of the Company has approved the Letter of Offer on August 27, 2026.

In this regard, please find enclosed the soft copy of the Letter of Offer dated August 27, 2026, for the Rights Issue of Anondita Medicare Limited. The Company is also submitting this Letter of Offer with the Securities and Exchange Board of India (“SEBI”) for its information in compliance with the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and SEBI Circular bearing no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2025/31 dated March 11, 2025.

The above information is also available on the Company's website, i.e., www.anonditamedicare.com
You are requested to kindly take the same on records.

Thanking You,
Sincerely,

For **ANONDITA MEDICARE LIMITED**

(BHAWNA BISHT)
Company Secretary & Compliance Officer
Membership No.: A70843



UNIT



OFFICE



DIPPING AREA



TESTING AREA

Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com | accounts@anonditahealthcare.com
Website: www.anonditamedicare.com



Please scan the QR Code to view the LOF

Letter of Offer
Dated August 27, 2026
For eligible equity shareholders only

Anondita Medicare Limited

Our Company was originally incorporated as a public limited company under the name "Anondita Medicare Limited" under the provisions of the Companies Act, 2013, vide certificate of incorporation dated March 12, 2024, issued by the Registrar of Companies, Central Registration Centre, bearing Corporate Identification Number L22193DL2024PLC428183. Prior to incorporation, the business of our Company was carried on by our Promoter, Mr. Anupam Ghosh, as a sole proprietorship under the name "M/s Anondita Healthcare", the entire business of which, including all assets and liabilities, was transferred to our Company pursuant to a Business Transfer Agreement dated April 01, 2024. For details of changes in the name and registered office of our Company, see "General Information" on page 1.

Registered Office: Flat No. 704, Narmada Block, N6, Sector-D, Pocket-6, Vasant Kunj, New Delhi - 110070, India
Corporate Office: D-001, Sector 80, Noida, Gautam Buddha Nagar, Noida, Uttar Pradesh-201301
Telephone: 0120-4520300
Contact Person: Ms. Bhawna Bisht, Company Secretary and Compliance Officer
E-mail: info@anonditamedicare.com,
Website: www.anonditamedicare.com,
Corporate Identity Number: L22193DL2024PLC428183

PROMOTER OF OUR COMPANY: MR. ANUPAM GHOSH, MRS. SONIA GHOSH AND MR. RESHANT GHOSH			
FOR PRIVATE CIRCULATION TO ELIGIBLE EQUITY SHAREHOLDERS OF ANONDITA MEDICARE LIMITED (THE "COMPANY" OR THE "ISSUER") ONLY			
ISSUE OF UP TO 9,58,000 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹10 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹950/- PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 940/- PER RIGHTS EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹9,101.00 LAKHS* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 97 RIGHTS EQUITY SHARE FOR EVERY 1831 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON WEDNESDAY, SEPTEMBER 02, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, PLEASE SEE "TERMS OF THE ISSUE" BEGINNING ON PAGE 67. <i>*Assuming full subscription. Subject to finalization of Basis of Allotment.</i>			
WILFUL DEFAULTER OR FRAUDULENT BORROWER CONFIRMATIONS			
Neither our Company nor our Promoters or any of our Directors have been or are identified as Wilful Defaulters or Fraudulent Borrowers by the Reserve Bank of India ("RBI") or any other Government Authority.			
GENERAL RISKS			
Investment in equity and equity-related securities involves a degree of risk, and investors should not invest any funds in this offer unless they can afford to take the risk with such investment. Investors are advised to read the risk factors carefully before taking an investment decision in this offering. For taking an investment decision, investors shall rely on their own examination of our Company and the Issue, including the risks involved. The securities have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of this document. Specific attention of investors is invited to the section of "Risk Factors" beginning on page 17.			
COMPANY'S ABSOLUTE RESPONSIBILITY			
Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Letter of Offer contains all information with regard to the Company and the Issue, which is material in the context of the Issue, and that the information contained in this Letter of Offer is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held, and that there are no other facts, the omission of which makes this Letter of Offer as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect.			
LISTING			
The existing Equity Shares of our Company are listed on the Emerge Platform of the National Stock Exchange of India Limited ("NSE SME"). Our Company has received "in-principle" approval from NSE for the listing of the Rights Equity Shares, vide its letter dated August 25, 2026. Further, the Company shall make necessary applications to NSE to obtain trading approvals for the Rights Entitlements, as required under the SEBI ICDR Master Circular (as defined hereinafter). For the purposes of the Issue, the Designated Stock Exchange is NSE.			
REGISTRAR TO THE ISSUE			
 Skyline Financial Services Private Limited CIN: U74899DL1995PTC071324 D-153A, Ist Floor, Okhla Industrial Area, Phase – I, New Delhi - 110020 Tel: 011-40450193-197 E-mail: ipo@skylinerta.com Investor Grievance E-mail: grievances@skylinerta.com Website: www.skylinerta.com Contact Person: Mr. Anuj Rana SEBI Registration No.: INR000003241			
ISSUE PROGRAMME			
LAST DATE FOR CREDIT OF RIGHTS ENTITLEMENT	DATE OF OPENING THE ISSUE	LAST DATE FOR ON MARKET RENUNCIATION OF RIGHTS ENTITLEMENTS*	DATE OF CLOSING OF THE ISSUE**
Friday, September 04, 2026	Wednesday, September 09, 2026	Friday, September 11, 2026	Tuesday, September 22, 2026
DATE OF FINALISATION OF BASIS OF ALLOTMENT (ON OR ABOUT)	DATE OF ALLOTMENT (ON OR ABOUT)	DATE OF CREDIT OF RIGHTS EQUITY SHARES (ON OR ABOUT)	DATE OF LISTING (ON OR ABOUT)
Wednesday, September 23, 2026	Wednesday, September 23, 2026	Thursday, September 24, 2026	Friday, September 25, 2026

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat accounts of the Renouncees on or prior to the Issue Closing Date.

** Our Board or the Fund-Raising Committee will have the right to extend the Issue Period as it may determine from time to time but not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

(This page has intentionally been left blank)

TABLE OF CONTENTS

SECTION I - GENERAL	01
DEFINITIONS AND ABBREVIATIONS	01
NOTICE TO INVESTORS	09
PRESENTATION OF FINANCIAL INFORMATION AND OTHER INFORMATION	11
FORWARD LOOKING STATEMENTS	13
SUMMARY OF THE LETTER OF OFFER	14
SECTION II - RISK FACTORS	17
SECTION III - INTRODUCTION	33
THE ISSUE	33
GENERAL INFORMATION	35
CAPITAL STRUCTURE	38
OBJECTS OF THE ISSUE	40
STATEMENT OF POSSIBLE SPECIAL TAX BENEFITS	52
SECTION IV - OUR MANAGEMENT	56
SECTION V - FINANCIAL INFORMATION	58
FINANCIAL STATEMENTS	58
FINANCIAL INFORMATION	59
DETAILED RATIONALE FOR THE ISSUE PRICE	59
SECTION VI - REGULATORY APPROVALS AND STATUTORY DISCLOSURES	61
GOVERNMENT AND OTHER APPROVALS	61
REGULATORY AND STATUTORY DISCLOSURES	62
SECTION VII - ISSUE INFORMATION	67
TERMS OF THE ISSUE	67
RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES	91
RESTRICTIONS ON PURCHASES AND REALES	92
SECTION VIII - OTHER INFORMATION	95
MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION	95
DECLARATION	96

SECTION I: GENERAL

DEFINITIONS AND ABBREVIATIONS

This Letter of Offer uses the definitions and abbreviations set forth below, which you should consider when reading the information contained herein. The following list of certain capitalised terms used in this Letter of Offer is intended for the convenience of the reader/prospective investor only and is not exhaustive.

Unless the context otherwise indicates or implies, the following terms shall have the meanings provided below in this Letter of Offer, and references to any statute or regulations or rules or policies or guidelines will include any amendments or modifications or re-enactments thereto, from time to time.

GENERAL TERMS

TERM/ABBREVIATION	DESCRIPTION
“Anondita Medicare Limited”, “AML”, “Anondita”, “The Company”, “Our Company”, or “Issuer” or “Issuer Company”	Unless the context otherwise indicates or implies, Anondita Medicare Limited, a public limited company incorporated under the provisions of the Companies Act, 2013 and having its Registered Office situated at Flat No. 704, Narmada Block, N6, Sector-D, Pocket-6, Vasant Kunj, New Delhi - 110070, India.
“We”, “Our”, “Us”, or “our Group”	Unless the context otherwise indicates or implies or unless otherwise specified, refers to our Company along with our Subsidiary, as applicable, on a consolidated basis.
“you”, “your”, or “yours”	Prospective Investor in this Issue.

COMPANY RELATED TERMS

TERM/ABBREVIATION	DESCRIPTION
“Articles of Association” or “Articles”	Articles of association of our Company, as amended from time to time.
Associate Companies	A body corporate in which our Company has a significant influence, but which is not a subsidiary of our Company, and includes a joint venture company.
Audit Committee	Audit Committee of our Board, constituted in accordance with Section 177 of the Companies Act, 2013 and rules made thereunder.
Audited Consolidated Financial Statements	The audited consolidated financial statements of our Company and its Subsidiary as at and for the year(s) ended March 31, 2026, comprising the consolidated balance sheet, the consolidated statement of profit and loss (including other comprehensive income), the consolidated statement of changes in equity and the consolidated statement of cash flows for the year(s) then ended, together with a summary of material accounting policies and other explanatory information, prepared in accordance with Indian GAAP.
Audited Standalone Financial Statements	The audited standalone financial statements of our Company as at and for the year(s) ended March 31, 2026, comprising the standalone balance sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone statement of cash flows for the year(s) then ended, together with a summary of material accounting policies and other explanatory information, prepared in accordance with Indian GAAP.
Auditor	The auditor of our Company, being M/s Jain Chopra & Company, Chartered Accountants, having firm registration number 002198N
“Board of Directors” or “Board” or “our Board”	The board of directors of our Company, or a duly constituted committee thereof. For details, see “Our Management” on page 56.
Central Registration Centre or “CRC”	An initiative of the Ministry of Corporate Affairs in Government Process Re-engineering, with the specific objective of providing speedy incorporation-related services in line with global best practices.
“Chief Financial Officer” or “CFO”	The Chief Financial Officer of our Company, Mrs. Sunita Naithani.
Company Secretary and Compliance Officer	The Company Secretary and Compliance Officer of our Company, Ms. Bhawna Bisht. For details, see “Our Management” on page 57.
Corporate Office	The corporate office of our Company situated at D-001, Sector 80, Gautam Budh Nagar, Noida, Uttar Pradesh 201301.
Directors	The directors on our Board, as may be appointed from time to time. For details, see “Our Management” on page 57.

Equity Shares	Equity shares of our Company of face value of ₹10/- each, unless otherwise specified in the context thereof.
Equity Shareholders	Persons holding Equity Shares of our Company.
Executive Director(s)	The Executive Directors of our Company, appointed as per the Companies Act, 2013 and the SEBI LODR Regulations. For details, see “Our Management” on page 57.
Group Companies	In terms of the SEBI ICDR Regulations, companies (other than our Promoters and Subsidiary) with which there are related party transactions, as disclosed in our financial statements in accordance with the applicable accounting standards, and any other companies considered material by our Board in accordance with the Materiality Policy.
Independent Director(s)	The non-executive, independent Directors of our Company, appointed as per the Companies Act, 2013 and the SEBI LODR Regulations. For details, see “Our Management” on page 57.
ISIN	International Securities Identification Number of the Equity Shares of our Company, being INE0VTV01012.
Key Managerial Personnel	Key managerial personnel of our Company determined in accordance with Regulation 2(1)(bb) of the SEBI ICDR Regulations, as disclosed in “Our Management” on page 57.
Managing Director	Managing Director of our Company, being Mr. Anupam Ghosh.
Materiality Policy	The policy adopted by our Board for identification of group companies, material outstanding litigation and outstanding dues to material creditors, in accordance with the disclosure requirements under the SEBI ICDR Regulations.
“Memorandum of Association” or “Memorandum”	Memorandum of association of our Company, as amended from time to time.
“Nomination and Remuneration Committee”	Nomination and Remuneration Committee of our Board, constituted in accordance with Section 178 of the Companies Act, 2013 and rules made thereunder.
Non-Executive Director(s)	The non-executive Directors of our Company, appointed as per the Companies Act, 2013 and the SEBI LODR Regulations.
Non-Residents	A person resident outside India, as defined under FEMA.
“NRIs” or “Non-Resident Indians”	A person resident outside India, as defined under FEMA, and who is a citizen of India or a Person of Indian Origin under the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, as amended from time to time.
Peer Review Auditor	The Independent auditor of our Company holding a valid peer review certificate no.020188, being M/s TASH & Associates, Chartered Accountants (FRN: 017326N).
Person or Persons	Any individual, sole proprietorship, unincorporated association, unincorporated organisation, body corporate, corporation, company, partnership, limited liability company, joint venture, trust or any other entity or organisation validly constituted and/or incorporated in the jurisdiction in which it exists and operates, as the context requires.
Promoters / Our Promoters / Promoters of the Company	The promoters of our Company, being Mr. Anupam Ghosh, Mrs. Sonia Ghosh, Mr. Reshant Ghosh.
Promoter Group	Unless the context requires otherwise, the promoter group of our Company as determined in accordance with Regulation 2(1)(pp) of the SEBI ICDR Regulations.
Registered Office	Flat No. 704, Narmada Block, N6, Sector-D, Pocket-6, Vasant Kunj, New Delhi - 110070, India.
Senior Management	Senior management personnel of our Company determined in accordance with Regulation 2(1)(bbbb) of the SEBI ICDR Regulations.
Stakeholders Relationship Committee	Stakeholders Relationship Committee of our Board, constituted in accordance with Section 178 of the Companies Act, 2013 and rules made thereunder.
Statutory Auditor	The statutory auditors of our Company, being M/s Jain Chopra & Company, Chartered Accountants, having firm registration number 002198N.
Subsidiary	As on the date of this Letter of Offer, our Company has one subsidiary, namely Anondita Healthcare and Rubber Products India Limited.

ISSUE RELATED TERMS

TERM/ABBREVIATION	DESCRIPTION
Additional Rights Equity Shares	The Rights Equity Shares applied for or allotted under this Issue in addition to the Rights Entitlement.
“Allotment” or “Allot” or “Allotted”	Allotment of Rights Equity Shares pursuant to the Issue.

Allotment Account(s)	The account(s) opened with the Banker(s) to the Issue, into which the Application Money, with respect to successful Applicants, will be transferred on the Transfer Date in accordance with Section 40(3) of the Companies Act, 2013.
Allotment Account Bank(s)	Bank(s) which are clearing members and registered with SEBI as bankers to an issue and with whom the Allotment Accounts will be opened, in this case being Axis Bank Ltd.
Allotment Advice	The note or advice or intimation of Allotment sent to each successful Applicant who has been or is to be Allotted the Rights Equity Shares pursuant to the Issue, after approval of the Basis of Allotment by the Designated Stock Exchange.
Allotment Date	Date on which the Allotment is made pursuant to the Issue.
Allottee(s)	Person(s) to whom the Rights Equity Shares are Allotted pursuant to the Issue.
“Applicant(s)” or “Investor(s)”	Eligible Equity Shareholder(s) and/or Renouncee(s) who are entitled to make an application for the Rights Equity Shares pursuant to the Issue in terms of this Letter of Offer.
Application	Application made through submission of the Application Form or plain paper application to the Designated Branch(es) of the SCSBs or online/electronic application through the website of the SCSBs (if made available by such SCSBs) under the ASBA process, to subscribe to the Rights Equity Shares at the Issue Price.
Application Form	Unless the context otherwise requires, an application form (including online application form available for submission of application through the website of the SCSBs, if made available by such SCSBs, under the ASBA process) used by an Applicant to make an application for the Allotment of Rights Equity Shares in the Issue.
Application Money	Aggregate amount payable in respect of the Rights Equity Shares applied for in the Issue at the Issue Price.
“Application Supported by Blocked Amount” or “ASBA”	Application (whether physical or electronic) used by Applicant(s) to make an application authorising the SCSB to block the Application Money in a specified bank account maintained with the SCSB.
ASBA Account	An account maintained with SCSBs and specified in the Application Form or plain paper Application, as the case may be, by the Applicant for blocking the amount mentioned in the Application Form or in the plain paper Application.
ASBA Circulars	Collectively, SEBI circular bearing reference number SEBI/CFD/DIL/ASBA/1/2009/30/12 dated December 30, 2009, SEBI circular bearing reference number CIR/CFD/DIL/1/2011 dated April 29, 2011, the SEBI ICDR Master Circular (to the extent it pertains to the rights issue process) and any other circular issued by SEBI in this regard, including any subsequent circulars or notifications issued by SEBI.
Banker to the Issue	Axis Bank Ltd.
Banker to the Issue Agreement	Agreement dated August 27, 2026, entered into by and among our Company, the Registrar to the Issue, and the Banker to the Issue for, among other things, collection of the Application Money from Applicants/Investors, transfer of funds to the Allotment Account, and refund of the whole or part of the application amounts, on the terms and conditions thereof.
Basis of Allotment	The basis on which the Rights Equity Shares will be Allotted to successful Applicants, in consultation with the Designated Stock Exchange, as described in “Terms of the Issue” beginning on page 85.
“Controlling Branches” or “Controlling Branches of the SCSBs”	Such branches of the SCSBs which coordinate with the Registrar to the Issue and the Stock Exchange, a list of which is available on SEBI’s website, updated from time to time, or at such other website(s) as may be prescribed by SEBI from time to time.
Demographic Details	Details of Investors, including the Investor’s address, PAN, DP ID, Client ID, bank account details and occupation, where applicable.
Depository(ies)	NSDL and CDSL, or any other depository registered with SEBI under the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, as amended, read with the Depositories Act, 1996.
Designated Branch(es)	Such branches of the SCSBs which shall collect the Applications used by the ASBA Investors, a list of which is available on the website of SEBI and/or such other website(s) as may be prescribed by SEBI from time to time.
Designated Stock Exchange	National Stock Exchange of India Limited (NSE).
“Draft Letter of Offer” or “DLOF”	Draft Letter of Offer dated August 01, 2026, filed with the Stock Exchange.

Eligible Equity Shareholder(s)	Equity Shareholders as on the Record Date. Please note that only those Equity Shareholders who have provided an Indian address to our Company are eligible to participate in the Issue. For further details, see “Notice to Investors” and “Restrictions on Purchases and Resales” beginning on pages 09 and 92, respectively.
“Equity Shareholder(s)” or “Shareholders”	Holder(s) of the Equity Shares of our Company.
Fraudulent Borrower	Fraudulent Borrower(s) as defined under Regulation 2(1)(III) of the SEBI ICDR Regulations.
Gross Proceeds	The gross proceeds raised through the Issue.
Issue	This issue of up to 9,58,000* Rights Equity Shares of the face value of ₹10/- each for cash at a price of ₹950/- per Rights Equity Share (including a premium of ₹940/- per Rights Equity Share) aggregating up to ₹9,101.00 lakhs on a rights basis to the Eligible Equity Shareholders of our Company in the ratio of 97 Rights Equity Share for every 1831 Equity Shares held by the Eligible Equity Shareholders on the Record Date. *Assuming full subscription in the Issue. Subject to finalisation of the Basis of Allotment.
Issue Closing Date	Tuesday, September 22, 2026
Issue Materials	Collectively, this Letter of Offer, Draft Letter of Offer, the Application Form, the Rights Entitlement Letter and any other material relating to the Issue.
Issue Opening Date	Wednesday, September 09, 2026
Issue Period	The period between the Issue Opening Date and the Issue Closing Date, inclusive of both days, during which Applicants/Investors can submit their applications, in accordance with the SEBI ICDR Regulations.
Issue Price	₹ 950/- per Rights Equity Share.
Issue Proceeds	The gross proceeds raised through the Issue.
Issue Size	The issue of up to 9,58,000 Rights Equity Shares aggregating up to ₹9,101.00 lakhs. *Assuming full subscription in the Issue. Subject to finalisation of the Basis of Allotment.
“Letter of Offer” or “LOF”	This letter of offer dated August 27, 2026, filed with the Stock Exchange and SEBI.
Listing Agreements	The uniform listing agreements entered into between our Company and the Stock Exchange in terms of the SEBI LODR Regulations.
Monitoring Agency	Infomerics Valuation and Rating Limited
Monitoring Agency Agreement	Agreement dated August 27, 2026, between our Company and the Monitoring Agency in relation to monitoring of the Gross Proceeds.
Multiple Application Forms	More than one application form submitted by an Eligible Equity Shareholder/Renouncee in respect of the same Rights Entitlement available in their demat account. However, additional applications in relation to Additional Rights Equity Shares with/without using additional Rights Entitlements will not be treated as multiple applications.
Net Proceeds	Issue Proceeds less the estimated Issue related expenses. For further details, see “Objects of the Issue” beginning on page 40.
Off Market Renunciation	The renunciation of Rights Entitlements undertaken by the Investor by transferring its Rights Entitlements through off-market transfer through a depository participant, in accordance with the SEBI ICDR Master Circular, circulars issued by the Depositories from time to time and other applicable laws. Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncee on or prior to the Issue Closing Date.
On Market Renunciation	The renunciation of Rights Entitlements undertaken by the Investor by trading its Rights Entitlements over the secondary market platform of the Stock Exchange through a registered stock broker, in accordance with the SEBI ICDR Master Circular, circulars issued by the Stock Exchange from time to time and other applicable laws, on or before Friday, September 11, 2026.
Qualified Institutional Buyers or QIBs	Qualified institutional buyers as defined under Regulation 2(1)(ss) of the SEBI ICDR Regulations.
Record Date	Designated date for the purpose of determining the Equity Shareholders who would be eligible to apply for the Rights Equity Shares in the Issue, subject to the terms and conditions set out in the Issue Materials, to be decided prior to the filing of the Letter of Offer, being Wednesday, September 02, 2026 .

Refund Bank	Axis Bank Ltd.
“Registrar to the Issue” or “Registrar” or “RTI” or “Registrar and Share Transfer Agent” or “Share Transfer Agent” or “RTA”	Skyline Financial Services Private Limited.
Registrar Agreement	Agreement dated August 01, 2026 between our Company and the Registrar to the Issue in relation to the responsibilities and obligations of the Registrar to the Issue pertaining to this Issue.
Renouncee(s)	Person(s) who has/have acquired Rights Entitlements from the Eligible Equity Shareholders on renunciation, in accordance with the SEBI ICDR Master Circular.
Renunciation Period	The period during which the Eligible Equity Shareholders can renounce or transfer their Rights Entitlements, which shall commence from the Issue Opening Date. Such period shall close on Friday, September 11, 2026, in case of On Market Renunciation. Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncee on or prior to the Issue Closing Date.
Rights Entitlement(s)	Number of Rights Equity Shares that an Eligible Equity Shareholder is entitled to, in proportion to the number of Equity Shares held by the Eligible Equity Shareholder on the Record Date, in this case being 97 Rights Equity Share(s) for every 1831 Equity Share(s) held by an Eligible Equity Shareholder on the Record Date.
Rights Entitlement Letter	Letter including details of the Rights Entitlements of the Eligible Equity Shareholders. The details of Rights Entitlements are also accessible on the website of our Company.
Rights Equity Shares	Equity shares of our Company to be Allotted pursuant to this Issue on a fully paid-up basis on Allotment.
Rights Equity Shareholders	Holder of the Rights Equity Shares pursuant to this Issue.
SCSB(s)	Self-certified syndicate banks registered with SEBI, which act as a banker to the Issue and which offer the facility of ASBA. A list of all SCSBs is available at www.sebi.gov.in , or such other website as updated from time to time.
Specific Investor(s)	Regulation 77B of the SEBI ICDR Regulations defines specific investor(s) as any investor who is eligible to participate in the Issue and (a) whose name has been disclosed by our Company in terms of Regulation 84(1)(f)(i) of the SEBI ICDR Regulations; or (b) whose name has been disclosed by our Company in terms of Regulation 84(1)(f)(ii) of the SEBI ICDR Regulations.
Stock Exchange	Stock exchange where the Equity Shares are presently listed, i.e. the Emerge Platform of the National Stock Exchange of India Limited (“NSE SME”).
Transfer Date	The date on which the Application Money blocked in the ASBA Account will be transferred to the Allotment Account(s) in respect of successful Applications, upon finalisation of the Basis of Allotment, in consultation with the Designated Stock Exchange.
Wilful Defaulter	Wilful defaulter as defined under Regulation 2(1)(III) of the SEBI ICDR Regulations.
Working Days	All days on which commercial banks in Delhi are open for business. Further, in respect of the Issue Period, working day means all days, excluding Saturdays, Sundays and public holidays, on which commercial banks in Delhi are open for business. Furthermore, in respect of the time period between the Issue Closing Date and the listing of Equity Shares on the Stock Exchange, working day means all trading days of the Stock Exchange, excluding Sundays and bank holidays, as per circulars issued by SEBI.

CONVENTIONAL AND GENERAL TERMS OR ABBREVIATIONS

TERM/ABBREVIATION	DESCRIPTION
“₹” or “Rs.” or “Rupees” or “INR”	Indian Rupee
Aadhaar	Aadhaar card
AGM	Annual general meeting of the Shareholders of our Company
AIF(s)	Alternative investment funds, as defined and registered with SEBI under the Securities and Exchange Board of India (Alternative Investment Funds) Regulations, 2012
Arbitration Act	Arbitration and Conciliation Act, 1996
“Accounting Standards”	Accounting standards issued by the ICAI
Basic EPS	Net Profit for the year attributable to owners of the Company/ weighted average number of Equity Shares outstanding during the year.

“Bharatiya Nagrik Suraksha Sanhita” or “BNSS”	The Bharatiya Nagrik Suraksha Sanhita, 2023
“Bharatiya Nyaya Sanhita” or “BNS”	The Bharatiya Nyaya Sanhita, 2023
bps	Basis points. One basis point is equal to one-hundredth of a percentage point (0.01%).
NSE	National Stock Exchange of India Limited
NSE SME / NSE Emerge	SME Platform of the National Stock Exchange of India Limited
CAGR	Compounded annual growth rate
Calendar Year	Calendar year ending December 31
Category I AIF	AIFs who are registered as “Category I Alternative Investment Funds” under the SEBI AIF Regulations.
Category I FPIs	FPIs who are registered as “Category I foreign portfolio investors” under the SEBI FPI Regulations.
CBDT	Central Board of Direct Taxes, Government of India
CCPA	Central Consumer Protection Authority
CDSL	Central Depository Services (India) Limited
CIN	Corporate identification number
Central Government	Central Government of India
Client ID	The client identification number maintained with one of the Depositories in relation to the demat account
Companies Act	Companies Act, 1956 and the Companies Act, 2013, as applicable
Companies Act, 1956	The Companies Act, 1956, along with the relevant rules made thereunder
Companies Act, 2013	The Companies Act, 2013, along with the relevant rules made thereunder
Cost of Goods Sold	Cost of materials consumed, purchase of stock-in-trade and change in inventories of finished goods/work-in-progress/stock-in-trade (excluding direct overheads and wages)
CPC	Code of Civil Procedure, 1908
CrPC	Code of Criminal Procedure, 1973, as replaced by BNSS
CSR	Corporate social responsibility
Depositories Act	Depositories Act, 1996
Depository	A depository registered with SEBI under the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018
Diluted EPS	Net Profit for the year attributable to owners of the Company/weighted average number of Equity Shares outstanding during the year, as adjusted for the effect of dilutive equity shares
DIN	Director identification number
“DP” or “Depository Participant”	Depository participant as defined under the Depositories Act
DP ID	Depository participant’s identification number
DPIIT	Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry (formerly Department of Industrial Policy and Promotion)
EBIT	Earnings before interest and taxes
EBITDA	EBITDA is calculated as profit before exceptional items and tax plus finance costs, depreciation and amortisation expenses, excluding other income (other than other non-operating income)
EGM	Extraordinary General Meeting
EPS	Earnings per share
ESG	Environmental, social and governance
EUR	Euro
FDI	Foreign direct investment
FEMA	Foreign Exchange Management Act, 1999
FEMA Rules	Foreign Exchange Management (Non-debt Instruments) Rules, 2019
“Financial Year” or “Fiscal Year” or “Fiscal” or “FY”	Period of 12 months ending March 31 of that particular year
FDI Policy	Consolidated Foreign Direct Investment Policy notified by DPIIT, as amended and in effect from time to time
FEMA ODI Regulations	Foreign Exchange Management (Overseas Investment) Regulations, 2022
FEMA ODI Rules	Foreign Exchange Management (Overseas Investment) Rules, 2022

FIR	First information report
FPI	Foreign portfolio investors as defined and registered under the SEBI FPI Regulations
FVCI	Foreign venture capital investors as defined and registered under the SEBI FVCI Regulations
GAAP	Generally Accepted Accounting Principles in India
GBP	Great Britain Pound
GOI	Government of India
Government	Central Government and/or the State Government, as applicable
GST	Goods and Services Tax
ICAI	Institute of Chartered Accountants of India
ICSI	Institute of Company Secretaries of India
IFRS	International Financial Reporting Standards issued by the International Accounting Standards Board
Ind AS	Indian Accounting Standards as specified under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015
Ind GAAP	Generally Accepted Accounting Principles in India
India	Republic of India
Income-Tax Act	Income-tax Act, 1961
IPC	Indian Penal Code, 1860, as replaced by BNS
IST	Indian Standard Time
MCA	Ministry of Corporate Affairs, Government of India
MCLR	Marginal Cost of Funds based Lending Rate
“Mn” or “mn”	Million
MSME	Micro, Small and Medium Enterprise
Mutual Fund	Mutual fund registered with SEBI under the Securities and Exchange Board of India (Mutual Funds) Regulations, 1996
NACH	National Automated Clearing House
NBFC	Non-banking financial company
NCLT	Hon’ble National Company Law Tribunal
NEFT	National electronic fund transfer
Net Worth	Net worth as defined under Regulation 2(1)(hh) of the SEBI ICDR Regulations
Net Asset Value per Equity Share	Net Worth/ number of Equity Shares issued, subscribed and fully paid outstanding as at the end of the year
NR	Non-resident or person(s) resident outside India, as defined under FEMA
NRE	Non-resident external
NRE Account	Non-resident external account
NRO	Non-resident ordinary
NRO Account	Non-resident ordinary account
NSDL	National Securities Depository Limited
“OCBs” or “Overseas Corporate Body”	A company, partnership, society or other corporate body owned directly or indirectly to the extent of at least 60% by NRIs, including overseas trusts, in which not less than 60% of the beneficial interest is irrevocably held by NRIs directly or indirectly
OCI	Overseas citizen of India
P/E Ratio	Price to earnings ratio
PAN	Permanent account number
PAT	Profit after tax
RBI	Reserve Bank of India
“Return on Net Worth” or “RoNW”	Net Profit for the year attributable to owners of the Company/Net Worth
RoC	Registrar of Companies, Delhi (RoC Delhi I)
RTGS	Real time gross settlement
SCRA	Securities Contracts (Regulation) Act, 1956
SCRR	Securities Contracts (Regulation) Rules, 1957
SEBI	The Securities and Exchange Board of India
SEBI Act	The Securities and Exchange Board of India Act, 1992

SEBI AIF Regulations	The Securities and Exchange Board of India (Alternative Investment Funds) Regulations, 2012
SEBI FPI Regulations	The Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2019
SEBI FVCI Regulations	The Securities and Exchange Board of India (Foreign Venture Capital Investors) Regulations, 2000
SEBI ICDR Regulations	The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018
SEBI ICDR Master Circular	The SEBI Master Circular bearing number HO/49/14/14(2)2026-CFD-POD2/I/4518/2026, originally issued June 21, 2023 and last updated February 9, 2026, read with the SEBI Rights Issue Circular.
“SEBI LODR Regulations” or “SEBI Listing Regulations” or “LODR”	The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
SEBI LODR Master Circular	The SEBI master circular bearing number HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as updated from time to time.
SEBI Rights Issue Circular	The SEBI circular bearing number SEBI/HO/CFD/CFD-PoD-1/P/CIR/2025/31 dated March 11, 2025.
SEBI Takeover Regulations	The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
SEBI VCF Regulations	The Securities and Exchange Board of India (Venture Capital Funds) Regulations, 1996, as repealed and replaced by the SEBI AIF Regulations
STT	Securities transaction tax
State Government	Government of a state of India
TM	Trademark
UPI	Unified Payment Interface
USD	United States Dollar
“U.S.” or “USA” or “United States”	United States of America, its territories or possessions, any state of the United States, and the District of Columbia
US GAAP	Generally accepted accounting principles in the U.S.
VCFs	Venture Capital Funds as defined in and registered with SEBI under the SEBI VCF Regulations or the SEBI AIF Regulations, as the case may be

INDUSTRY RELATED TERMS

TERM/ABBREVIATION	DESCRIPTION
ANDA	Abbreviated New Drug Application
API	Active Pharmaceutical Ingredient
CDSCO	Central Drugs Standard Control Organisation of the Ministry of Health and Family Welfare
CEP	Certificate of Suitability
cGMP	Current Good Manufacturing Practices
CMO	Contract Manufacturing Organisation
DSIR	Department of Scientific & Industrial Research, Ministry of Science and Technology, Government of India
GCP	Good Clinical Practice
IPM	Indian Pharmaceutical Market
NABL	The National Accreditation Board for Testing and Calibration Laboratories
WHO	World Health Organization
WHO GMP	World Health Organization Good Manufacturing Practices

The words and expressions used but not defined in this Letter of Offer will have the same meaning as assigned to such terms under the Companies Act, the SEBI ICDR Regulations, the SCRA, the Depositories Act and the rules and regulations made thereunder.

NOTICE TO INVESTORS

The distribution of this Letter of Offer, Draft Letter of Offer, the Application Form and the Rights Entitlement Letter, and the issue of Rights Entitlements and Rights Equity Shares, to persons in certain jurisdictions outside India may be restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer, Draft Letter of Offer or the Application Form may come are required to inform themselves about and observe such restrictions.

Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders and will electronically dispatch through email and physical dispatch through speed post the Letter of Offer, the Application Form, the Rights Entitlement Letter and any other material relating to the Issue (collectively, the "Issue Materials") to those who have a registered address in India or who have provided an Indian address to our Company. Where such Eligible Equity Shareholders have provided a valid e-mail address to our Company, the Issue Materials will be sent only to such e-mail address; where an e-mail address has not been provided, the Issue Materials will be physically dispatched, on a reasonable effort basis, to the Indian address provided. Overseas Shareholders who do not update our records with an Indian address or the address of a duly authorised representative in India, prior to the date on which we propose to dispatch the Issue Materials, shall not be sent the Issue Materials.

Investors can also access this Letter of Offer, Draft Letter of Offer and the Application Form from the websites of our Company, the Registrar and the Stock Exchange.

Our Company and the Registrar will not be liable for non-dispatch of physical copies of Issue Materials, including the Letter of Offer, the Rights Entitlement Letter and the Application Form, where the Issue Materials have been sent to the registered e-mail addresses of the Eligible Equity Shareholders.

The Rights Entitlement and the Rights Equity Shares may not be offered or sold, directly or indirectly, and this Letter of Offer, Draft Letter of Offer, and any other Issue Materials may not be distributed, in whole or in part, in or into any jurisdiction (other than in India), except in accordance with legal requirements applicable in such jurisdiction. Receipt of this Letter of Offer, Draft Letter of Offer or any other Issue Materials (including by way of electronic means) will not constitute an offer, invitation to or solicitation by anyone in any jurisdiction or in any circumstances in which such an offer, invitation or solicitation is unlawful or not authorised, or to any person to whom it is unlawful to make such an offer, invitation or solicitation. In those circumstances, this Letter of Offer, Draft Letter of Offer, and any other Issue Materials must be treated as sent for information only and should not be acted upon for subscription to Rights Equity Shares, and should not be copied or re-distributed.

Any person who makes an application to acquire Rights Entitlements and the Rights Equity Shares offered in the Issue will be deemed to have declared, represented, warranted and agreed that such person is authorised to acquire the Rights Entitlements and the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in such person's jurisdiction and India, without requirement for our Company to make any filing or registration (other than in India).

Any person who acquires Rights Entitlements or Rights Equity Shares will be deemed to have represented, warranted and agreed, by accepting the delivery of the Letter of Offer, that it is not, and that at the time of subscribing for the Rights Equity Shares or the Rights Entitlements it is either in India or is in compliance with the laws of its jurisdiction, and in each case is authorised to acquire the Rights Entitlement and the Rights Equity Shares in compliance with all applicable laws and regulations.

Our Company reserves the right to treat as invalid any Application Form that: (i) appears to our Company or its agents to have been executed in, electronically transmitted from or dispatched from the United States or any other jurisdiction where the offer and sale of the Rights Equity Shares is not permitted under the laws of such jurisdiction; (ii) does not include the relevant certifications set out in the Application Form, including that the person submitting and/or renouncing the Application Form is outside the United States and is eligible to subscribe for the Rights Equity Shares under applicable securities laws; (iii) where a registered Indian address is not provided; or (iv) where our Company believes acceptance of such Application Form may infringe applicable legal or regulatory requirements; and our Company shall not be bound to issue or allot any Rights Equity Shares in respect of any such Application Form.

Neither the receipt of this Letter of Offer nor any sale of Rights Equity Shares hereunder shall, under any circumstances, create any implication that there has been no change in our Company's affairs from the date hereof, or that the information contained herein is correct as at any time subsequent to the date of this Letter of Offer. The contents of this Letter of Offer should not be construed as legal, tax, business, financial or investment advice. Prospective investors should consult their own counsel, business advisor and tax advisor as to the legal, business, tax and related matters concerning the offer of the Rights Equity Shares or Rights Entitlements.

Investors are advised to make their independent investigations and ensure that the number of Rights Equity Shares applied for do not exceed the applicable limits under laws or regulations.

The Rights Entitlements and the Rights Equity Shares have not been approved or disapproved by any regulatory authority, nor has any regulatory authority passed upon or endorsed the merits of the offering of the Rights Entitlements, the Rights Equity Shares or the accuracy or adequacy of this Letter of Offer. Any representation to the contrary is a criminal offence in certain jurisdictions.

The Issue Materials are supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

NO OFFER IN THE UNITED STATES

Neither our Company, nor any person acting on behalf of our Company, will accept a subscription or renunciation or purchase of the Equity Shares and/or Rights Entitlements from any person, or the agent of any person, who appears to be, or who our Company, or any person acting on behalf of our Company, has reason to believe is, in the United States when the buy order is made. No Application Form should be postmarked in the United States, electronically transmitted from the United States or otherwise dispatched from the United States or from any other jurisdiction where it would be illegal to make an offer of securities under this Letter of Offer. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders and will dispatch the Letter of Offer, the Application Form and other applicable Issue Materials primarily to the e-mail addresses of Eligible Equity Shareholders who have provided an Indian address to our Company. Any person who acquires Rights Entitlements or Equity Shares will be deemed to have declared, warranted and agreed, by accepting the delivery of this Letter of Offer, that it is not, and that at the time of subscribing for the Equity Shares or the Rights Entitlements it will not be, in the United States and is authorised to acquire the Rights Entitlements and the Equity Shares in compliance with all applicable laws and regulations.

The Rights Entitlements and the Equity Shares have not been approved or disapproved by the U.S. Securities and Exchange Commission, any other federal or state securities commission in the United States, the securities authorities of any non-United States jurisdiction or any other U.S. or non-U.S. regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the offering of the Rights Entitlements, the Equity Shares or the accuracy or adequacy of this Letter of Offer. Any representation to the contrary is a criminal offence in the United States and may be a criminal offence in certain other jurisdictions.

In making an investment decision, investors must rely on their own examination of our Company and the terms of the Issue, including the merits and risks involved.

PRESENTATION OF FINANCIAL INFORMATION AND OTHER INFORMATION

Certain Conventions

Unless otherwise specified or the context otherwise requires, all references in this Letter of Offer to (i) the 'US' or 'U.S.' or the 'United States' are to the United States of America, its territories and possessions, any state of the United States, and the District of Columbia; (ii) 'India' are to the Republic of India and its territories and possessions; and (iii) the 'Government' or 'GoI' or the 'Central Government' or the 'State Government' are to the Government of India, Central or State, as applicable.

Unless otherwise specified, any time mentioned in this Letter of Offer is in IST. Unless indicated otherwise, all references to a year in this Letter of Offer are to a Calendar Year. Unless stated otherwise, all references to page numbers in this Letter of Offer are to the page numbers of the Draft Letter of Offer. In this Letter of Offer, references to the singular also refer to the plural and one gender also refers to any other gender, where applicable.

Financial Data

Our Company's Financial Year commences on April 1 of each calendar year and ends on March 31 of the following calendar year. Unless otherwise stated, references in this Letter of Offer to a particular 'Financial Year' or 'Fiscal Year' or 'Fiscal' are to the financial year ended March 31.

Our Company prepares its financial statements in accordance with Indian GAAP, the Companies Act and other applicable statutory and/or regulatory requirements. Our Company publishes its financial statements in Indian Rupees. Any reliance by persons not familiar with Indian accounting practices on the financial disclosures presented in this Letter of Offer should accordingly be limited.

In this Letter of Offer, any discrepancies in any table between the total and the sums of the amounts listed are due to rounding off, and unless otherwise specified, all financial numbers in parenthesis represent negative figures. All figures in decimals have been rounded off to the second decimal and all percentage figures have been rounded off to two decimal places. Any figures sourced from third-party industry sources may be rounded off to other than two decimal points to conform to their respective sources. Our Company has presented all numerical information in this Letter of Offer in "lakh" units, or in whole numbers where the numbers have been too small to represent in lakh. One lakh represents 1,00,000.

Unless stated otherwise, throughout this Letter of Offer, all figures have been expressed in Rupees, in lakhs.

Non-GAAP Measures

We have included certain non-GAAP financial measures and certain other statistical information relating to our operations and financial performance (collectively, "Non-GAAP Financial Measures") in this Letter of Offer, including return on net worth and net asset value per share. These Non-GAAP Financial Measures are not required by or presented in accordance with Indian GAAP. We compute and disclose such Non-GAAP Financial Measures as we consider them useful measures of our business and financial performance, and because such measures are frequently used by securities analysts, investors and others to evaluate the operational performance of other companies in our industry. These Non-GAAP Financial Measures are not a measurement of our financial performance or liquidity under Indian GAAP, IFRS or US GAAP, and should not be considered in isolation or construed as an alternative to cash flows, profit/(loss) for the year, or any other measure of financial performance derived in accordance with Indian GAAP, IFRS or US GAAP. Other companies may calculate these Non-GAAP Financial Measures differently, limiting their usefulness as a comparative measure, and you should not consider them in isolation or as substitutes for analysis of our financial position or results of operations as reported under GAAP.

Market and Industry Data

Unless stated otherwise, market, industry and demographic data used in this Letter of Offer has been obtained from market research, publicly available information and various industry publications and sources (collectively, the "Sources"). Industry publications generally state that the information they contain has been obtained from sources believed to be reliable, but that the accuracy and completeness of that information is not guaranteed.

Statements from third parties that involve estimates are subject to change, and actual amounts may differ materially from those included in this Letter of Offer. Industry sources and publications may also base their information on estimates, projections, forecasts and assumptions that may prove to be incorrect. Industry sources and publications are also prepared based on information as of specific dates and may no longer be current or reflect current trends. Accordingly, investment decisions should not be based solely on such information.

Currency of Presentation

All references to:

'INR', '₹', 'Indian Rupees' and 'Rupees' are to the legal currency of the Republic of India;

‘US\$’, ‘USD’, ‘\$’ and ‘U.S. dollars’ are to the legal currency of the United States of America; and

‘EUR’, ‘€’ and ‘Euro’ are to the legal currency of the European Union.

Please note:

Our Company has presented certain numerical information in this Letter of Offer in “lakh” units. One lakh represents 1,00,000. All numbers in this document have been presented in lakh, or in whole numbers where the numbers have been too small to present in lakh. Any percentage amounts, as set forth in “Risk Factors” and elsewhere in this Letter of Offer, unless otherwise indicated, have been calculated based on our Company’s Audited Financial Statements referred to above.

Conversion Rates for Foreign Currency:

The conversion rate for the following foreign currency is as follows:

Sr. No. / Currency	As of March 30, 2026 ¹	As of March 28, 2025 ²
1 USD	94.65	85.58

Source: <https://www.rbi.org.in/scripts/referenceratearchive.aspx>

¹ Since March 31, 2026, was a holiday, the exchange rate was considered as on March 30, 2026, being the last working day prior to March 31, 2026.

² Since March 31, 2025, was a holiday, the exchange rate was considered as on March 28, 2025, being the last working day prior to March 31, 2025.

FORWARD LOOKING STATEMENTS

Certain statements contained in this Letter of Offer that are not statements of historical fact constitute “forward-looking statements.” Investors can generally identify forward-looking statements by words or phrases such as “aim”, “anticipate”, “believe”, “continue”, “can”, “could”, “estimate”, “expect”, “expected to”, “intend”, “likely”, “may”, “objective”, “plan”, “potential”, “project”, “propose”, “pursue”, “shall”, “should”, “will”, “would” or other similar expressions. Statements that describe our Company’s objectives, strategies, plans, targets or goals are also forward-looking statements. However, these words are not the exclusive means of identifying such statements.

All statements in this Letter of Offer regarding our Company’s expected financial condition, results of operations, business strategy, business plans, prospects, proposed utilisation of the proceeds of the Issue, future growth and expansion plans are forward-looking statements. These forward-looking statements include, without limitation, statements relating to our Company’s operations, funding plans, repayment of borrowings, working capital requirements, general corporate purposes and other matters discussed in this Letter of Offer that are not historical facts.

These forward-looking statements (whether made by our Company or any third party) are based on current expectations, assumptions, estimates and beliefs of our Company’s management, and involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of our Company to differ materially from those expressed or implied by such forward-looking statements.

Forward-looking statements are subject to various risks, uncertainties and assumptions, including, but not limited to, the following factors:

- General economic, business and market conditions in India and globally;
- Changes in laws, regulations and government policies applicable to the sectors in which our Company operates;
- Volatility or adverse developments in the capital markets;
- Our Company's ability to successfully complete the Issue and utilise the proceeds in accordance with the stated objects;
- Availability, continuity and cost of funding and working capital;
- Fluctuations in operating costs and their impact on financial performance;
- Competition in the markets in which our Company operates and the ability to sustain competitive positioning;
- Our Company's ability to manage its existing operations and future growth efficiently;
- Delays in receipt of statutory, regulatory or stock exchange approvals, if any; and
- Any unforeseen events, disruptions, natural calamities or force majeure events that may adversely affect our Company's operations or financial condition.

Additional factors that could cause actual results, performance or achievements of our Company to differ materially are discussed in the section titled “Risk Factors” forming part of this Letter of Offer.

The forward-looking statements contained in this Letter of Offer are based on the beliefs of our Company’s management, as well as assumptions made by, and information currently available to, our Company’s management. While our Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date of this Letter of Offer, no assurance can be given that such expectations will prove to be correct. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

All forward-looking statements in this Letter of Offer speak only as of the date of this Letter of Offer or such other dates as may be specified herein. Our Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law, SEBI regulations or stock exchange requirements.

In accordance with applicable SEBI regulations and stock exchange requirements, our Company will ensure that Eligible Equity Shareholders are informed of material developments, if any, until the grant of listing and trading approvals for the Equity Shares issued pursuant to the Issue.

SUMMARY OF THE LETTER OF OFFER

The following is a general summary of certain disclosures included in this Letter of Offer and is not exhaustive, nor does it purport to contain a summary of all the disclosures in this Letter of Offer or all details relevant to prospective Investors.

PRIMARY BUSINESS OF THE COMPANY

Our Company is a manufacturer of male condoms in a variety of flavours, marketed and sold under our flagship brand "COBRA." We have an installed production capacity of nearly 869 million condoms per annum, as per a certificate issued by Mr. Er. Vinod Kumar Goel, Chartered Engineer, dated February 02, 2026, supported by 15 operational manufacturing lines at our manufacturing facility situated at D-001, Sector 80, Gautam Budh Nagar, Noida, Uttar Pradesh 201301. To follow sustainable production practices, our Company uses CNG as a clean, environmentally friendly manufacturing fuel for its manufacturing plant.

Our Promoter, Mr. Anupam Ghosh, entered this industry in 1999, undertaking orders for the sale and packaging of condoms through his proprietorship, M/s Healthcare Products. In 2004, he set up his own condom manufacturing plant under the same proprietorship and commenced manufacturing operations. In 2013, the proprietorship was renamed "M/s Anondita Healthcare." The entire running business of M/s Anondita Healthcare, including all assets and liabilities, was subsequently transferred to our Company pursuant to a Business Transfer Agreement dated April 1, 2024.

Having supplied our products to various pharmaceutical companies for many years as a manufacturing partner, we subsequently ventured into the consumer market by launching our own brand, Cobra Condoms. Our brand is 100% electronically tested and is available in a range of flavours, including Strawberry, Mint, Chocolate, Butterscotch, Coffee and Bubblegum, using export-quality packing material to uphold our standards and industry requirements. Encouraged by market demand and consumer response, we have also commenced production of female condoms, for which our Company holds a patent, placing us among a limited number of manufacturers globally with this capability.

Manufacturing Facility:

Our Company operates a state-of-the-art manufacturing facility strategically located in Noida, Uttar Pradesh, encompassing a total built-up area of approximately 1,00,000 square feet (9,290 square metres), providing ample space for our current operations and future expansion plans. Our manufacturing capability is supported by 15 operational manufacturing lines, each equipped with an average of 1,100 moulds, together capable of producing 16,500 condoms every 3 minutes at full capacity (1,100 moulds × 15 manufacturing lines). The number of moulds and machine speed can be adjusted to produce the desired output. Our facility is equipped with advanced machinery including in-house foil printing machines for high-speed foil packaging and a 6-colour rotogravure printing machine for high-quality prints across our packaging and labelling and adheres to stringent quality control measures to ensure our products meet international standards.

Capacity Utilisation:

Our installed and actual production capacity for the last three fiscal years is set out below:

(Units in Lakhs)

Particulars	FY 2026	FY 2025	FY 2024
Installed Capacity	8,690.00	5,620.00	5,620.00
Actual Capacity	4321.30	2,588.35	2,199.48
Utilisation (%)	80.67%	46.05%	39.14%

(As per certificate issued by Mr. JP Sood, Chartered Engineer, dated June 4, 2025, certifying our installed capacity as of Fiscal 2025. This certificate is valid for the Financial Year 2025. Actual Capacity includes both standard and sub-standard/scrap product; Installed Capacity is computed on the basis of 3 shifts per day, while Actual Capacity is computed on the basis of 2 shifts per day.)

Our product and service offerings broadly include:

Manufacturing and Product Range: Manufacture of male latex condoms across multiple flavour variants under the COBRA brand, together with female condoms under our patented technology. Production is carried out across our 15 manufacturing lines, equipped with automated dipping, curing, testing and foiling/packing machinery, with each unit subjected to 100% electronic pinhole testing before packaging.

Institutional and Government Sales: The Company supplies its products directly to various Government procurement agencies, State AIDS Control Societies, and other institutional customers through competitive tender processes. Products are manufactured and supplied in accordance with customer-specific specifications, including prescribed packaging, branding, and labelling requirements. The Company regularly participates in tenders floated by agencies such as the Central Medical Services Society (CMSS) and other Government procurement organizations.

Trade and Distribution: The Company's domestic trade and distribution network is managed through its subsidiary, **Anondita Healthcare and Rubber Products India Limited**, supported by a dedicated sales force comprising Zonal Sales Managers, Regional Sales Managers, and Area Sales Managers. The distribution network includes Super Distributors, Distributors, and Retailers across multiple cities in India.

In addition to sales through its subsidiary's distribution network, the Company also undertakes direct sales of its **COBRA** brand products through its authorised distributor, **M/s Calcutta Cosmetics**, as well as through various wholesalers, thereby ensuring wider market penetration and enhanced product availability across the country.

Quality Assurance: A multi-stage quality control process spanning raw material quarantine, in-process checks at compounding, dipping and post-treatment stages, 100% electronic testing and visual inspection, and final quality checks prior to storage and shipment.

Our customer base primarily comprises government procurement agencies and AIDS Control Societies, trade distributors and retailers, and our own subsidiary and group entities engaged in the marketing of our products. Through this integrated model of manufacturing, quality assurance and multi-channel distribution, our Company positions itself as an established and experienced condom manufacturer in India, with plans to expand into export markets, including through the pursuit of UN qualification for our products.

Mission and Vision

Our Company is dedicated to making a significant impact in the battle against HIV/AIDS and the prevention of unintended pregnancies, and to developing safe and effective methodologies in furtherance of that goal. We are committed to a world where individuals can practise safe behaviours and live free from the threat of HIV/AIDS and unintended pregnancies.

INTENTION AND EXTENT OF PARTICIPATION IN THE ISSUE BY OUR PROMOTERS AND PROMOTER GROUP:

Our Promoters, Mr. Anupam Ghosh, Mrs. Sonia Ghosh and Mr. Reshant Ghosh, vide their letters dated August 01, 2026, had confirmed their intention not to subscribe to their Rights Entitlements under this Issue and to renounce the same in favour of specific investor(s) to be identified by the Company, in accordance with Regulation 77B of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations").

Subsequently, as no specific investor(s) could be identified or finalised for allotment of the Rights Entitlements so renounced, our Promoters have, as of August 27, 2026, confirmed their intention to renounce their entire Rights Entitlements in favour of the public at large instead, through the renunciation mechanism prescribed under the SEBI ICDR Regulations, in the manner set out under "Terms of the Issue" of this Letter of Offer. Accordingly, no specific investor(s) have been identified or disclosed in connection with this Issue, and the provisions of Regulation 77B of the SEBI ICDR Regulations are not applicable.

Intention to Subscribe to Rights Entitlement

None of our Promoters intend to subscribe to their Rights Entitlements.

Intention to Subscribe to Additional Rights Equity Shares

Not applicable, in view of our Promoters' decision not to subscribe to their Rights Entitlements.

Intention to Renounce Rights Entitlements to Specific Investors

Our Promoters, Mr. Anupam Ghosh, Mrs. Sonia Ghosh and Mr. Reshant Ghosh, vide their letters dated August 01, 2026, had confirmed their intention not to subscribe to their Rights Entitlements under this Issue and to renounce the same in favour of specific investor(s) to be identified by the Company, in accordance with Regulation 77B of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations").

Subsequently, as no specific investor(s) could be identified or finalised for allotment of the Rights Entitlements so renounced, our Promoters have, as of August 27, 2026, confirmed their intention to renounce their entire Rights Entitlements in favour of the public at large instead, through the renunciation mechanism prescribed under the SEBI ICDR Regulations, in the manner set out under "Terms of the Issue" of this Letter of Offer. Accordingly, no specific investor(s) have been identified or disclosed in connection with this Issue, and the provisions of Regulation 77B of the SEBI ICDR Regulations are not applicable.

Minimum Public Shareholding

Our Company is currently in compliance with the minimum public shareholding requirements under Regulation 38 of the SEBI LODR Regulations and Rule 19A of the SCRR, and shall ensure continued compliance post completion of the Rights Issue. Since our Promoters do not intend to subscribe to their Rights Entitlements or to any additional Rights Equity Shares, and shall instead renounce their entire Rights Entitlements in favour of specific investor(s), the Issue is not expected to result in any increase in Promoter shareholding, and shall accordingly not adversely affect our Company's continued compliance with the minimum public shareholding requirements.

ALLOTMENT OF THE UNDER-SUBSCRIBED PORTION OF THE ISSUE:

Our Company does not intend to allot the under-subscribed portion of the Rights Equity Shares in this Issue to any specific investor(s). Accordingly, no specific investor(s) have been identified or disclosed in connection with this Issue, and the provisions of Regulation 84(1)(f)(ii) of the SEBI ICDR Regulations are not applicable to this Issue.

WILFUL DEFAULTER OR A FRAUDULENT BORROWER:

Neither our Company, nor our Promoters or any of our Directors have been or are identified as Wilful Defaulters or Fraudulent Borrowers by the Reserve Bank of India ("RBI") or any other Government Authority.

SUMMARY OF MATERIAL OUTSTANDING LITIGATIONS:

The following table provides a summary of proceedings involving (i) criminal liability; (ii) regulatory matters involving material violations; (iii) economic offences; and (iv) other pending matters which, if decided adversely, may materially and adversely affect the operations or financial position of our Company, in accordance with the disclosures required under the SEBI ICDR Regulations, as at March 31, 2026:

Nature of Cases	Proceedings involving criminal liability	Proceedings before regulatory authorities involving material violations	Matters involving economic offences	Other pending matters (civil)	Aggregate amount involved (₹ in Lakhs)*
By our Company	4	Nil	Nil	3	Nil
Against our Company	Nil	Nil	Nil	1	77.23
By our Subsidiary	Nil	Nil	Nil	Nil	NA
Against our Subsidiary	Nil	Nil	Nil	Nil	NA

* The aggregate amount for the 4 criminal and 3 civil proceedings by our Company has not been separately quantified in the source data available.

Note: The litigation information set out above has been extracted from the due diligence report issued by Nandwani & Associates (Advocates and Legal Consultants) dated August 01, 2026.

Details of Pending Litigation

OTHER CONFIRMATIONS:

Except as stated below, our Company has been in compliance with the equity listing agreement and the SEBI LODR Regulations, 2015 during the three years immediately preceding the date of this Letter of Offer: -

Sl. No.	Stock Exchange	Amount of penalty (in ₹ including GST)	Reason for penalty imposition	Status
1	NSE	64,900/-	Delay in submission of disclosure of Related Party Transactions under Regulation 23(9) of the SEBI LODR Regulations, for the half year ended September 30, 2025 (11 days of delay)	Our Company has paid the penalty.

SECTION III: RISK FACTORS

An investment in equity shares involves a high degree of risk. You should carefully consider all the information in this Letter of Offer, including the risks and uncertainties described below, before making an investment in our Equity Shares. This section should be read together with our Fiscal 2026 Audited Consolidated Financial Statements.

The risks and uncertainties described below are not the only risks that we currently face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business, financial condition, results of operations and cash flows. If any or some combination of the following risks, or other risks that are not currently known or believed to be adverse, actually occur, our business, financial condition and results of operations could suffer, the trading price of, and the value of your investment in, our Equity Shares could decline and you may lose all or part of your investment.

This Letter of Offer also contains forward-looking statements that involve risks, assumptions, estimates and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the considerations described below and elsewhere in this Letter of Offer.

Unless specified or quantified in the relevant risk factors below, we are not in a position to quantify the financial or other implications of any of the risks described in this section. In this section, unless the context otherwise indicates or implies, "we", "us" and "our" refer to our Company together with our Subsidiaries.

RISKS MATERIAL TO OUR COMPANY AND ITS BUSINESS

1. Our Company had significant negative cash flows from investing activities in Fiscal 2026, and may continue to have negative cash flows in the future.

Our Company had net cash outflow from investing activities of ₹6,142.17 lakhs in Fiscal 2026, compared to ₹2,559.43 lakhs in Fiscal 2025, primarily on account of capital expenditure incurred towards property, plant and equipment as we expanded our manufacturing capacity. While our cash flow from financing activities was strongly positive in Fiscal 2026 (₹6,681.84 lakhs), driven substantially by proceeds from our initial public offering, including ₹6,470.55 lakhs from share premium, our Company's cash flow position remains sensitive to the timing and scale of our capital expenditure, including our proposed female condom manufacturing facility. Any sustained negative cash flow from investing activities without a corresponding source of financing could adversely affect our business, financial condition and results of operations. For further details, see "Financial Information" on page 59.

2. We depend on our top 10 customers for a significant portion of our revenue, and the loss of a major customer could adversely affect our business.

As per our Audited Financial Statements, our top 10 customers contributed ₹6,019.06 lakhs, or approximately 99.46%, of our revenue from operations for Fiscal 2025. the corresponding top-10 customer concentration figure for Fiscal 2026, based on our revenue from operations of ₹11,169.62 lakhs for that year, Given this continuing concentration, any dispute with, disqualification by, or reduction in orders from one or more of our major customers particularly government procurement agencies, which represent a substantial portion of this concentration could adversely affect our cash flows, liquidity and results of operations.

3. Our Company's total borrowings have increased, and rising interest costs or recall of loans could adversely affect our liquidity.

As per our audited standalone financial results, our Company's long-term borrowings stood at ₹2,359.62 lakhs and short-term borrowings at ₹967.80 lakhs as of March 31, 2026, aggregating ₹3,327.42 lakhs, compared to an aggregate of approximately ₹2,739.10 lakhs (secured loans of ₹2,715.37 lakhs and unsecured loans of ₹23.73 lakhs) as of March 31, 2025, as disclosed in our Prospectus. Any increase in interest rates would increase our debt servicing costs, and any unsecured lender seeking early recall of loans could require us to arrange alternative financing on terms that may not be commercially favourable, adversely affecting our cash flow and financial condition.

4. A majority of assets, including both movable and immovable, may not yet have been transferred into the name of our Company.

At the time of our Prospectus, certain assets and liabilities transferred to our Company pursuant to the Business Transfer Agreement dated April 1, 2024 remained registered in the name of the erstwhile proprietorship, M/s Anondita Healthcare, notwithstanding an irrevocable power of attorney executed by our Promoter, Mr. Anupam Ghosh, for transfer of immovable assets. Continued delay in completing these transfers could affect our ability to access certain licenses, permits or legal endorsements in our Company's own name, and contracts created under the erstwhile proprietorship may face enforceability challenges if counterparties insist on documentation in our Company's name.

5. Our revenue is concentrated in a limited number of states, and a decline in business from these states could adversely affect our revenue.

As disclosed in our Prospectus, Delhi, Uttar Pradesh and Haryana together contributed 100.00% of our revenue from operations for Fiscal 2025 (Delhi and Uttar Pradesh alone contributing 73.85% and 24.86% respectively). It should be noted that this concentration is partly attributable to accounting treatment sales to the Central Medical Services Society, a central government procurement agency supplying multiple states and union territories, are recorded as Delhi sales as CMSS is registered in Delhi rather than reflecting the true geographic reach of our products. Nonetheless, any adverse political, regulatory or competitive development in these states could adversely affect our revenue.

6. Our Corporate Office and manufacturing facility are leased from a Promoter Group entity and shared with another Promoter Group company.

Our Registered Office in Vasant Kunj, New Delhi is held in the name of our Company. Our Corporate Office and manufacturing facility in Noida, Uttar Pradesh is leased from our Group entity, Anondita Healthcare Products Private Limited, vide lease agreement dated July 18, 2024, and is also used by another Promoter Group entity. We cannot assure you that this arrangement will continue on commercially acceptable terms, and any requirement to vacate or relocate, whether on account of non-renewal, termination, or otherwise, could disrupt our operations and require us to incur higher costs for alternative premises.

7. Our Directors have limited experience managing the affairs of a listed company.

At the time of our initial public offering, our Directors did not have prior experience with listed companies. Our Company has since been listed on the SME Platform of NSE for a period of approximately since our listing. While our Directors have accordingly gained some experience with listed-company compliance and governance requirements over this period, this experience remains relatively limited compared to boards with longer listed-company tenures, which may increase the risk of inadvertent non-compliance with SEBI regulations, erroneous disclosures, or delayed intimations, any of which could affect our reputation and subject us to regulatory scrutiny.

8. There may be potential conflicts of interest between our Company, our Subsidiary, our Group Companies and other entities promoted by our Promoters.

Our Subsidiary and several Promoter Group companies, including Anondita Healthcare Products Private Limited, Anondita Latex Products (India) Private Limited, Anondita Exultia Healthcare Private Limited and Anondita Healthcare Private Limited, are permitted under their respective constitutional documents to undertake business similar to ours, and our Promoters Mr. Anupam Ghosh, Mrs. Sonia Ghosh and Mr. Reshant Ghosh serve as directors on the boards of our Subsidiary and certain Group Companies. This overlap creates potential for conflicts of interest in the allocation of business opportunities. Our Company has executed a non-compete agreement dated September 9, 2024 with these entities to mitigate this risk; however, we cannot assure you that conflicts will not arise, or that they will always be resolved in a manner favourable to our Company.

9. Our business requires significant working capital, and our inability to procure adequate working capital on favourable terms could adversely affect our operations.

Our working capital requirements have grown substantially in line with our revenue, with our Total Current Assets increasing from ₹4,050.40 lakhs as of March 31, 2025 to ₹7,663.11 lakhs as of March 31, 2026, and our management estimates project this to increase further to approximately ₹13,617.17 lakhs by March 31, 2027, as described in "Objects of the Issue Funding the Working Capital Requirements of our Company" on page 45. Delays in procuring adequate working capital, whether through internal accruals, bank facilities, or the proceeds of this Issue, could impair our ability to procure raw materials, maintain production continuity, or meet customer delivery timelines.

10. Any delay, interruption or increase in the cost of our raw materials, including due to geographical concentration of our suppliers, could adversely affect our business .

Our cost of materials consumed increased from ₹3,376.69 lakhs in Fiscal 2025 to ₹5,221.13 lakhs in Fiscal 2026, reflecting our reliance on key raw materials including natural rubber latex, ammonia, calcium carbonate, caustic soda, sulphur and various other chemical inputs and packaging materials sourced from third-party suppliers. **A significant portion of our purchases from our key suppliers is concentrated in certain geographical regions, particularly Uttar Pradesh. Any disruption affecting these regions, including due to natural calamities, adverse weather conditions, transportation or logistics disruptions, regulatory actions, labour-related issues, public health events or other unforeseen circumstances, may affect the availability or timely supply of raw materials and other inputs required for our manufacturing operations.** While we have not experienced significant supply disruptions in recent years, any delay by our suppliers, whether due to their own regulatory or operational difficulties, **geographical concentration or other factors**, or any sustained increase in raw material costs that we are unable to pass on to customers, particularly government customers operating under fixed tender pricing, could adversely affect our margins and results of operations.

11. We are subject to extensive government regulation specific to the manufacture of condoms, and any change in such regulation could increase our compliance costs.

Our manufacturing, packaging, labelling and marketing activities are governed by the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945, including Schedule R, which prescribes detailed standards for rubber latex condoms. Any violation is punishable by fine, imprisonment, or both. The Government of India has, in the past, proposed the Drugs, Medical Devices and Cosmetics Bill, 2022, which may eventually replace the existing framework; any such change, or any other change in regulatory policy, could require us to alter our manufacturing processes, incur additional compliance costs, or delay the launch of new products, including our proposed female condom range.

12. We are required to maintain and renew numerous statutory and regulatory approvals to operate our business.

Our operations require approvals under central, state and local regulations administered by authorities including the CDSCO, the Rubber Board, State Drug Licensing Authorities, and environmental and factory-safety regulators under the Factories Act, 1948, the Water (Prevention and Control of Pollution) Act, 1974, and the Air (Prevention and Control of Pollution) Act, 1981. While we have not had material instances of failure to obtain, maintain or renew required approvals to date, we cannot assure you that all approvals will continue to be granted, renewed or maintained without interruption, and failure to do so could adversely affect our ability to operate.

13. Our inability to accurately forecast demand may result in excess or insufficient inventory, adversely affecting our business.

Our inventory increased from ₹896.28 lakhs as of March 31, 2025 to ₹1,349.14 lakhs as of March 31, 2026, and our business depends on our ability to accurately forecast demand based on market and distributor feedback to plan production accordingly. While we have not experienced material financial losses attributable to demand forecasting errors in the three years preceding our Prospectus, any future underestimation of demand could constrain our ability to fulfil orders, while overestimation could result in excess inventory and associated carrying costs, either of which could adversely affect our financial condition and results of operations.

RISKS RELATING OBJECTS OF THE ISSUE

14. Our funding requirements and proposed deployment of the Net Proceeds are based on management estimates and have not been independently appraised.

Our funding requirements and the proposed deployment of the Net Proceeds, including amounts towards capital expenditure for our proposed female condom manufacturing facility, working capital and General Corporate Purposes, are based on internal management estimates, quotations obtained from vendors, and our current business plan. These estimates have not been appraised by any bank, financial institution, or other independent agency, and there can accordingly be no assurance that they accurately reflect our actual future requirements.

These estimates may require revision on account of a variety of factors that may not be within the control of our management, including changes in our financial condition, revisions to our business plan or strategy, prevailing market conditions, the competitive environment in which we operate, delays in receipt of vendor supplies, cost overruns on our proposed capital expenditure, and fluctuations in interest rates or foreign exchange rates, particularly given that a portion of our raw material requirements and our proposed export operations are linked to international markets.

In the event of any increase in the actual utilisation of funds earmarked for the Objects, or any shortfall of funds arising out of such variation, our Company may need to seek additional debt or equity financing, which may not be available to us on favourable terms, or at all, or may be required to reallocate funds from the other Objects or from General Corporate Purposes. Any of the foregoing may adversely affect the implementation of the Objects and, consequently, our business, financial condition, results of operations and cash flows. Prospective investors are accordingly cautioned to place appropriate reliance on our management's judgment, rather than any independent verification, when evaluating the proposed use of the Net Proceeds. For further details, see "Objects of the Issue" on page 40.

15. Our capital expenditure estimates are based on vendor quotations with limited validity periods, and we may incur higher capital expenditure if fresh quotations are obtained at increased prices.

The estimated cost of machinery and equipment for our proposed female condom manufacturing facility, as set out in "Objects of the Issue" on page 40, is based on quotations received by our Company from various vendors, including Super White Engineering Works, M.P. Scale Corporation, 4G International, Apolo Plast Industries, Astek Quality Instruments and Pioneer Fabrication Ltd., among others.

The completion of this Issue is subject to, among other things, receipt of in-principle and final approvals from NSE and other requisite regulatory approvals, and the rights issue process itself, from Board approval to listing, involves a

prescribed timeline under the SEBI ICDR Regulations. As a result, actual receipt of the Net Proceeds and their deployment towards the purchase of machinery is likely to occur significantly after the date of the quotations on which our cost estimates are based, and in most cases after the stated validity period of such quotations has lapsed.

Consequently, we may be required to obtain fresh quotations from the same or alternate vendors at the time of actual procurement, and there can be no assurance that such fresh quotations will be available on the same terms, or that the cost of machinery and equipment will not be materially higher than our current estimates. Any such increase in cost may require us to utilise a higher proportion of the Net Proceeds and/or our internal accruals than currently estimated, reallocate funds from our other Objects, or seek additional financing on terms that may not be favourable, or at all. This may adversely affect the implementation and timely commissioning of our proposed manufacturing facility, and consequently our business, financial condition, results of operations and cash flows.

16. The aggregate cost of machinery identified for our proposed female condom facility exceeds the amount allocated from the Net Proceeds towards this Object, and we are dependent on internal accruals to fund the shortfall.

Our identified machinery requirements for the proposed female condom manufacturing facility, comprising two complete production lines (latex and non-latex/nitrile) along with ancillary equipment including attritor mills, moulds, testing and packing machinery, aggregate to approximately ₹5,458.01 lakhs. Of this amount, we propose to allocate ₹5,000.00 lakhs from the Net Proceeds towards this Object, with the balance of approximately ₹458.01 lakhs, together with our overall total estimated project cost, proposed to be funded through our internal accruals, as further described in "Objects of the Issue Means of Finance" on page 41.

In accordance with Regulation 62(1)(c) of the SEBI ICDR Regulations, we are required to demonstrate firm arrangements of finance through verifiable means for at least 75% of the amount to be funded otherwise than through the Issue. Any inability to demonstrate such firm arrangements, whether through an auditor's certificate, bank statements, or otherwise, could affect our ability to proceed with the Issue in its current form, or could require us to revise the scope of this Object.

Any further shortfall in internal accruals, whether on account of lower than anticipated profitability, working capital demands elsewhere in our business, or any further increase in the cost of machinery identified above, could delay commissioning of the proposed facility, require us to reduce the scope of the project, defer or curtail our other Objects, or seek additional debt or equity financing on terms that may not be favourable to us, or at all. Any of the foregoing could adversely affect our ability to realise the anticipated benefits of this capital expenditure and, consequently, our business, financial condition and results of operations.

17. Our Promoters are not subscribing to this Issue and have confirmed their intention to renounce their entire Rights Entitlements in favour of the public at large, which may result in dilution of their shareholding in our Company.

The identity of the persons who may ultimately acquire or subscribe to the Rights Entitlements renounced by our Promoters in favour of the public at large, and the number of Rights Entitlements ultimately acquired or subscribed to by them, will not be known or disclosed in advance. Accordingly, as of the date of this Letter of Offer, investors are unable to evaluate the identity, financial strength, business background, or intentions of such persons, including whether they intend to be long-term or short-term holders of our Equity Shares, or whether they may seek Board representation or otherwise influence our governance and strategy following completion of the Issue.

There can be no assurance that the interests of persons who may ultimately acquire or subscribe to such Rights Entitlements will be aligned with the interests of our Company or our other shareholders, including in relation to matters requiring shareholder approval, dividend policy, or our long-term business strategy, including in relation to the proposed female condom manufacturing facility. Any change in our shareholding pattern or the acquisition of a significant shareholding by such persons could adversely affect our Company's governance, business strategy, or the trading price of our Equity Shares.

18. In the absence of Promoter subscription, successful completion of the Issue is significantly more dependent on subscription by public shareholders and other eligible investors.

In a typical rights issue, promoter subscription to the full extent of their entitlement provides a significant, and often decisive, contribution towards achieving minimum subscription. As our Promoters are not contributing towards subscription levels in this Issue, the entire burden of achieving the applicable minimum subscription threshold falls upon public Eligible Equity Shareholders exercising their Rights Entitlements and other eligible investors, including persons who may acquire or subscribe to the Rights Entitlements renounced by our Promoters in favour of the public at large.

Any shortfall in subscription by public Eligible Equity Shareholders or other eligible investors, without an offsetting contribution from our Promoters, meaningfully increases the risk that the minimum subscription

requirement applicable to this Issue, as described in risk factor 28 below, will not be achieved. This risk is heightened in circumstances of adverse market conditions, weak investor sentiment towards SME-listed issuers generally, or a decline in the trading price of our Equity Shares prior to or during the Issue Period, any of which could reduce the willingness of public shareholders or other eligible investors to apply for Rights Equity Shares at the Issue Price. In the event minimum subscription is not achieved, our Company will not receive any of the Net Proceeds, and the implementation of each of our Objects would be delayed or would not proceed, as further described in risk factor 28 below.

19. The 90% minimum subscription requirement under the SEBI ICDR Regulations applies to this Issue, and if not met, all application monies will be refunded and the Issue will not proceed.

In terms of Regulation 86(1) of the SEBI ICDR Regulations, a rights issue is, in general, required to receive minimum subscription of 90% of the Issue. The proviso to Regulation 86(1) exempts an issuer from this requirement only where (i) the objects of the issue involve financing other than financing of capital expenditure for a project, and (ii) the promoters and promoter group undertake to subscribe fully to their portion of the rights entitlement and do not renounce their rights except within the promoter group or to specific investor(s) disclosed by the issuer.

As our Objects include capital expenditure for a project, namely, our proposed female condom manufacturing facility, the first limb of this exemption is not satisfied, regardless of our Promoters' decision not to subscribe to their Rights Entitlements and to renounce the same in favour of the public at large under the applicable renunciation mechanism. Accordingly, our Company does not qualify for the exemption under the proviso to Regulation 86(1), and the standard requirement of 90% minimum subscription, as set out under Regulation 86(1) of the SEBI ICDR Regulations, applies to this Issue.

In the event minimum subscription of 90% of the Issue is not achieved, in accordance with Regulation 86(2) of the SEBI ICDR Regulations, our Company will be required to refund all application monies received from investors forthwith, but not later than four days from the closure of the Issue, and the Issue will not proceed. In such an event, our Company would not receive any of the Net Proceeds, and the proposed deployment of funds towards our capital expenditure for the female condom manufacturing facility, our working capital requirements, and General Corporate Purposes would be correspondingly delayed or may not be undertaken at all, which may adversely affect our business plans, liquidity position, growth strategy and financial condition.

20. A substantial portion of the Net Proceeds is proposed to be used for working capital and General Corporate Purposes, which may not result in measurable or immediate outcomes.

Out of the Net Proceeds, we propose to utilise ₹2,574.96 lakhs towards funding our short-term working capital requirements, and up to 25% of the Gross Proceeds towards General Corporate Purposes, together representing a substantial proportion of the overall Issue size. Unlike our capital expenditure Object, funds allocated to working capital and General Corporate Purposes are not earmarked for the creation of any specific identifiable asset, and will instead be deployed at our management's discretion across routine operational needs, including procurement of raw materials, financing of trade receivables, inventory holding, and other exigencies arising in the ordinary course of business, as further described in "Objects of the Issue" on page 40.

The utilisation of such funds may accordingly not result in any immediate, direct, or readily quantifiable improvement in our revenue, profitability, or the trading price of our Equity Shares, in the manner that a specific, identifiable capital asset might. Any inefficiency in the deployment of these funds, adverse changes in the market or competitive conditions in which we operate, or operational challenges in translating additional working capital into revenue growth, could diminish the anticipated benefits of this utilisation, and investors are cautioned not to assume that deployment of these funds will result in a corresponding or proportionate improvement in our financial performance.

21. Our working capital estimates are based on projected revenue growth that may not materialise.

Our estimated working capital requirement for Fiscal 2027 and Fiscal 2028, as set out in "Objects of the Issue – Funding the Working Capital Requirements of our Company" on page 45, is based on projected turnover of approximately ₹205 crore and ₹450 crore respectively, growing further to approximately ₹950 crore by Fiscal 2029. These projections are driven by a combination of factors, including anticipated growth in orders from Government procurement agencies and AIDS Control Societies, continued growth in sales under our own brands, our recently commissioned additional manufacturing capacity for male condoms, and the anticipated commissioning and scale-up of our proposed female condom manufacturing facility.

Each of these growth drivers is subject to significant uncertainty. Our ability to secure and execute Government

tenders is dependent on factors outside our control, including budgetary allocations and procurement policy; our own-brand growth is dependent on continued market acceptance and competitive dynamics; and our female condom facility is a new product category for us, the commissioning and ramp-up of which is subject to the execution risks described in risk factor 31 below. If actual revenue growth over Fiscal 2027 to Fiscal 2029 is lower than currently projected, our actual working capital requirements, including our holding periods for trade receivables, inventory and trade payables, may differ materially from our current estimates. In such an event, the amount allocated under this Object may prove excessive relative to our actual needs, or, if our estimates understate our requirements, insufficient, either of which could require us to revise our business plan or seek additional working capital financing through other means.

22. Our entry into female condom manufacturing is a new product category for us, and any delay or failure in successfully commissioning or scaling this facility could adversely affect the returns expected from this Object.

While our Company holds a patent for the process of manufacturing advanced latex and synthetic female condom production systems, and has an established track record in the manufacture of male condoms, we have not previously manufactured female condoms at a commercial scale. The manufacturing process for female condoms, including the specific machinery, moulds, and quality control procedures involved, differs from our existing male condom manufacturing process, and successful commercialisation will require us to achieve the manufacturing quality, consistency, and production efficiency necessary to compete in this segment.

In addition, our ability to sell female condoms in both domestic and international markets, including through government procurement channels, may require us to obtain specific regulatory certifications, including WHO/UNFPA pre-qualification, as referenced under "Objects of the Issue – Funding of General Corporate Purposes" on page 49. There can be no assurance as to the timeline on which such certifications will be obtained, or that we will obtain them at all.

Any delay in commissioning our proposed facility, any inability to achieve our anticipated production volumes or product quality standards, any delay in obtaining requisite regulatory certifications, or any failure to achieve market acceptance for our female condom products, whether in India or in export markets, may adversely affect our ability to realise the anticipated revenue and returns from this capital expenditure, and consequently our business, financial condition, results of operations and cash flows.

23. Our proposed female condom facility and a portion of our growth strategy are dependent on export demand and international market conditions, which are outside our control.

Our Company has, during the current financial year, commenced international business operations and received export orders aggregating approximately ₹48.50 crore from customers in South Africa, with deliveries scheduled to be completed by September 2026, and anticipates further export orders aggregating approximately ₹50.00 crore over the following six months, primarily for the supply of female condoms. Our proposed female condom manufacturing facility is intended to cater primarily to international markets, given the significant global supply-demand gap in this segment, estimated at approximately 700 million to 1.5 billion pieces annually.

Our ability to realise the anticipated returns from this capital expenditure is accordingly linked to factors outside our control, including the level of international demand for female condoms, currency fluctuations affecting the Rupee realisation from our export sales, changes in trade policy or import tariffs in destination countries, and the import, quality certification and regulatory requirements applicable in each such jurisdiction. Any adverse development in any of these areas, or our inability to secure anticipated export orders at the volumes or pricing currently assumed in our revenue projections, could adversely affect our ability to realise the anticipated benefits of this Object, and consequently our business, financial condition and results of operations.

24. Reduction in issue size or ratio to avoid fractional entitlements may marginally restrict the funds available under the Objects.

The rights entitlement ratio applicable to this Issue is required to be structured such that Eligible Equity Shareholders' entitlements do not result in fractional Rights Entitlements, and such that the resultant Rights Equity Shares can be traded and allotted in whole market lots on the SME Platform of NSE Limited, being 200 Equity Shares per lot. In order to satisfy this requirement while remaining within our overall fund-raising cap, our Company may be required to finalise a rights entitlement ratio and consequent issue size that results in aggregate Net Proceeds marginally lower than the maximum amount otherwise permissible.

While such a ratio enhances the ease of allotment, post-Issue tradability, and settlement of Rights Equity Shares, and avoids the administrative and cost burden associated with disposal of odd lots, it may result in a modest shortfall between the funds we are able to raise through this Issue and the funds required to fully implement each of our Objects at the scale currently contemplated. Any such shortfall may require us to fund the difference through internal accruals, or, if internal accruals prove insufficient, to scale back, defer, or reprioritise among our Objects, or to seek

additional financing through other means, which may not be available on favourable terms, or at all.

25. Deployment of the Net Proceeds is at the discretion of our Board and is not subject to independent monitoring beyond the statutory threshold.

Deployment of the Net Proceeds within the broad parameters set out under "Objects of the Issue" on page 40. is entirely at the discretion of our Board or a duly constituted committee thereof, subject only to the overall limits prescribed under the SEBI ICDR Regulations, including the 25% cap on utilisation towards General Corporate Purposes. Beyond the periodic reporting obligations of our Monitoring Agency, Infomerics Valuation and Rating Limited, appointed under Regulation 82 of the SEBI ICDR Regulations, and the disclosures required to be made to our Audit Committee and the Stock Exchange under the SEBI LODR Regulations, the manner, timing and quantum of deployment of the Net Proceeds is not subject to independent third-party oversight or appraisal.

Any revision to the deployment schedule set out under "Objects of the Issue," including reallocation of funds between our capital expenditure, working capital and General Corporate Purposes Objects, may be undertaken with only the approval of our Board, in accordance with applicable law, without requiring fresh shareholder approval in most circumstances. Accordingly, there can be no assurance that the actual deployment of the Net Proceeds will not differ, potentially materially, from our currently stated business plan and the estimates set out in this Letter of Offer, and prospective investors must rely on the collective judgment of our management and Board in this regard.

26. Any inability of our Monitoring Agency to continue monitoring utilisation of the Net Proceeds could reduce the transparency of fund deployment to our shareholders.

We have appointed Infomerics Valuation and Rating Limited as our Monitoring Agency, in accordance with Regulation 82 of the SEBI ICDR Regulations, to monitor the utilisation of the Gross Proceeds of this Issue and to submit periodic reports to our Audit Committee in this regard, as described under "Objects of the Issue – Monitoring Utilisation of Funds from the Issue" on page 50.

Any termination of this engagement, resignation by the Monitoring Agency, or any circumstance in which the Monitoring Agency is unable to continue discharging its obligations whether on account of regulatory action against the Monitoring Agency, conflict of interest, or otherwise could result in a period during which utilisation of the Net Proceeds is not subject to independent monitoring, until such time as our Company identifies and appoints a replacement Monitoring Agency in compliance with applicable SEBI regulations. During any such interim period, the transparency and independent verification ordinarily afforded to our shareholders in relation to the deployment of the Net Proceeds may be reduced, and our shareholders would be required to rely more heavily on our Board's own representations regarding fund utilisation until a replacement is appointed and reporting resumes.

27. We may be unable to complete the manufacture, purchase, and installation of proposed machinery within our estimated timelines.

The activity-wise implementation schedule for our proposed capital expenditure, including foundation work for machine installation, placement of purchase orders, delivery of machinery, and installation and commissioning, as set out under "Objects of the Issue Activity-wise Completion Schedule" on page 40, is dependent on a number of sequential steps, each of which is subject to its own timing risk. As of the date of this Letter of Offer, our Company has not placed purchase orders for any of the identified machinery, and the schedule is accordingly contingent upon the date of Board approval of the Objects, the timing of receipt of the Net Proceeds, and the delivery timelines separately committed to by each of our vendors.

Delays on account of vendor non-performance, disruptions in the supply chain or logistics network (including for imported components), delays in obtaining any applicable regulatory or environmental approvals for our expanded facility, or other factors beyond our control, including those described in risk factor 24 above, could delay the commissioning of our proposed female condom manufacturing facility beyond our currently estimated timelines. Any such delay would correspondingly postpone the anticipated commercial benefits of this capital expenditure, including the incremental revenue contemplated in our working capital and revenue projections, and could adversely affect our business, financial condition, results of operations and cash flows.

28. Public shareholders who do not subscribe to or renounce their Rights Entitlements may experience dilution.

Eligible Equity Shareholders as on the Record Date who do not apply for Rights Equity Shares pursuant to their Rights Entitlement within the Issue Period, and who do not renounce their Rights Entitlement in favour of a Renouncee, will not receive any Rights Equity Shares in this Issue. To the extent such Rights Entitlements are otherwise subscribed, whether by other Eligible Equity Shareholders applying for additional Rights Equity Shares, Renouncees, or the specific investor(s) to whom our Promoters have renounced their entitlements, such non-participating shareholders will experience a reduction in their proportional shareholding and voting interest in our

Company upon completion of the Issue.

Given that our Promoters are not subscribing to this Issue, the relative impact of public shareholder participation on the ultimate post-Issue shareholding pattern is more significant than would ordinarily be the case, and shareholders who do not exercise or renounce their Rights Entitlements should be aware that their proportional ownership may accordingly be diluted to a greater extent than in a rights issue where promoters subscribe fully.

29. Investors will be subject to market risk between payment for Rights Equity Shares and the commencement of trading.

Investors who apply for and are Allotted Rights Equity Shares in this Issue will be able to trade such Rights Equity Shares only after they have been credited to the investor's demat account and such Equity Shares have been listed and permitted to trade on the SME Platform of NSE Limited. Since payment for Rights Equity Shares (through the ASBA process) occurs prior to Allotment, and Allotment in turn precedes listing and the grant of trading approval, there is an inherent time gap during which an investor's funds are committed to the Issue Price without the ability to trade out of the position.

Investors will accordingly be subject to market risk, including the risk of a decline in the trading price of our Equity Shares below the Issue Price, throughout this period, and there can be no assurance that trading approval will be granted by NSE in a timely manner, or that the Rights Equity Shares Allotted to an investor will be credited to the investor's demat account without delay, notwithstanding the timelines prescribed under the SEBI ICDR Master Circular.

30. Our Company will not distribute the Letter of Offer to overseas shareholders who have not provided an Indian address for service of documents.

In accordance with applicable restrictions on the circulation of offer materials in various overseas jurisdictions, our Company will not distribute the Letter of Offer, the Application Form, the Rights Entitlement Letter or other Issue Materials to Eligible Equity Shareholders who have not provided a valid address in India, or the address of a duly authorised representative in India, for service of documents. Where an Eligible Equity Shareholder has provided a valid e-mail address to our Company, Issue Materials will be sent to such e-mail address; where no e-mail address has been provided, Issue Materials will be dispatched, on a reasonable effort basis, only to the Indian address on record.

Eligible Equity Shareholders whose registered address is outside India, and who have not updated their records with our Company or the Registrar to provide an Indian address prior to the relevant cut-off date, will accordingly not receive the Issue Materials and may, as a practical matter, be unable to participate in this Issue, notwithstanding their entitlement to do so as a shareholder of our Company as on the Record Date, resulting in dilution of their shareholding to the extent they are unable to exercise or renounce their Rights Entitlements.

31. Overseas shareholders, including those with a registered address in the United States, may be unable to participate in this or future rights offerings by our Company.

Our Equity Shares have not been and will not be registered under the U.S. Securities Act or the securities laws of any state of the United States, and any offer of rights to holders of Equity Shares with a registered address in the United States would require either an effective registration statement under the U.S. Securities Act, or an available exemption from such registration requirement. Our Company has no obligation to prepare, file, or maintain any such registration statement in connection with this Issue or any future rights offering.

Accordingly, shareholders with a registered address in the United States may be unable to participate in this Issue, or in any future rights offering undertaken by our Company, and may as a result experience dilution of their proportionate shareholding without recourse, other than to the extent our Company elects, at its discretion, to make alternative arrangements (such as disposal of the relevant rights or securities for the benefit of such holders, on terms that cannot be predicted in advance).

32. Foreign investment restrictions under Indian law may limit our ability to attract foreign investors.

Under the foreign exchange regulations currently in force in India, transfers of Equity Shares between residents and non-residents, and issuances of Equity Shares to non-residents (including in connection with any renunciation of Rights Entitlements to a specific investor who is a non-resident), are freely permitted, subject to compliance with the pricing guidelines, sectoral caps and other requirements prescribed by the RBI under FEMA and rules made thereunder. Where such transfers or issuances do not fall within the prescribed exceptions, prior approval of the RBI is required.

We cannot assure you that our interpretation of the applicable foreign exchange regulations, including in connection with the specific investor mechanism under this Issue, will be upheld by Indian regulatory authorities, and any

adverse change in regulatory interpretation, or delay in obtaining any requisite RBI approval, could affect our Company's ability to attract foreign investors, whether as specific investor(s) under this Issue or otherwise. In addition, shareholders seeking to repatriate sale proceeds from India will require a no-objection or tax clearance certificate from the income tax authorities, and the Government of India retains the power to impose foreign exchange restrictions in certain emergency situations, any of which could adversely affect foreign investor participation in, and consequently the market price of, our Equity Shares.

33. Any future issuance of Equity Shares, including to the specific investor(s) under this Issue, or sales by significant shareholders, may affect the trading price of our Equity Shares.

Following completion of this Issue, our Company may, in the future, undertake further issuances of Equity Shares, convertible securities, or securities linked to our Equity Shares, whether by way of preferential allotment, further rights issue, or otherwise. In addition, the specific investor(s) who are Allotted Rights Equity Shares pursuant to the renunciation by our Promoters under this Issue, and any of our Promoters, Promoter Group members, or other significant shareholders, may, at their discretion and subject to applicable lock-in or other regulatory restrictions, if any, sell, pledge, or otherwise encumber their Equity Shares in the future.

Any such future issuance or sale, or any market perception that such an issuance or sale is likely to occur particularly given the currently undisclosed identity and intentions of the specific investor(s) under this Issue, as described in risk factor 26 above could dilute existing shareholders and adversely affect the trading price of our Equity Shares, our ability to raise further capital on favourable terms, and overall investor confidence in our Company, regardless of our underlying operating performance.

34. Rights of shareholders under Indian law may differ from, or be more limited than, rights under the laws of other jurisdictions.

The corporate affairs of our Company are governed by the Companies Act, the rules and regulations issued by SEBI and other applicable regulatory authorities, and our Memorandum and Articles of Association. Indian legal principles relating to these matters, including the validity of corporate procedures, directors' fiduciary duties and liabilities, and shareholders' rights and remedies, may differ, potentially materially, from the principles that would apply to a company incorporated in another jurisdiction. Under the Companies Act, the voting rights of an equity shareholder are required to be in proportion to such shareholder's share in the paid-up equity share capital of our Company, subject to Section 106(1) of the Companies Act, which permits our Articles to restrict voting rights in respect of shares on which calls or other sums payable remain unpaid, or over which our Company has exercised a right of lien.

Further, while the Companies Act generally requires an Indian company to offer pre-emptive rights to existing equity shareholders in proportion to their shareholding prior to any new issuance of equity shares (as is being done through this Issue), unless such pre-emptive rights are waived by special resolution, investors resident in jurisdictions that do not permit the exercise of such pre-emptive rights without our Company filing an offering document or registration statement with the relevant authority in that jurisdiction will be unable to exercise their pre-emptive rights unless we elect to make such a filing, which we may not do. In such circumstances, and to the extent new securities are instead issued to a custodian for disposal on behalf of such investors, the value ultimately realised, and the transaction costs associated therewith, cannot be predicted in advance, and such investors' proportional interest in our Company would, in any event, be diluted.

EXTERNAL RISK FACTORS

Risk Relating to India

35. Escalation of geopolitical conflicts involving the United States, Israel, Iran and other countries may adversely affect the Indian economy, financial markets and our business.

Recent geopolitical developments, including the ongoing Russia-Ukraine conflict, military actions and heightened tensions involving the United States, Israel and Iran, as well as increasing geopolitical tensions in other regions, have contributed to uncertainty in global financial markets. Any escalation of such conflicts may disrupt global trade, supply chains and international capital flows, including our supply of imported raw materials (such as latex) and our export operations to international markets, including South Africa.

Geopolitical instability may result in volatility in commodity prices, disruptions in shipping routes, increased freight and insurance costs, inflationary pressures and fluctuations in foreign exchange rates. India is substantially dependent on imports of crude oil and certain other essential commodities, and any disruption in global energy markets may adversely affect India's inflation, fiscal position and exchange rate stability, in turn increasing our input and operating costs. Heightened geopolitical uncertainty may also increase volatility in Indian capital markets and reduce availability of capital, adversely affecting our business, financial condition and the trading price of our Equity Shares.

36. A downgrade in India's sovereign credit ratings may affect the trading price of our Equity Shares.

Our borrowing costs and access to debt capital markets depend significantly on India's sovereign credit ratings. Any adverse revision to India's credit ratings by international rating agencies may adversely impact our ability to raise financing and the terms on which such financing is available. A downgrade may occur due to changes in government tax or fiscal policy, or other factors outside our control, which could adversely affect our ability to fund our growth — including our proposed female condom manufacturing facility on favourable terms.

37. If the rate of Indian price inflation increases, our business and results of operations may be adversely affected.

Inflation rates in India have historically been volatile, increasing costs such as rent, personnel costs, and raw material prices, including natural rubber latex and other chemical inputs central to our manufacturing process. If we are unable to accurately estimate or control such costs, or to pass on increased costs to our institutional and government customers (whose pricing is often fixed under tender terms), our margins and results of operations may be adversely affected.

38. As a listed company, our Company is subject to obligations and reporting requirements under the SEBI Listing Regulations, and any non-compliance may render us liable to penalties.

The Equity Shares of our Company are listed on the SME Platform of NSE. We are accordingly subject to the obligations and reporting requirements prescribed under the SEBI LODR Regulations and other applicable SEBI regulations. While we strive to meet these obligations, we cannot assure you there will be no non-compliance in future our Company has previously been subject to a penalty levied by NSE for delayed disclosure, as set out in "Other Regulatory and Statutory Disclosures" on page 62 and any further regulatory action could affect our reputation, divert management attention, and adversely affect our business and the trading price of our Equity Shares.

39. Natural calamities, climate change and health epidemics or pandemics could adversely affect our business, financial condition and results of operations.

Natural calamities such as floods or earthquakes could disrupt our manufacturing operations at our facility in Noida, damage our assets, or disrupt our supply chain. Separately, our Company's own products are positioned around public health objectives the prevention of HIV/AIDS and unintended pregnancies and any future health epidemic or pandemic could affect demand for our products in either direction: reduced economic activity and disrupted distribution may adversely affect sales, while, as was observed during the COVID-19 pandemic in relation to related contraceptive and protective-equipment demand, certain health crises may also affect government procurement priorities and budgets in ways that are difficult to predict.

40. Changing laws, rules and regulations and legal uncertainties may adversely affect our business, and failure to comply with existing laws could subject us to enforcement action.

Our business is governed by various laws and regulations, including the Micro, Small and Medium Enterprises Development Act, 2006, the Sale of Goods Act, 1930, the Delhi Shops and Establishments Act, 1954 (applicable to our registered office) and the Uttar Pradesh Shops and Commercial Establishments Act (applicable to our manufacturing facility in Noida), the Biomedical Waste Management Rules, applicable pollution control and environmental regulations administered by the Uttar Pradesh Pollution Control Board, and various laws relating to employment. Taxation and securities laws have been increasing in stringency and may become more stringent. Any failure to comply with applicable laws could subject us to enforcement actions and penalties, and changes in law, or political instability affecting the pace of economic liberalisation, could adversely affect our business, financial condition and results of operations.

41. We are subject to regulatory, economic, social and political uncertainties and other factors beyond our control.

We are incorporated in India, conduct our business in India, and our Equity Shares are listed on the SME Platform of NSE. Our business, operations and the market price of our Equity Shares may accordingly be affected by factors including exchange rate fluctuations and currency controls (relevant given our export operations), scarcity of credit or financing in India, prevailing income conditions among our institutional and consumer customers, public health developments in India or globally, macroeconomic factors and interest rate movements, volatility in Indian stock exchanges, decline in India's foreign exchange reserves, downgrading of India's sovereign debt rating, and difficulty in developing necessary business partnerships on commercially acceptable terms.

42. In the event we undertake future acquisitions, mergers or similar corporate actions, we may be affected by the Competition Act, 2002, and any adverse application or interpretation could adversely affect our

business.

The Competition Act, 2002 prohibits practices having an appreciable adverse effect on competition in India, including agreements involving determination of prices or market-sharing, and abuse of a dominant position. Acquisitions of shares, assets, or mergers crossing prescribed asset and turnover thresholds require mandatory notification to and approval by the Competition Commission of India. The Competition (Amendment) Act, 2023 has introduced deal value thresholds, expedited review timelines, and enhanced penalties for non-disclosure, which may result in additional compliance costs for any future corporate actions we undertake, including in relation to our Subsidiary or Group Companies.

43. Companies operating in India are subject to a variety of taxes and surcharges, which are subject to change.

We are subject to central and state taxes and levies, including income tax, GST, stamp duty, tax on dividends, and other special taxes and surcharges introduced from time to time. The Indian tax scheme is extensive and subject to change; any future increase in corporate tax rates or introduction of new levies may affect our tax efficiency and result in significant additional tax liability, adversely affecting our cash flows and results of operations.

44. Changes in technology may render our current manufacturing processes or products less competitive, or require us to make substantial capital investments.

The condom manufacturing industry is subject to continual technological change, including advances in latex and non-latex materials, testing methodologies (such as electronic pinhole testing under ISO 4074), and automation. Although we strive to upgrade our technology and machinery including through our proposed investment in automated dipping, curing and testing equipment for our female condom facility we cannot assure you that we will keep pace with technological developments, that our investments will perform as expected, or that competitors' technology will not render our products less competitive. The cost of implementing new technology could be significant and may adversely affect our financial condition and results of operations.

45. We are dependent on the availability and price of natural rubber latex and other key raw materials, which are subject to price volatility.

Our manufacturing process is dependent on natural rubber latex and various chemical inputs, prices of which are subject to fluctuation based on global commodity markets, weather conditions affecting rubber cultivation, and currency movements given a portion of our raw materials may be imported. Any sustained increase in the price of latex or other key inputs, without a corresponding ability to pass on such costs particularly given fixed pricing under government tender contracts may adversely affect our margins and results of operations.

46. A significant portion of our revenue is derived from government procurement agencies and AIDS Control Societies, and any change in government health policy, procurement practices, or budgetary allocation could adversely affect our business.

Government procurement agencies and AIDS Control Societies represented a substantial portion of our revenue, including approximately ₹3,453.22 lakhs in Fiscal 2025 and 5724.04 Lakhs in Fiscal 2026. Our participation in government tenders is dependent on prevailing government policy on contraceptive and public health procurement, budgetary allocations, and our continued eligibility (including as an MSME) to participate in and win such tenders. Any adverse change in government health policy priorities, reduction in procurement budgets, or loss of MSME or other eligibility status could adversely affect this revenue stream and our overall financial performance.

47. We are subject to extensive environmental, health and safety regulations relevant to our chemical- and rubber-based manufacturing process.

Our manufacturing process involves the use of chemicals, including vulcanising agents, activators and other compounds, and is subject to environmental regulations governing effluent discharge, hazardous waste, and workplace safety, administered by the Uttar Pradesh Pollution Control Board and other authorities. Any change in such regulations, or any finding of non-compliance, could require us to incur additional compliance costs, modify our manufacturing processes, or could result in penalties, any of which could adversely affect our business and results of operations.

48. Our export operations expose us to risks arising from the import regulations and public health policies of destination countries.

We have received export orders from customers in South Africa and anticipate further export orders, primarily for male condoms. Our ability to complete such exports, and to expand into additional export markets, is dependent on satisfying the import, quality certification (including WHO/UNFPA pre-qualification) and regulatory requirements of destination countries, as well as those countries' own public health procurement policies and

budgets, over which we have no control. Any adverse change in such requirements or policies could adversely affect our export revenue and growth plans.

49. We may face increasing competition from both organised and unorganised players in the condom manufacturing industry, which could affect our market share and margins.

We compete with other domestic and international manufacturers of male and female condoms, including large organised players with greater financial resources, as well as unorganised regional manufacturers competing primarily on price. Increased competition, including from new entrants attracted by growing demand for contraceptive products in India, may require us to reduce prices or increase spending on marketing and product development, which could adversely affect our margins and profitability.

50. Currency fluctuations may adversely affect the cost of imported raw materials and capital equipment, and the realisation from our export revenue.

To the extent our raw materials or capital equipment (including machinery for our proposed female condom facility) are imported, and our export sales are denominated in foreign currency, fluctuations in the exchange rate between the Indian Rupee and relevant foreign currencies may increase our costs or reduce the Rupee value of our export realisations, adversely affecting our margins and results of operations.

51. Our patent for female condom manufacturing technology may not provide the competitive protection we anticipate, and we may face challenges in enforcing or maintaining it.

We hold a patent for the process of manufacturing advanced latex and synthetic female condom production systems, which we believe supports our proposed expansion into this segment. There can be no assurance that this patent will not be challenged, that it will provide effective protection against competitors developing similar processes, or that we will be able to enforce it cost-effectively. Any erosion of this competitive advantage could adversely affect the anticipated returns from our proposed capital expenditure.

52. Attracting and retaining a skilled and unskilled workforce, particularly for our expanding manufacturing operations, may be challenging.

Our operations are dependent on a workforce of 430 employees, the substantial majority of whom are workmen involved in manufacturing operations. As we expand our facility to include female condom production, we will need to recruit and train additional skilled and unskilled personnel. Any inability to attract, train or retain adequate personnel, or any labour unrest, could disrupt our manufacturing operations and adversely affect our business and results of operations.

53. Our insurance coverage may not be adequate to protect us against all losses, and any uninsured loss could adversely affect our financial condition.

While we maintain insurance policies covering certain risks, including burglary, stock and machinery, and marine cargo, our insurance may not cover all risks, including product liability, business interruption, or losses arising from fire, terrorism or certain other events. Any uninsured or inadequately insured loss, including damage to our manufacturing facility or machinery, could require us to incur significant unplanned expenditure and adversely affect our business, financial condition and results of operations.

54. Political or regulatory developments specific to the healthcare and contraceptive products sector may adversely affect our business.

Our products are subject to sector-specific regulatory oversight relating to medical devices, quality standards and, in the case of government procurement, compliance with tender-specific labelling and packaging requirements. Any adverse change in the regulatory classification, quality standards, or government policy applicable to contraceptive products, whether in India or in our export markets, could require us to modify our products or processes, or could adversely affect demand, and consequently our business and results of operations.

RISKS RELATING TO OUR RIGHTS EQUITY SHARES AND THIS ISSUE

55. Our funding requirements and proposed deployment of the Net Proceeds are based on management estimates and have not been independently appraised, and may be subject to change based on various factors, some of which are beyond our control.

Our funding requirements and deployment of the Net Proceeds are based on internal management estimates and current market conditions, and have not been appraised by any bank, financial institution or other independent agency. In the absence of such independent appraisal, our funding requirements may be subject to change based on various factors beyond our control. Deployment of the Net Proceeds will be at the discretion of our Board, though

monitored by our Monitoring Agency, Infomerics Valuation and Rating Limited. Accordingly, prospective investors will need to rely upon our management's judgment with respect to the use of the Net Proceeds. For details, see "Objects of the Issue" on page 40.

56. Recent changes to the regulatory framework for rights issues, including faster timelines and modified procedures, may lead to investor confusion or non-compliance, which could adversely affect the subscription process.

SEBI, through the SEBI (Issue of Capital and Disclosure Requirements) (Amendment) Regulations, 2025, notified on March 3, 2025 and published in the Official Gazette on March 8, 2025, has significantly amended the regulatory framework governing rights issues, followed by SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2025/31 dated March 11, 2025, introducing Faster Rights Issues and flexibility of allotment to specific investor(s), alongside stricter timelines and procedural requirements. This amended framework applies to all rights issues approved by the Board on or after April 7, 2025, and accordingly applies to this Issue. Investors unfamiliar with the revised process including faster turnaround times, stricter demat credit timelines, and procedural differences from earlier rights issues may face difficulty complying, and any failure to do so may result in rejected or invalid applications. For details, see "Terms of the Issue" on page 67.

57. Applicants to this Issue are not allowed to withdraw their Applications after the Issue Closing Date.

In terms of the SEBI ICDR Regulations, Applicants are not permitted to withdraw Applications after the Issue Closing Date. There is no assurance that material adverse changes in national or international economic conditions, or other events, will not arise between the Issue Closing Date and Allotment. Should the market price of our Equity Shares decline below the Issue Price during this period, Applicants will be required to complete their purchase at the Issue Price regardless, resulting in an immediate unrealised loss, and we may complete Allotment notwithstanding such events.

58. Failure to exercise or sell the Rights Entitlements will cause them to lapse without compensation and result in dilution of shareholding.

Rights Entitlements not exercised prior to the Issue Closing Date will lapse without any consideration to the holder. Eligible Equity Shareholders who fail to exercise their Rights Entitlements will experience dilution of their proportionate ownership and voting interest in our Company. Even where Rights Entitlements are sold, the consideration received may not fully compensate for the resulting dilution. Renouncees may also be unable to apply where off-market or on-market renunciation is not completed in time for credit to their demat account prior to the Issue Closing Date. For details, see "Terms of the Issue" on page 67.

59. Your ability to acquire and sell the Equity Shares offered in the Issue is restricted by the distribution, solicitation and transfer restrictions set forth in this Letter of Offer.

No actions have been taken to permit a public offering of the Equity Shares in any jurisdiction except India, and our Equity Shares have not and will not be registered under the U.S. Securities Act or the securities laws of any jurisdiction other than India. You are required to inform yourself of and observe these restrictions; see "Notice to Investors," "Other Regulatory and Statutory Disclosures No Offer in the United States" and "Restrictions on Purchases and Resales" on pages 09, 62, 64 and 92 respectively.

60. Eligible Equity Shareholders who have not provided an Indian address will not receive the Issue Materials and may be unable to participate.

Our Company will not distribute Issue Materials to shareholders who have not provided a valid address in India, on account of circulation restrictions applicable in various overseas jurisdictions. Such shareholders may accordingly be excluded from participating in this Issue notwithstanding holding Equity Shares as of the Record Date.

61. Any future issuance of Equity Shares by our Company may dilute your shareholding and adversely affect the trading price of our Equity Shares.

Any future issuance of Equity Shares, whether to specific investor(s) pursuant to this Issue or otherwise, may dilute your shareholding and adversely affect the trading price of our Equity Shares, potentially affecting our ability to raise capital in the future or investors' perception of such future issuances.

62. Our Equity Shares may experience price and volume fluctuations.

The market price of our Equity Shares may be volatile due to factors beyond our control, including volatility in Indian and global securities markets, our results of operations, competitor performance, developments in the healthcare and consumer products sector, investor perceptions of our future performance, and significant developments in India's economic and fiscal policies. The Stock Exchange itself may also experience significant

price and volume fluctuations affecting the market price of our Equity Shares. Investors should not rely on recent trends to predict future performance.

63. No market for the Rights Entitlements may develop, and their price may be volatile.

No assurance can be given that an active trading market for Rights Entitlements will develop on NSE during the Renunciation Period, or that sufficient liquidity will exist. The price of Rights Entitlements will depend on supply and demand specific to Rights Entitlements as well as the quoted price of our Equity Shares; a decline in our Equity Share price will adversely affect the trading price of Rights Entitlements. As Rights Entitlements trade on a separate segment from our Equity Shares, their trading may not track Equity Share trading.

64. As our Rights Equity Shares will initially be listed only on the SME Platform of NSE, they may experience lower liquidity than mainboard-listed securities.

The SME Platform of NSE (Emerge) typically experiences lower trading volumes and investor participation than the mainboard segment. Any future migration of our Equity Shares to the mainboard is subject to fulfilment of prescribed eligibility conditions under applicable SEBI regulations, and there can be no assurance that such migration will occur, or as to its timing. Limited liquidity on the SME Platform may adversely affect a shareholder's ability to sell Equity Shares, or the price realised on sale.

65. Holders of Equity Shares may be restricted in their ability to exercise pre-emptive rights under Indian law and thereby suffer future dilution.

Under the Companies Act, our Company must offer equity shareholders pre-emptive rights before issuing new equity shares, unless waived by special resolution. However, investors in jurisdictions that do not permit exercise of such rights without our filing a registration statement will be unable to exercise them unless we elect to make such a filing, which we may not do. Where new securities are instead issued to a custodian for sale on the investor's behalf, the value realised and associated costs cannot be predicted, and the investor's proportional interest in our Company would be diluted.

66. Investors may be subject to Indian taxes arising from capital gains on sale of the Rights Equity Shares.

Capital gains from the sale of equity shares in an Indian company are generally taxable in India, and securities transaction tax (STT) is levied on transfer. Long-term capital gains (holding period exceeding 12 months) exceeding ₹1,00,000 on STT-paid transactions on a recognised stock exchange are taxed at 12.5% (plus applicable surcharge and cess); gains on transfers not attracting STT are also taxed at 12.5% without indexation benefit. Short-term capital gains (holding period of 12 months or less) are taxed at 20% (plus applicable surcharge and cess), subject to STT having been paid. Relief may be available under an applicable double taxation avoidance treaty, subject to conditions; however, Indian tax treaties generally do not limit India's ability to tax capital gains, and investors may accordingly be liable to tax both in India and in their home jurisdiction. Investors are advised to consult their own tax advisors.

67. Restrictions on daily price movements of our Equity Shares may adversely affect a shareholder's ability to sell, or the price realised.

NSE may impose circuit filters or other restrictions on price movement of our Equity Shares without prior notice to us, and such restrictions may change without our knowledge. Where such restrictions apply, shareholders' ability to sell Equity Shares, or the price at which they are able to do so, may be adversely affected.

68. The Rights Entitlement of Eligible Equity Shareholders holding Equity Shares in physical form may lapse if they fail to furnish their demat account details to the Registrar in time.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Master Circular, credit of Rights Entitlements and Allotment shall be made in dematerialised form only. Our Company has opened a demat suspense escrow account, namely "ANONDITA MEDICARE LIMITED RIGHTS ISSUE SUSPENSE ESCROW DEMAT ACCOUNT," to which Rights Entitlements will be credited for Eligible Equity Shareholders holding Equity Shares in physical form as on the Record Date, and in certain other circumstances (frozen demat accounts, unclaimed suspense accounts, disputed ownership, etc.). Such shareholders must furnish requisite details (self-attested PAN, client master sheet, proof of ownership, etc.) to our Company or the Registrar no later than two clear Working Days prior to the Issue Closing Date, i.e., by Tuesday, September 15, 2026, failing which their Rights Entitlements will lapse and extinguish without any claim against our Company. For details, see "Terms of the Issue" on page 67.

69. Eligible Equity Shareholders holding Equity Shares in physical form will have no voting rights in respect of Rights Equity Shares until their demat account details are furnished and shares transferred from the suspense account.

Physical-form shareholders must furnish demat account details to the Registrar no later than two clear Working Days prior to the Issue Closing Date to enable credit at least one day before closure; failure to do so results in lapse of the Rights Entitlement. Further, pursuant to SEBI's press release dated December 3, 2018, transfers of listed Equity Shares cannot be processed in physical form (except transmission or transposition) with effect from April 1, 2019.

70. SEBI's revised regulatory framework governing rights issues introduces compressed timelines and mandatory ASBA-only applications; any failure to comply may adversely affect an investor's ability to subscribe.

SEBI's Master Circular bearing reference number HO/49/14/14(2)2026-CFD-POD2/I/4518/2026, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2025/31 dated March 11, 2025, has streamlined the rights issue process, including shorter issue timelines, revised procedures for credit and trading of Rights Entitlements, allotment mechanisms, and mandatory application through ASBA. Any failure by investors to comply with these requirements including timely demat account updates, monitoring Rights Entitlement credit, or submitting valid ASBA applications within prescribed timelines may result in rejection of their application or inability to participate.

71. The identity and shareholding impact of the specific investor(s) to whom our Promoters are renouncing their Rights Entitlements is not yet determined, and their participation could result in a concentrated shareholder base.

As disclosed in "Summary of the Letter of Offer," our Promoters do not intend to subscribe to their Rights Entitlements and instead intend to renounce them entirely to specific investor(s) under Regulation 77B of the SEBI ICDR Regulations. The identity, quantum, and resultant shareholding of such specific investor(s) will only be disclosed through a public advertisement closer to the Issue Opening Date. Investors evaluating this Issue at the time of this Letter of Offer are accordingly unable to assess the post-Issue shareholding pattern, governance influence, or alignment of interest of such specific investor(s) with our Company's other shareholders.

72. The Equity Shares may trade at a price lower than the Issue Price after listing, and shareholders who have applied for Rights Equity Shares will not be able to withdraw their applications.

The Issue Price of ₹950/- per Rights Equity Share has been determined by our Board and is disclosed in this Letter of Offer. Investors who apply for Rights Equity Shares are contractually bound to pay the Issue Price on application, and, in terms of the SEBI ICDR Regulations, are not permitted to withdraw their Applications after the Issue Closing Date, even in the event of adverse changes in market, business, or economic conditions between the Issue Closing Date and the date of Allotment.

The trading price of our Equity Shares on NSE may, at any time during this period, fall below the Issue Price on account of factors that may or may not be within our control, including volatility in the broader securities markets, our own operating performance, or investor sentiment towards our Company or the industry in which we operate. In such an event, shareholders who have applied for Rights Equity Shares would be paying a price higher than the prevailing market price for our Equity Shares, and would suffer an immediate, unrealised loss on Allotment. We cannot assure you that the trading price of our Equity Shares will not decline below the Issue Price at any point during or after the Issue Period.

73. Fractional or rounded-down Rights Entitlements arising from the Rights Entitlement ratio may result in certain shareholders receiving proportionately fewer shares than others.

Depending on the Rights Entitlement ratio finalised by our Board, shareholders whose existing holding does not divide evenly into whole Rights Entitlements may receive fractional entitlements, which will be dealt with in accordance with our Board-approved policy (including consolidation and separate Allotment to successful applicants for the fractional portion). Such shareholders may, as a result, experience marginally greater dilution than shareholders whose holdings divide evenly under the ratio.

74. Foreign investment restrictions under Indian law may limit our ability to attract foreign investors, which may adversely affect the market price of our Equity Shares.

Transfers of shares between residents and non-residents, and issuances to non-residents, are freely permitted subject to compliance with FEMA and RBI requirements; non-compliant transactions require prior RBI approval. We cannot assure you that our bona fide interpretation of applicable law will be upheld by Indian regulators, and any adverse change in interpretation could impact our ability to attract foreign investors. Additionally, repatriation of sale proceeds requires a no-objection or tax clearance certificate, and the Government of India may impose foreign exchange restrictions in certain emergency situations.

75. Rights of shareholders under Indian law may differ from, or be more limited than, rights under the laws of other jurisdictions.

Our Company's affairs are governed by the Companies Act, SEBI regulations, and our Memorandum and Articles of Association. Indian legal principles relating to directors' fiduciary duties, shareholder remedies and corporate procedure may differ from an investor's home jurisdiction. Voting rights are proportionate to paid-up equity capital held, subject to Section 106(1) of the Companies Act, which permits restriction of voting rights where calls or other sums payable remain unpaid, or where the Company has exercised a lien.

76. Continued listing of our Equity Shares on the SME Platform of NSE is subject to our ongoing compliance with applicable listing conditions, and any non-compliance could adversely affect shareholders.

Our Company is required to continue satisfying the eligibility and compliance conditions applicable to SME-listed issuers under the SEBI LODR Regulations and NSE's listing requirements. Any failure to comply including the kind of delayed disclosure that resulted in the penalty previously levied by NSE, as disclosed in "Other Regulatory and Statutory Disclosures" on page 62. could result in further penalties, restriction on trading (including a shift to trade-for-trade basis), or in more serious cases, risk to continued listing, any of which could adversely affect the market price and liquidity of our Equity Shares.

SECTION III: INTRODUCTION

THE ISSUE

The Issue has been authorized by way of resolution passed by our Board on August 01, 2026, pursuant to Section 62(1)(a) and other applicable provisions of the Companies Act, 2013. The terms and conditions of the Issue including the Rights Entitlement, Issue Price, Record Date, timing of the Issue and other related matters, have been approved by a resolution passed by our Board / Rights Issue Committee at its meeting held on August 27, 2026.

The following is a summary of the Issue. This summary should be read in conjunction with, and is qualified in its entirety by, more detailed information in the section entitled “Terms of the Issue” beginning on page 67.

Rights Equity Shares being offered by our Company	Upto 9,58,000 Rights Equity Shares
Rights Entitlement for the Rights Equity Shares	97 Rights Equity Share for every 1831 Equity Share held on the Record Date*
Fractional Entitlement	For Equity Shares being offered on a rights basis under the Issue, if the shareholding of any of the Eligible Equity Shareholders is less than 19 (Nineteen) Equity Shares or is not in multiples of 1,831 (One Thousand Eight Hundred and Thirty-One), the fractional entitlement of such Eligible Equity Shareholders shall be ignored for computation of the Rights Entitlement. However, Eligible Equity Shareholders whose fractional entitlements are being ignored as above will be given preference in the Allotment of one additional Equity Share each, if such Eligible Equity Shareholders have applied for additional Equity Shares over and above their Rights Entitlement, if any. As our Company is listed on the SME Platform of NSE, Rights Entitlements can be sold on the online mechanism of the Stock Exchange only in the market lot of 200 (Two Hundred) Rights Entitlements. Eligible Equity Shareholders holding Rights Entitlements less than the said market lot, or in a quantity that is not in multiples thereof, will accordingly be unable to sell such Rights Entitlements through the online mechanism, and may, at their discretion, renounce the same through off-market transfer in accordance with the applicable provisions of the SEBI ICDR Regulations.
Record Date	Wednesday, September 02, 2026
Face Value per Equity Share	₹10 (Rupees Ten only)
Issue Price	₹950/- per Rights Equity Share (including a premium of ₹940/- per Rights Equity Share)
Issue Size	Upto ₹9,101.00 lakhs* (Rupees Nine Thousand One Hundred and One Lakh Only)
Voting Rights and Dividend	The Equity Shares issued pursuant to this Issue shall rank pari-passu in all respects with the Equity Shares of our Company.
Equity Shares issued, subscribed, paid-up and outstanding prior to the Issue	1,80,86,618 Equity Shares. For details, see “Capital Structure” beginning on page 38.
Equity Shares outstanding after the Issue (assuming full subscription for and Allotment of the Rights Entitlement)	1,90,44,618 Equity Shares of Face value ₹ 10 (Ten) each
Security Codes for the Equity Shares	ISIN for Equity Shares:INE0VTV01012 NSE SME:758740 NSE Symbol: ANONDITA
ISIN for Rights Entitlements	INE0VTV20012
Terms of the Issue	For further information, see “ <i>Terms of the Issue</i> ” Beginning on page 67.
Use of Issue Proceeds	For further information, see “ <i>Objects of the Issue</i> ” Beginning on page 40.

For details in relation to fractional entitlements, see “Terms of this Issue – Fractional Entitlements” on page 82.

Terms of Payment

Payment Schedule is as follows:

Amount payable per Rights Equity Share	Face Value(₹)	Premium(₹)	Total amount payable per Rights Equity Share (including premium) (₹)
On Application (i.e., along with the Application Form)	10/-	940/-	950/-

GENERAL INFORMATION

Our Company was incorporated as a public limited company with the name of "Anondita Medicare Limited" under the Companies Act, 2013 vide certificate of incorporation dated March 12, 2024, issued by Registrar of Companies, Central Registration Centre, bearing CIN L22193DL2024PLC428183. Prior to this, the business of the company was run by our current promoter, Mr. Anupam Ghosh, as a sole proprietorship under the name of M/s Anondita Healthcare. Further, the entire business of M/s Anondita Healthcare, including all assets and liabilities, was transferred to our company, Anondita Medicare Limited, vide Business Transfer Agreement dated April 01, 2024. The company operates a manufacturing facility at Noida, Uttar Pradesh, with a large installed capacity and follows electronic quality testing standards. Anondita Medicare primarily caters to the domestic market, including institutional and government supply channels, and operates in the sexual wellness segment of the healthcare industry.

Key Performance Indicators (KPIs) of Company:

Particular	(Rs. crore)		
	FY24 (A)	FY25 (A)	FY26 (A)
Total Operating Income	46.43	60.51	111.69
EBITDA	9.21	18.24	41.06
PBT	5.15	14.60	36.51
PAT	3.87	10.91	26.82
Total Debt	24.01	27.39	33.27
Tangible Net worth	10.58	19.36	19.36
EBITDA Margin	19.84%	30.15%	36.77%
PAT Margin	8.28%	17.84%	23.64%

REGISTERED OFFICE

Flat No.704 Narmada Block, N6, Sec-D, Pkt-6 Vasant Kunj,
New Delhi, India-110070.

CORPORATE OFFICE

D-001, Sector 80, Gautam Budh Nagar, Noida, Uttar Pradesh 201301

CORPORATE IDENTITY NUMBER

L22193DL2024PLC428183

REGISTRATION NUMBER

428183

COMPANY SECRETARY & COMPLIANCE OFFICER

Ms. Bhawna Bisht

Address: D-001, Sector 80, Gautam Budh Nagar, Noida, Uttar Pradesh 201301

Tel: +919220322218

E-mail: secretarial@anonditamedicare.com

REGISTRAR OF COMPANIES:

Registrar of Companies, Delhi

Address: 4th Floor, IFCI Tower, 61, Nehru Place, New Delhi – 110019

Tel: 011-26235703, 26235708

Fax: 011-26235702

Email: roc.delhi@mca.gov.in

Website: www.mca.gov.in

STATUTORY AUDITOR OF THE COMPANY

M/s Jain Chopra & Company, Chartered Accountants
Address: 1960, First Floor, Outram Line, GTB Nagar, Delhi-110009
Tel: 011-42171194
E-mail: jainchopra.company@gmail.com
Peer Review Certificate No.: 024275
Firm Registration No.: 002198N
Contact Person: CA Rajesh Kumar
Designation: Partner
ICAI Membership No.: 501860

REGISTRAR TO COMPANY

MAASHITLA SECURITIES PRIVATE LIMITED

451, Krishna Apra Business Square, Netaji Subhash Place, Pitampura, Delhi - 110034, India
Tel: 011-45121795
E-mail: ipo@maashitla.com
Contact person: Mr. Mukul Agrawal
Website: www.maashitla.com
SEBI Registration No.: INR000004370
CIN: U67100DL2010PTC208725

REGISTRAR TO THE ISSUE

SKYLINE FINANCIAL SERVICES PRIVATE LIMITED

D-153A, Ist Floor, Okhla Industrial Area, Phase – I, New Delhi - 110020
Tel: 011-40450193-197
E-mail: ipo@skylinerta.com
Investor grievance ID: grievances@skylinerta.com
Contact person: Mr. Anuj Rana
Website: www.skylinerta.com
SEBI Registration No.: INR000003241
CIN: U74899DL1995PTC071324

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre- Issue or post- Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Forms, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, please see “Terms of the Issue” beginning on page 67.

DETAILS OF AUDITORS

Our Company has received the written consent of M/s Jain Chopra and Company, Chartered Accountants holding a valid peer review certificate issued by the Institute of Chartered Accountants of India (“ICAI”), vide their letter dated August 01, 2026, to the inclusion of their name in this Letter of Offer, Draft Letter of Offer, the Application Form, and other issue-related documents, in respect of (i) the statement of special tax benefits available to our Company and its shareholders dated August 01, 2026; and (ii) the certificates issued by them in their capacity as Independent Chartered Accountants to our Company, and such consent has not been withdrawn as of the date of this Letter of Offer.

BANKER TO THE ISSUE

Axis Bank Limited
Address: 3rd Floor, Trishul Opp.Samrtheswar Temple, Law Garden, Ellis Bridge, Ahmedabad 380 006
Contact Person: Mr. Ram Sharan Singh
Website: www.axisbank.com
E-mail: Ram1.Singh@axis.bank.in
SEBI Registration No.: INBI00000017

Self-Certified Syndicate Banks (“SCSBs”)

The list of banks that have been notified by SEBI to act as the SCSBs for the ASBA process is provided on the website of

SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34 and updated from time to time. For a list of branches of the SCSBs named by the respective SCSBs to receive the ASBA Forms from the Designated Intermediaries, please refer to the above-mentioned link.

CREDIT RATING

As there is no Issue of convertible debt instruments, there is no credit rating required for Issue.

DEBENTURE TRUSTEE

As there is no issue of convertible debt instruments, the appointment of a debenture trustee is not required for the Issue.

MONITORING AGENCY

Our Company has appointed a monitoring agency, in accordance with Regulation 82 of the SEBI ICDR Regulations, prior to filing of the Letter of Offer with the Stock Exchange.

Infomerics Valuation and Rating Limited.

Flat No. 104/108, First Floor, Golf Apartments, Sujan Singh Park,

Maharishi Ramanna Marg, New Delhi-110003

E-mail: vineet@infomerics.com

Investor grievance ID: SEBI_investorgrievance@infomerics.com

Contact person: Mr. Vineet Kumar

Website: www.infomerics.com

SEBI Registration No.: IN/CRA/007/2015

BOOK BUILDING PROCESS

As the Issue is a rights issue, the Issue shall not be made through the book building process.

MINIMUM SUBSCRIPTION

In terms of Regulation 86(1) of the SEBI ICDR Regulations, a minimum subscription of 90% of the Issue is required to be received. The provision exempting an issuer from this requirement is available only where the objects of the issue do not involve financing of capital expenditure for a project, and the Promoters undertake to subscribe fully to their Rights Entitlement and do not renounce their rights except within the Promoter Group or to specific investor(s) disclosed by the issuer. As the objects of this Issue include capital expenditure towards our Company's proposed female condom manufacturing facility, the aforesaid exemption is not available to our Company, and the requirement of minimum subscription of 90%, as set out under Regulation 86(1) of the SEBI ICDR Regulations, shall be applicable to this Issue.

In accordance with Regulation 86(2) of the SEBI ICDR Regulations, in the event of non-receipt of the minimum subscription referred to above, all Application monies received shall be refunded to the respective Applicants forthwith, but not later than four days from the Issue Closing Date.

UNDERWRITING

This Issue is not underwritten.

FILING

A copy of this Letter of Offer has been filed with the National Stock Exchange of India Limited, being the Designated Stock Exchange, and with the Securities and Exchange Board of India for information and dissemination on its website along with the fee specified in Schedule III, as required under Regulation 71 of the SEBI ICDR Regulations, the SEBI ICDR Master Circular, and other applicable circulars issued by SEBI from time to time.

CAPITAL STRUCTURE

The Capital Structure of our Company before the Issue and after giving effect to the Issue, as at the date of this Letter of Offer, is set forth below:

(In ₹ Lakhs, except share data)

No.	Particulars	Aggregate Nominal Value	Aggregate Value at Issue Price
A	Authorised Share Capital		
	2,00,00,000 Equity Shares of ₹10 each	2,000.00	--
B	Issued, Subscribed & Paid-up Share Capital prior to the Issue		
	1,80,86,618 Equity Shares of ₹10 each*	1,808.66	--
C	Present Issue in terms of this Letter of Offer**		
	Up to 9,58,000 Rights Equity Shares of face value ₹10 each ⁽¹⁾	95.80	Up to 9,101.00
D	Issued, Subscribed & Paid-up Share Capital after the Issue⁽²⁾		
	1,90,44,618 Equity Shares of face value ₹10 each	1,904.46	1,80,923.87
E	Securities Premium Account		
	Before the Issue		5,721.73
	After the Issue		14,726.93

*Excludes 2,85,000 outstanding convertible warrants of our Company. In the event such warrants are converted into Equity Shares prior to the Record Date, the issued, subscribed and paid-up share capital prior to the Issue, and consequently the Rights Entitlement ratio, shall stand revised accordingly.

**Assuming full subscription for and Allotment of the Rights Equity Shares and subject to finalisation of the Basis of Allotment.

(1) The Issue has been authorised by our Board pursuant to a resolution dated August 01, 2026. The terms of the Issue, including the Record Date and the Rights Entitlement ratio, have been approved by a resolution passed by our Board of Rights Issue Committee at its meeting held on August 27, 2026.

(2) Assuming full subscription for and Allotment of the Rights Equity Shares and subject to finalisation of the Basis of Allotment.

Notes to the Capital Structure:

1. The Company does not have any employee stock option scheme or employee stock purchase scheme.
2. As on the date of this Letter of Offer, our Company has 2,85,000 outstanding convertible warrants, which would entitle the holder(s) thereof to acquire further Equity Shares upon conversion. Other than the aforesaid warrants, our Company does not have any outstanding options, convertible loans, debentures or other securities convertible at a later date into Equity Shares.
3. All Equity Shares are fully paid-up and there are no partly paid Equity Shares outstanding as on the date of this Letter of Offer, except 2,85,000 convertible warrants allotted to Mr. Anupam Ghosh, Promoter of our Company, which remain outstanding and unconverted as on the date of this Letter of Offer.
4. At any given time, there shall be only one denomination of the Equity Shares.
5. Our Company has not issued any Equity Shares for consideration other than cash in the one year preceding the date of filing of this Letter of Offer.
6. No Equity Shares or Convertible Securities have been acquired by our Promoters or Promoter Group in the one year immediately preceding the date of filing of this Letter of Offer with the Designated Stock Exchange, except 2,85,000 convertible warrants were allotted to Mr. Anupam Ghosh, Promoter of our Company on July 08, 2026. If such allotment occurred within the one-year period preceding the date of filing of this Letter of Offer, the same shall require disclosure herein.
7. The ex-rights price of the Equity Shares, arrived at in accordance with Regulation 10(4)(b) of the SEBI Takeover Regulations, is ₹1106.54 per Equity Share.

8. Shareholding pattern of our Company as per the last filing with the Stock Exchange in compliance with the provisions of the SEBI Listing Regulations:

1. The shareholding pattern of our Company as on March 31, 2026 can be accessed on the website of The National Stock Exchange of India Limited (NSE) at <https://www.nseindia.com/companies-listing/corporate-filings-shareholding-pattern?symbol=ANONDITA&tabIndex=sme#>
2. The statement showing holding of Equity Shares of persons belonging to the category “Promoters and Promoter Group,” including details of lock-in, pledge and encumbrance thereon, as on March 31, 2026, can be accessed on the website of NSE at <https://www.nseindia.com/companies-listing/corporate-filings-shareholding-pattern?symbol=ANONDITA&tabIndex=sme#>
3. The statement showing holding of securities (including Equity Shares, warrants and convertible securities) of persons belonging to the category “Public,” including Equity Shareholders holding more than 1% of the total number of Equity Shares, as on March 31, 2026, as well as details of shares which remain unclaimed for public, can be accessed on the website of NSE at <https://www.nseindia.com/companies-listing/corporate-filings-shareholding-pattern?symbol=ANONDITA&tabIndex=sme#>

9. Details of the Equity Shareholders holding more than 1% of the issued and paid-up Share Capital as on March 31, 2026 is as follows:

S. No.	Name of the Equity Shareholders	No. of Equity Shares held	Percentage of Equity Shares held (%)
1.	Anupam Ghosh	1,12,11,591	61.99%
2.	Sageone - Flagship Growth 2	3,17,000	1.75%
3.	Sageone - Flagship Growth OE Fund	5,28,000	2.92%
4.	Vikasa India EIF I Fund - Incube Global Opportunities	3,84,000	2.12%
5.	Sagar P Brahmhatt	2,24,200	1.24%
6.	Siddharth Iyer	2,31,000	1.28%
7.	Moheet Vinodkumar Agarwal	5,51,800	3.05%
8.	Vanaja Sundar Iyer	2,87,000	1.59%
9.	Ritu Bapna	3,46,000	1.91%
10.	Mansi Share & Stock Broking Private Limited	2,95,000	1.63%

OBJECTS OF THE ISSUE

Our Company intends to utilise the Net Proceeds from this Issue towards funding of the following objects:

- Capital expenditure towards plant and machinery for latex and non-latex female condoms;
- Funding the short-term working capital requirements of our Company; and
- General Corporate Purposes.

(collectively, the “Objects”)

The main objects and objects incidental or ancillary to the main objects as stated in the Memorandum of Association of our Company enable our Company to undertake its existing business activities and the activities proposed to be funded from the Net Proceeds.

Net Proceeds

The details of the Net Proceeds are summarised below:

(₹ in Lakhs)

Particulars	Estimated Amount
Issue Proceeds*	9,101.00
Less: Estimated Issue related expenses**	546.06
Net Proceeds	8,554.94

*Assuming full subscription and Allotment of the Rights Equity Shares.

**Please see “Estimated Issue Expenses” on page 49 of this Letter of Offer.

Utilisation of the Net Proceeds

Our Company proposes to utilise the Net Proceeds in accordance with the details set out below:

(₹ in Lakhs)

Particulars	Amount*
Capital expenditure towards plant and machinery for latex and non-latex female condoms	5,000.00
Funding the short-term working capital requirements of our Company	2,574.96
General Corporate Purposes**	979.98
Net Proceeds	8,554.94

*Assuming full subscription and Allotment of the Rights Equity Shares, subject to adjustment upon finalisation of the Issue related expenses and the Issue Price.

**The amount utilised for General Corporate Purposes shall not exceed 25% of the Gross Proceeds, in accordance with the SEBI ICDR Regulations.

Proposed Schedule of Implementation and Deployment of Net Proceeds

The following table sets forth the details of the schedule of the expected deployment of the Net Proceeds:

(₹ in Lakhs)

Particulars	Amount to be funded from the Net Proceeds	Estimated deployment in Fiscal 2027
Capital expenditure towards plant and machinery for latex and non-latex female condoms	5,000.00	5,000.00
Funding the short-term working capital requirements of our Company	2,574.96	2,574.96
General Corporate Purposes	979.98	979.98
Net Proceeds	8,554.94	8,554.94

* Assuming full subscription and Allotment of the Rights Equity Shares, subject to adjustment upon finalisation of the Issue related expenses and the Issue Price.

Our Company's funding requirements and the deployment schedule set out above are based on our current business plan, and are subject to revision in the future at the discretion of our Board, in accordance with the objects of the Issue. Our Company proposes to deploy the entire Net Proceeds towards the Objects during Fiscal 2027.

Our Company may have to revise its funding requirements and deployment on account of a variety of factors, such as our financial condition, business and strategy, and external factors such as market conditions, competitive environment and interest or exchange rate fluctuations, which may not be within the control of our management. For further information, see “Risk Factors – Our funding requirements and proposed deployment of Net Proceeds are based on management estimates and have not been independently appraised” on page 19.

Subject to applicable law, if the actual utilisation towards any of the Objects is lower than the proposed deployment, such balance will be used for future growth opportunities, including funding of the other Objects, if required. In the event the Net Proceeds are not utilised (in full or in part) for the Objects during the period stated above, for reasons including but not limited to any deferment or postponement of the objects, our Company will utilise such unutilised Net Proceeds in the subsequent periods, as may be determined by our Board, in accordance with applicable law.

Means of Finance

The total estimated cost of the proposed female condom manufacturing facility (latex and non-latex lines), based on management estimates, is set out below, together with the proposed means of financing the same:

(₹ in Lakhs)

Particulars	Amount
Total estimated project cost (female condom manufacturing facility)	5,458.01
Amount to be financed from the Net Proceeds	5,000.00
Amount to be financed from internal accruals	458.01

Our Company proposes to meet the entire requirement of funds for the aforesaid Object from the Net Proceeds and its existing identifiable internal accruals. Accordingly, in terms of the SEBI ICDR Regulations, our Company confirms that there is no requirement to make firm arrangements of finance through verifiable means towards 75% of the stated means of finance, as the means of finance for the aforesaid Object comprises solely of the Net Proceeds and existing identifiable internal accruals of our Company.

DETAILS OF THE OBJECTS OF THIS ISSUE

The details in relation to the Objects of this Issue are set forth below:

1. Capital expenditure towards plant and machinery for latex and non-latex female condoms

Our Company is a leading manufacturer of male condoms under the flagship brand “**COBRA**” and holds a patent for the process and technology for manufacturing advanced latex and non latex female condom production systems.

The Company proposes to establish a dedicated manufacturing facility for **latex and non-latex female condoms** at its adjacent leasehold property located at **D-002, Sector 80, Noida – 201305, Uttar Pradesh**, adjoining its existing manufacturing facility in Sector 80, Noida.

The proposed facility is intended to cater primarily to **international markets**, leveraging the significant global supply gap and growing demand for female condoms. The Company believes that its patented technology, existing manufacturing expertise, established quality systems and international certifications will provide a strong foundation for developing and scaling this product segment.

On an ongoing basis, our Company invests in the purchase of equipment and machinery utilised in carrying out its business operations, based on future requirements estimated by our management. The total estimated cost of the proposed female condom manufacturing facility is ₹5,458.01Lakhs, of which our Company proposes to utilise ₹5,000.00 lakhs from the Net Proceeds, with the balance to be met from internal accruals as set out under “Means of Finance” above.

Rationale for the Proposed Capital Expenditure

The proposed investment in machinery is aimed at enabling our Company to enter and scale in the female condom manufacturing segment, leveraging our existing patent and process expertise in latex product manufacturing. The acquisition of the proposed machinery is expected to enable our Company to manufacture female condoms at scale to meet international quality standards, improve production capacity, and position our Company to participate in procurement programmes of international organisations and government agencies. Additionally, the investment in machinery will provide financial benefits to our Company through depreciation, as per applicable accounting and tax provisions.

Our management has obtained quotations from vendors and is yet to place any orders or enter into definitive agreements for purchase of such machinery. The amount to be spent and machinery to be procured by our Company will depend upon business requirements and technology advancement. Details of the equipment and machinery for which vendor quotations have been obtained are set forth below:

Sr. No.	Details of the Equipment Required	Quantity	Name of Vendor/Supplier	Cost of the Equipment (₹)	Quotation Date	Validity Up To	Estimated Amount (₹ in Lakhs)	% of Equipment for which Orders are Yet to be Placed	Value of Equipment for which Orders are Yet to be Placed (₹ in Lakhs)
1	Two Lines Female Condoms (Nitrile) Production– Production Line with Conveyor, SS304/SS316 Tanks & Vessels, Oven & Heating System, PLC/HMI/VFD & Electrical, Utilities & Piping, Installation & Commissioning, Testing & Documentation, Packing/Freight & Insurance, Engineering & Project Management	2	Pioneer Fabrication Ltd.	11,20,00,000 per unit	July 24, 2026	6 Months	2,240.00	100%	2,240.00
2	Two Lines Female Condom Production (Latex) – Production Line & Conveyor, SS304/SS316 Tanks & Vessels, Oven & Heating System, PLC/HMI/VFD & Electrical, Utilities & Piping, Installation & Commissioning, Testing & Documentation, Packing/Freight &	2	Pioneer Fabrication Ltd.	9,70,00,000 per unit	July 24, 2026	6 Months	1,940.00	100%	1,940.00

	Insurance, Engineering & Project Management								
3	Attritor Mill – Non-FLP, SS 316, Batch Type, Capacity: 545 litres gross, Blade type: one 16-blade attrition impeller, Motor: 20 HP/1440 rpm, 3-Phase Non-FLP (CG Make), M.O.C.: Stainless Steel (AISI-304) contact parts, Cylindrical Heating/Cooling Jacket, with Ceramic Grinding Media (15 mm, hardened ceramic, initial quantity 500 kg)	4	Chemmaco Machinery	₹6,40,000 each + ₹50,000 (L.S. for grinding media)	July 22, 2026	3 Month	27.60	100%	27.60
4	Washing M/C – Washer Extractor, High Spin, Suspended, Full Stainless Steel Outer Body/Inner Basket/Outer Drum (SS304 Grade), Computer/Microprocessor Controlled, Capacity: 120 kg	4	Super White Engineering Works (Garments Finishing Equipments)	18,50,000 per unit	July 16, 2026	3 Months	74.00	100%	74.00
5	Tumble Dryer M/c – Drying Tumbler, PLC Controlled with 5 Program Storage, Cool Down Feature, Full Stainless Steel Inner Cylinder (SS316), Capacity: 120 kg	2	Super White Engineering Works (Garments Finishing Equipments)	9,95,000 per unit	July 21, 2026	3 Months	19.90	100%	19.90
6	Hydro Extractor M/c – Direct Drive Type, Capacity: 60 kg, Stainless Steel Inner Basket & Outer Body, DC Injection Brake System	2	Super White Engineering Works (Garments Finishing Equipments)	5,65,000 per unit	July 21, 2026	3 Months	11.30	100%	11.30
7	Female Glass Moulds	6,000	J.B.B Scientific Pvt. Ltd.	2,880 per unit	July 21, 2026	6 Months	172.80	100%	172.80
8	Chain Accessories/SS Parts/Plates	4	Mourya Engineering Works	17,34,200 per unit	July 21, 2026	6 Months	69.36	100%	69.36
9	4-Head ET Machine (4 Station), including all components and parts	4	Pioneer Fabrication Ltd.	62,50,000 per unit	July 24, 2026	6 Months	250.00	100%	250.00

10	Weight Balance– Electronic Scale, Capacity 500g x 0.001g, Make: Scaletech, One Year Warranty	20	M.P.Scale Corporatio n	19,250 per unit	July 21, 2026	3 Months	3.85	100%	3.85
11	Trolley – Pallet Truck, 5 Ton, PU Wheel	30	4G Internation al	29,500 per unit	July 21, 2026	3 Months	8.85	100%	8.85
12	Crates – Plastic Crate, HDPE Semi Fresh, Size 600x400x425 mm	14,000	Apolo Plast Industries	635 pe r unit	July 21, 2026	3 Months	88.90	100%	88.90
13	Water Testing – Automatic Condom Electrical Leak Tester, as per ISO 4074:2015, 12 Automatic Testing Heads, Make: Astek	2	Astek Quality Instruments	75,40,000 per unit	July 21, 2026	3 Months	150.80	100%	150.80
14	Bowl Vibratory Feeder – Model No. YMV-410 (Model Number YE 300T), Counterweight Vibration Automatic Linear Feeder, Direct Vibration, Track Length Customizable, M.S. Fabricated Table Structure Profile, for Bowl Feeder and Linear Feeder Attachment, Pneumatic Pick & Place System for Part Loading, Electric Control Panel with PLC/HMI (Make: Mitsubishi), Pneumatic Grippers (2) with flow controls (Make: Festo)	25	Yumi Enterprises	5,52,600 per unit	July 25, 2026	3 Months	138.15	100%	138.15
15	Conveyor-Based Condoms Packing Machine – for packing condoms in strips, with slitter and perforation cutting, with oil injector	25	Fill-N-Pack Machineries (Manufacturers of all types of Flexible Packaging Machineries)	10,50,000 per unit	July 25, 2026	3 Months	262.50	100%	262.50
	Total						5,458.01		5,458.01

***Note:** Items 1 & 2 (Pioneer Fabrication Ltd.) represent complete production lines for the latex and non-latex (nitrile) female condom manufacturing facilities respectively, each comprising the production line, conveyor, tanks and vessels, oven and heating system, PLC/HMI/VFD and electrical systems, utilities and piping, installation and commissioning, testing and documentation, the Company may, from time to time, be required to change or substitute the vendor(s) for the proposed facility due to unavoidable circumstances, commercial considerations, cost-effectiveness, availability of better-quality products or technology, improved technical specifications, or other operational requirements. Accordingly, the Company requests that it be permitted to change the vendor(s), if required, in the interest of cost efficiency, product quality, technological advancement and smooth implementation of the project.*

Percentage and Value of Equipment for which Orders are Yet to be Placed

As of the date of this Letter of Offer, our Company has not placed any purchase orders for the equipment set out in the table above. Accordingly, 100% of the equipment listed above, by both quantity and value, aggregating ₹5,458.01 lakhs, is yet to be ordered.

Notes

- Our Company has taken quotations from the vendors mentioned above.
- The above-mentioned machinery will be in addition to our Company's existing machinery and not a replacement of existing machinery.
- We have considered the above quotations for the budgetary estimate purpose and have not placed orders for them. The actual cost of procurement and actual supplier/dealer may vary.
- All quotations received from the vendors mentioned above are valid as on the date of this Letter of Offer. However, we have not entered into any definitive agreements with the vendors, and there can be no assurance that the same vendors would be engaged to eventually supply the machineries/equipment or at the same costs.
- The machinery/equipment models and quantity to be purchased are based on the present estimates of our management. The Management shall have the flexibility to revise such estimates (including but not limited to change of machinery or vendor or addition/deletion of any machinery) at the time of actual placement of the order.
- We are not acquiring any second-hand machinery.
- If the Net Proceeds allocated towards this Object are insufficient, such excess amount shall be met from our internal accruals, as set out under “Means of Finance” above.

There can be no assurance that the same suppliers would be engaged to eventually supply the machinery and material at the same cost. The above quotations are used only for the purpose of price estimation.

2. Funding the Short-Term Working Capital Requirements of our Company

Our business is working capital intensive and our Company funds a majority of our working capital requirement through internal accruals and banking limits. For the expansion of our business and to enter new geographical areas, our Company requires additional working capital which is based on our management estimations of the future business plan for the FY 2026-27.

Details of the estimation of the working capital requirement are set out below:

Assumption on Working Capital Requirement

(₹ in Lakhs)

Particulars	FY 2025 (Audited)	FY 2026 (Audited)	FY 2027 (Estimated)	FY 2028 (Estimated)
Sundry Debtors	1,660.42	3,798.80	6,427.72	12,500.00
Inventory	896.28	1,349.14	2,300.00	4,500.00
Short Term Loans and Advances	1,150.00	1,109.75	1,642.68	2,135.48
Other Current Assets	308.13	451.32	664.15	833.40
Total Current Assets	4,014.83	6,709.01	11,034.55	19,968.88
Sundry Creditors	352.58	793.87	1,204.12	1,324.53
Other Current Liabilities	454.81	657.47	1,223.22	1,345.54
Total Current Liabilities	807.39	1,451.34	2,427.34	2,670.07
Working Capital Gap	3,207.44	5,257.67	8,607.21	17,298.81

Proceeds from Rights Issue	–	–	2,574.96	0.00
Short Term Borrowings	1,548.34	967.80	1,000.00	1,100.00
Internal Accrual	1,659.10	4,289.87	5,032.25	16,198.81
Total	3,207.44	5,257.67	8,607.21	17,298.81

**Estimated*

The above working capital requirement has been estimated considering FY 2024-25 as the base year, as FY 2023-24 does not represent a full year of operations of our Company under its current corporate structure following the business transfer from the erstwhile proprietorship, M/s Anondita Healthcare, with effect from April 1, 2024.

Justification for Holding Period

Particulars	FY 2025 (Audited)	FY 2026 (Audited)	FY 2027 (Estimated)	FY 2028 (Estimated)
Sundry Debtors Holding Period	100	124	116	101
Inventory Holding Period	103	101	99	91
Sundry Creditor Holding Period	34	44	43	22

Basis of Estimation

Particulars	Basis of Estimation
Sundry Debtors	As per the Audited Financial Statements, the Company's revenue from operations increased from ₹6,051.52 lakhs in FY 2024-25 to ₹11,169.62 lakhs in FY 2025-26. During the same period, trade receivables (sundry debtors) increased from ₹1,660.42 lakhs to ₹3,798.80 lakhs. The average collection period for trade receivables remained in the range of approximately 100 to 124 days. The increase in Sundry Debtors during FY 2025-26 is primarily attributable to the significant growth in the Company's revenue and business volumes during the year, as referred to above. The Company witnessed increased sales, particularly from government and institutional customers, where the payment realization cycle is generally longer. Further, the execution of higher-value orders under the Company's own brand and increased supplies during the year resulted in a higher amount of receivables outstanding as at March 31, 2026. The increase in the Sundry Debtors holding period during FY 2025-26 is primarily attributable to sales made to government and institutional customers, where the payment realization cycle is comparatively longer. During the year, the Company also executed higher-value orders under its own brand and extended credit facilities to long-standing customers and business associates in accordance with established business practices. Accordingly, the increase in the debtor holding period is mainly due to the inherent payment cycle of government and institutional customers, the higher proportion of branded business, and the timing difference between sales and realization of outstanding amounts at the year-end. The higher order volumes

	from government institutions, coupled with the expansion of the Company's own branded business, resulted in a significant increase in revenue from operations during FY 2025-26 and consequently an increase in the absolute level of trade receivables. The Company continues to actively monitor and follow up on outstanding receivables. The increase in the debtor holding period is primarily a consequence of the Company's business growth and customer/payment profile and is not indicative of any material deterioration in the quality or recoverability of the Company's receivables. The sundry debtor holding period depends on a number of factors, including prevailing market conditions and customer demand. The Company may, at times, offer extended credit periods to boost its topline, retain existing clients, or acquire new clients, given that the market is fragmented and the Company faces intense competition among large organised players and small unorganised players engaged in this business. Going forward, the Company estimates that the debtor holding period will be maintained at approximately 116 days from FY 2026-27 onwards, and 101 days from FY 2027-28. The projected holding period takes into consideration the Company's planned expansion into various international markets, where the Company expects to receive partial or full advance payments from certain overseas customers, thereby supporting the overall receivables cycle. At the same time, the Company intends to maintain flexibility in extending credit to existing and prospective customers, wherever commercially appropriate and in line with prevailing market practices, with a view to supporting revenue growth, retaining existing customers and acquiring new customers..
Inventory	As per the audited financial statements for FY 2024-25, due to increase in the Company's turnover, its inventory level increased from ₹896.28 lakhs in FY 2024-25 to ₹1,349.14 lakhs in FY 2025-26. The Company's inventory mainly consists of raw materials and finished goods. Inventory levels are maintained by the Company depending upon demand. The inventory holding period has been in the range of approximately 101 to 103 days for the said period. The inventory holding period has gradually declined from 103 days in FY 2025 to 101 days in FY 2026, and is estimated to further decline to 99 days in FY 2027 and 91 days in FY 2028. The increase in the absolute inventory level is primarily due to the growth in business volumes, increased production requirements and the need to maintain adequate raw materials, work-in-progress and finished goods for timely execution of larger orders. However, the reduction in holding period reflects improved inventory turnover, better production planning and more efficient utilization of inventory. With increasing capacity utilization and higher sales volumes, the Company expects inventory to move faster, resulting in a lower number of inventory holding days. Going forward, the Company estimates maintaining the inventory holding period from Fiscal 2027 onwards as per prevailing market conditions and estimated topline growth in the future. By carrying inventory of its products, the Company will be able to acquire and service more customers, which will have a positive impact on its topline and bottom line..

Sundry Creditors	As per the audited financial statements, the Company's sundry creditors level increased from ₹352.58 lakhs in FY 2024-25 to ₹793.87 lakhs in FY 2025-26. The creditor holding period increased from 34 days in FY 2025 to 44 days in FY 2026, primarily due to higher procurement volumes corresponding to the increase in production and sales activities and the credit terms available from suppliers. The holding period is estimated at 43 days in FY 2027 and is expected to reduce to 22 days in FY 2028. The projected reduction is based on the expected improvement in business operations, procurement planning and settlement of supplier obligations in accordance with agreed credit terms.
Short Term Loans and Advances and Other Current Assets	The key items under this head are advances to suppliers/employees, advances to subsidiaries, balances with government authorities and prepaid expenses, etc. Going forward, the Company is expecting to make more advance payments to its suppliers for uninterrupted supply and to obtain better margins from them, and accordingly this is expected to increase in the near future. Except this, the Company does not foresee any major change and expects a proportional increase in line with the increase in operations and turnover.
Other Current Liabilities and Short-Term Provisions	Other current liabilities include advances from customers, provisions, statutory dues, expenses payable, etc. The major contributor of other current liabilities is advance received from customers, which the Company expects to reduce due to market conditions. Going forward, the Company does not foresee any other major change and expects an increase in proportion to the increase in operations and turnover.

Further, please refer to the following for working capital justification:

- The Company has been supplying condoms to various Government procurement agencies since 2016. Historically, the Company accepted only limited Government orders due to the relatively longer payment cycle of approximately 120 days, which required substantial working capital. Being an MSME, the Company was eligible to receive up to 25% of the tender quantity by matching the L1 (lowest bidder) price. Accordingly, the Company participated selectively in Government tenders to maintain a prudent working capital position.
- In the earlier years, the Company primarily undertook contract manufacturing (job work) for various reputed brands to ensure steady cash flows, as the volume of orders under its own brand was relatively limited. Alongside job work, the Company also marketed and sold products under its own brands in the domestic market.
- Over the past two years, the Company has strategically shifted its focus towards Government institutional business and strengthening its own brands. The infusion of funds through the Pre-IPO placement and the Initial Public Offering (IPO) has significantly strengthened the Company's working capital position, enabling it to participate in and execute substantially higher volumes of Government orders. Consequently, the Company now executes almost the full quantity of Government orders awarded to it while gradually reducing dependence on low-margin contract manufacturing for third-party brands. As a result, the Company's revenue mix has evolved to approximately 50% Government institutional sales and 50% own-brand sales. Up to FY 2025-26, the Company's entire turnover was generated from the domestic market.
- The Company's installed manufacturing capacity for male condoms was 562 million pieces per annum. In February 2026, the Company successfully commissioned an additional capacity of 307 million pieces per annum, increasing the total installed capacity to 869 million pieces per annum. Further, an additional capacity of 250 million pieces per annum is presently under

implementation, with trial runs already in progress. Commercial production from this expansion is expected to commence within the next 2–3 months.

- The Company's growth in turnover for FY 2026-27 is supported by its enhanced manufacturing capacity, continued strong demand from Government procurement agencies, and increasing sales under the Company's own brands. In line with the anticipated growth in business operations, the Company expects a corresponding increase in working capital requirements, primarily towards financing higher levels of trade receivables arising from Government and institutional sales, as well as maintaining adequate inventories of raw materials, work-in-progress, and finished goods to support the projected increase in production and sales.
- The Company has planned to undertake capital expenditure for establishing a female condom manufacturing facility through the proceeds of the proposed Rights Issue. The project envisages an initial installed manufacturing capacity of 120 million pieces per annum, with implementation commencing from FY 2026-27 onwards. The Company expects to operationalize approximately 60 million pieces per annum of this capacity during the current financial year, with the balance capacity to be commissioned in a phased manner thereafter.
- This expansion will mark the Company's entry into the female condom segment, which offers significant growth potential in both domestic and international markets. With the phased expansion and stabilization of the female condom manufacturing facility, along with continued growth in the male condom business, the Company expects its turnover to grow over the coming years. This growth is expected to be driven by higher production capacity, increasing Government procurement, expansion of branded sales, and the commencement of export business.

3. General Corporate Purposes

Our Company intends to deploy ₹979.98 lakhs from the Net Proceeds towards our general corporate purposes, as approved by our management, from time to time, subject to such amount not exceeding 25% of the Gross Proceeds, in compliance with the applicable laws. The general corporate purposes for which our Company proposes to utilise Net Proceeds include investments in the Subsidiary of our Company, capital expenditure requirements including for refurbishment, meeting exigencies and expenses incurred by our Company in the ordinary course of business, as may be applicable. The quantum of utilisation of funds towards each of the above purposes will be determined by our Board, based on the amount actually available under this head and the business requirements of our Company, from time to time.

In addition to the above, our Company may utilise the Net Proceeds towards other purposes relating to our business which are considered expedient and as approved periodically by our Board, subject to compliance with the necessary provisions of the Companies Act and in accordance with the stated objectives and our business. Our Company's management shall have flexibility in utilising any surplus amounts, if any. The quantum of utilisation of funds towards the above purpose will be determined by our Board and the business requirements of our Company, from time to time. In the event that we are unable to utilise the entire amount that we have currently estimated for use out of the Net Proceeds in a Fiscal, we will utilise such unutilised amount(s) in the subsequent Fiscals.

Estimated Issue Expenses

The total expenses of the Issue are estimated to be approximately Rs. 546.06 lakhs.

The estimated Issue related expenses are as follows:

(₹ in Lakhs)

Activity	Estimated amount* (₹ in Lakhs)	Percentage of total estimated Issue expenses (%)	Percentage of Issue Size (%)
Fees payable to intermediaries (including Advisors to the Issue, Consultant to the Issue, Registrar, Independent Chartered Account, the virtual data room provider in connection with due diligence for the Issue etc.)	415.01	76.00%	4.56%
Advertising, marketing and shareholder outreach expenses	16.38	3.00%	0.18%

Fees payable to SEBI, Stock Exchanges, depositories and other statutory fees	49.15	9.00%	0.54%
Printing and stationery, distribution, postage, etc.	10.92	2.00%	0.12%
Other expenses (including miscellaneous expenses and stamp duty)	54.61	10.00%	0.60%
Total estimated Issue expenses	546.06	100%	6.00%

** Subject to finalisation of Basis of Allotment. In case of any difference between the estimated Issue related expenses and actual expenses incurred, the shortfall, if any, shall be borne from the internal accruals and excess, if any, shall be adjusted with the amount allocated towards other objects of the issue.*

Bridge Financing Facilities

Our Company has not raised any bridge loans from any bank or financial institution as on the date of this Letter of Offer, which are proposed to be repaid from the Net Proceeds.

Interim Use of Net Proceeds

Our Company shall deposit the Net Proceeds, pending utilisation of the Net Proceeds for the purposes described above, by depositing the same with any scheduled commercial banks which are included in second schedule of Reserve Bank of India Act, 1934. Our Company confirms that pending utilization of the Net Proceeds towards the stated objects of the Issue, our Company shall not use/deploy the Net Proceeds for any investment in the equity markets.

Monitoring Utilisation of Funds from the Issue

Our Company has appointed Infomerics Valuation and Rating Limited as the Monitoring Agency, in accordance with Regulation 82 of the SEBI ICDR Regulations, to monitor the utilisation of the Net Proceeds. Our Company undertakes to deposit the Net Proceeds in a separate bank account, which shall be monitored by the Monitoring Agency for utilisation of the Net Proceeds. Our Company undertakes to place the report(s) of the Monitoring Agency before the Audit Committee upon receipt, without any delay.

Our Company will disclose, and continue to disclose, the utilisation of the Net Proceeds, including interim use, under a separate head in its balance sheet for such fiscal periods as required under the SEBI ICDR Regulations, the SEBI Listing Regulations and other applicable laws, specifying the purposes for which the Net Proceeds have been utilised. Our Company will also disclose, in its balance sheet for the applicable fiscal periods, details of any Net Proceeds that remain unutilised.

Pursuant to Regulation 32(3) read with Regulation 32(8) of the SEBI Listing Regulations, our Company shall, on a half-yearly basis, disclose to the Audit Committee the uses and applications of the Net Proceeds, which the Audit Committee shall discuss, monitor and approve along with our Board. On an annual basis, our Company shall prepare a statement of funds utilised for purposes other than those stated in this Letter of Offer and place it before the Audit Committee, together with such other disclosures as may be required, until the Net Proceeds have been utilised in full. The statement shall be certified by the Statutory Auditor(s) of our Company or a peer reviewed independent chartered accountant, which shall be submitted by our Company with the Monitoring Agency.

Further, pursuant to Regulation 32(1) read with Regulation 32(8) of the SEBI Listing Regulations, our Company shall furnish to the Stock Exchange, on a half-yearly basis, a statement indicating (i) deviations, if any, in the actual utilisation of the Net Proceeds from the Objects stated above; and (ii) category-wise details of any such variations. This statement will also be published on our website, and any explanation for such variation shall be included in our Directors' Report, after being placed before the Audit Committee.

Strategic or Financial Partners

There are no strategic or financial partners to the Objects of the Issue.

Appraising Entity

None of the Objects for which the Net Proceeds will be utilised have been appraised by any agency or financial institution.

Details of Variation in Objects of Previous Issue

Pursuant to Sections 13(8) and 27 of the Companies Act, 2013, our Company, at the Extraordinary General Meeting of its

members held on February 12, 2026, passed a special resolution ratifying the utilisation of the proceeds of our initial public offering (the "**IPO Proceeds**") up to December 31, 2025, and approving a variation in the objects and terms of utilisation of the unutilised portion of the IPO Proceeds, as disclosed in the Prospectus dated August 28, 2025.

As of December 31, 2025, our Company had utilised ₹5,089.12 lakhs (83.21%) of the net IPO Proceeds of ₹6,115.87 lakhs, with ₹1,026.59 lakhs remaining unutilised. In connection with the object relating to funding of capital expenditure requirements for the purchase of equipment/machineries for which ₹600.00 lakhs had been allocated in the Prospectus, of which only ₹70.40 lakhs (11.73%) had been utilised as of December 31, 2025. Our Company varied the source of procurement of the relevant equipment from an overseas vendor based in China to domestic vendors, primarily Pioneer Fabrication Limited (Meerut), together with certain other domestic vendors, without any change to the allocated amount of ₹600.00 lakhs.

This variation was undertaken on the basis of a detailed commercial and operational evaluation, having regard to, among other factors: (i) avoidance of customs duty and related levies of approximately 35–40% applicable to equipment imported from China; (ii) reduction in freight, insurance, port handling and inland transportation costs associated with overseas procurement; (iii) avoidance of the customs clearance procedures, documentation and inspection delays applicable to imports; (iv) more efficient installation and commissioning support available from domestic vendors, as compared to coordination with foreign technicians; and (v) a significant reduction in lead time, with procurement from China estimated to require 6 to 9 months as against a materially shorter timeline for domestic procurement, thereby mitigating the risk of delays to our projected turnover, including from our export operations.

Pursuant to this variation, certain equipment was procured from domestic vendors during the quarter ended December 31, 2025, including a CAM Indexing System from Camfield Engineers, a Linear Cartonning Machine from Keshav Pharmapack Technology, and a 125 KVA Genset from Innovative Retail Concepts Private Limited. Certain other equipment, including a Pinhole Testing Machine, continued to be procured from an overseas vendor, Guilin Golden Eagle Latex Technology Co., Ltd. Our Company has confirmed that utilisation of this capital expenditure shall remain strictly restricted to ₹600.00 lakhs, and any expenditure in excess of this amount shall be met entirely from our Company's internal resources.

In addition, at the same Extraordinary General Meeting, our Company's members approved (a) an increase in the allocation towards funding the working capital requirements from ₹3,500.00 lakhs to ₹3,778.41 lakhs, and (b) a corresponding reduction in, and restriction of, the object relating to unidentified acquisition and general corporate purposes with the unidentified acquisition component removed entirely and the object restricted to general corporate purposes only, reduced from ₹2,015.87 lakhs to ₹1,737.46 lakhs on account of a revision in the permissible limit for utilisation towards general corporate purposes under the SEBI ICDR Regulations, from 35% to 25% of the amount raised. Our Company has confirmed that no portion of the IPO Proceeds has been utilised towards any acquisition.

Other Confirmations

No part of the proceeds of the Issue will be paid by our Company to our Promoters, our Promoter Group, our Directors or our Key Managerial Personnel or Senior Management, except in the ordinary course of business and in compliance with applicable law.

Our Promoters, Promoter Group and Directors do not have any interest in the Objects of the Issue, and there are no material existing or anticipated transactions in relation to utilisation of the Net Proceeds with our Promoters, Promoter Group, Directors, Key Managerial Personnel, Senior Management or associate companies (as defined under the Companies Act, 2013).

Our Company does not require any material government or regulatory approvals in relation to the Objects of the Issue, except as may be otherwise stated in this Letter of Offer.

STATEMENT OF POSSIBLE SPECIAL TAX BENEFITS

Date: August 01, 2026

To,
The Board of Directors
Anondita Medicare Limited
Flat No. 704, Narmada Block, N6, Sector-D,
Pocket-6, Vasant Kunj,
New Delhi - 110070, India
Dear Sirs,

Re: Proposed rights issue of equity shares of face value of ₹10 each ("Equity Shares") of Anondita Medicare Limited ("Company" and such offering, the "Issue").

We hereby confirm the enclosed Annexure A and Annexure B (together, the "Annexures"), prepared by the Company, provide the special tax benefits available to the Company and to the shareholders of the Company as stated in those Annexures, under the Income-tax Act, 1961 (the "Act"), as amended by the Finance Act, 2025, applicable for the Financial Year 2025-26 relevant to the Assessment Year 2026-27, presently in force in India, and the Central Goods and Services Tax Act, 2017, the Integrated Goods and Services Tax Act, 2017 and the applicable State/Union Territory Goods and Services Tax Act, 2017 and the relevant rules, circulars and notifications made thereunder ("GST Acts"), as amended from time to time, the Customs Act, 1962 ("Customs Act") and the Customs Tariff Act, 1975 ("Tariff Act"), as amended by the Finance Act, 2025, applicable for the Financial Year 2025-26, presently in force in India. The Act, the GST Acts, Customs Act and Tariff Act, as defined above, are collectively referred to as the "Relevant Acts."

The benefits discussed in the enclosed Annexures are not exhaustive, and the preparation of the contents stated is the responsibility of the Company's management. We are informed that these Annexures are only intended to provide general information to investors and are neither designed nor intended to be a substitute for professional tax advice. In view of the individual nature of the tax consequences and the changing direct tax laws, each investor is advised to consult his or her own tax consultant with respect to the specific tax implications arising out of their participation in the proposed Issue. We are neither suggesting nor advising the investors to invest in the Issue relying on this statement.

We do not express any opinion or provide any assurance as to whether:

- (i) the Company, or its shareholders will continue to obtain these benefits in future; or
- (ii) the conditions prescribed for availing the benefits have been/would be met with; or
- (iii) the revenue authorities/courts will concur with the views expressed herein.

We assume no obligation to update the Annexures on any events subsequent to this date, which may have a material effect on the discussions herein.

The contents of the enclosed statement are based on information, explanations and representations obtained from the Company and based on our understanding of the business activities and operations of the Company.

This statement is prepared solely for inclusion in the Letter of Offer ("LOF") and the Draft Letter of Offer ("DLOF") in connection with the Issue, to be filed by the Company with the National Stock Exchange of India Limited and the Securities and Exchange Board of India, and is not to be used, referred to or distributed for any other purpose.

For **M/s TASH & Associates**
Chartered Accountants
ICAI Firm Registration No.: 017326N

Sd/-
CA Sapna
Partner
Membership No.: 525964
Place: Faridabad
Date: August 01, 2026
UDIN: 26525964GVBVZC3975

ANNEXURE A

STATEMENT OF POSSIBLE SPECIAL DIRECT TAX BENEFITS AVAILABLE TO THE COMPANY AND ITS SHAREHOLDERS

The statement of direct tax benefits enumerated below is as per the Income-tax Act, 1961 (“the Act”), as amended from time to time and applicable for Financial Year 2025-26 relevant to Assessment Year 2026-27:

SPECIAL DIRECT TAX BENEFITS AVAILABLE TO THE COMPANY

1. Lower corporate tax rate under Section 115BAA of the Act

As per Section 115BAA of the Act, inserted by the Taxation Laws (Amendment) Act, 2019, w.e.f. April 1, 2020 (i.e. Assessment Year 2020-21), domestic companies are granted an option to compute corporate tax at a reduced rate of 25.17% (22% plus surcharge of 10% and cess of 4%), subject to fulfilment of certain conditions. The option, once exercised through filing of Form 10-IC on or before the due date of filing the return of income, applies to subsequent assessment years. The concessional rate of 22% is subject to the company not availing, among others, the following deductions under the Act:

- Section 10AA: Tax holiday for units in a Special Economic Zone
- Section 32(1)(iia): Additional Depreciation
- Section 32AD: Investment Allowance
- Section 33AB/33ABA: Tea, coffee, rubber development/site restoration expenses
- Section 35(1)/35(2AA)/35(2AB): Expenditure on scientific research
- Section 35AD: Deduction for capital expenditure on specified businesses
- Section 35CCC/35CCD: Expenditure on agricultural extension/skill development
- Chapter VI-A, except Section 80JJAA and Section 80M

The total income of a company availing the concessional rate is required to be computed without set-off of any carried forward loss and depreciation attributable to the aforesaid deductions/incentives. Further, the provisions of Minimum Alternate Tax under Section 115JB of the Act are not applicable to companies availing the reduced tax rate, and any carried forward MAT credit cannot be claimed. The provisions do not specify any limitation on account of turnover, nature of business or date of incorporation; accordingly, all existing and new domestic companies are eligible to avail this concessional rate of tax.

Company and its material subsidiary (Anondita Healthcare and Rubber Products India Limited) have exercised the option under Section 115BAA by filing Form 10-IC.

2. Deduction in respect of inter-corporate dividends – Section 80M of the Act

As per the provisions of Section 80M of the Act, a domestic company (“Resident Corporate Shareholder”) can claim a deduction of an amount equal to dividends received from another domestic company, a foreign company, or a business trust. Such deduction shall be claimed from the gross total income of the Resident Corporate Shareholder and shall not exceed the amount of dividend distributed by it on or before the due date, being the date one month prior to the date for furnishing the return of income under Section 139(1) of the Act. The deduction under Section 80M is available even if the domestic company opts for the concessional tax rate under Section 115BAA of the Act.

3. Deduction under Section 80JJAA of the Act

As per the provisions of Section 80JJAA of the Act, where the gross total income of an assessee to whom the provisions of Section 44AB of the Act apply includes any profit and gains derived from business, such assessee is entitled to claim a deduction of an amount equal to thirty percent of additional employee cost incurred in the course of such business in the previous year, for three assessment years including the assessment year relevant to the previous year in which such employment is provided, subject to fulfilment of the conditions prescribed in Section 80JJAA(2) of the Act.

SPECIAL DIRECT TAX BENEFITS AVAILABLE TO THE SHAREHOLDERS

There are no special tax benefits available to the shareholders of the Company for investing in the Equity Shares of the Company. However, such shareholders shall be liable to concessional tax rates on certain incomes under the extant provisions of the Act. Further, it may be noted that these are general tax benefits available to equity shareholders; other shareholders holding any other type of instrument are not covered below.

1. The Company would be required to deduct tax at source on dividends paid to shareholders, at applicable rates specified under the Act, subject to the Double Taxation Avoidance Agreement (“DTAA”), in case of shareholders eligible to claim DTAA benefit. In case of shareholders who are individuals, Hindu Undivided Families, Association of Persons, Body of Individuals (whether incorporated or not) and every artificial juridical person, surcharge would be restricted to 15% if

income exceeds ₹1 crore; where income is between ₹50 lakhs and ₹1 crore, surcharge at 10% shall apply. Shareholders would be eligible to claim credit of such tax in their return of income.

2. As per Section 80M of the Act, a Resident Corporate Shareholder can claim a deduction of an amount equal to dividends received from another domestic company, a foreign company, or a business trust, as described above.
3. As per Section 112A of the Act, long-term capital gains arising from transfer of an equity share, or a unit of an equity-oriented fund or a unit of a business trust, shall be taxed at 12.5% (plus applicable surcharge and cess) (without indexation), subject to fulfilment of prescribed conditions, where such capital gains exceed ₹1,25,000.
4. As per Section 111A of the Act, short-term capital gains arising from transfer of a listed equity share, or a unit of an equity-oriented fund or a unit of a business trust, shall be taxed at 20% (plus applicable surcharge and cess), subject to fulfilment of prescribed conditions.
5. Non-resident shareholders can offer income to tax under the beneficial provisions of the DTAA, if any, subject to eligibility and furnishing of requisite documents such as a tax residency certificate, electronically filed Form 10F, and a No Permanent Establishment Certificate, as applicable, and would be eligible to claim foreign tax credit based on the local laws of their country of residence. Shareholders being individuals and HUFs can opt to be taxed as per the rates under Section 115BAC of the Act.

NOTES:

- i. The above statement of possible special tax benefits sets out the provisions of tax laws in a summary manner only and is not a complete analysis or listing of all potential tax consequences of the purchase, ownership and disposal of shares.
- ii. The above statement covers only certain special tax benefits under the Act, read with the relevant rules, circulars and notifications, and does not cover any benefit under any other law in force in India, nor any tax consequences outside India of an investment in the shares of an Indian company. The above are based on the existing provisions of tax laws and their interpretations, which are subject to change or modification by subsequent legislative, regulatory, administrative or judicial decisions, which could also be retrospective.
- iii. The above statement is as per the current direct tax laws relevant for Assessment Year 2026-27. Several of these benefits are dependent on the Company or its shareholders fulfilling the conditions prescribed under the relevant provisions of the tax laws.
- iv. In respect of non-residents, the tax rates and consequent taxation mentioned above will be further subject to any benefits available under the relevant DTAA, if any, entered into between India and the country in which the non-resident has fiscal domicile.
- v. This statement is intended only to provide general information to investors and is neither designed nor intended to be a substitute for professional tax advice. Each investor is advised to consult his or her tax advisor with respect to specific tax consequences of his/her investment in the shares of the Company.
- vi. No assurance is given that the revenue authorities/courts will concur with the views expressed herein. The views are based on the existing provisions of law and their interpretation, which are subject to change from time to time. We do not assume responsibility to update the views consequent to such changes.

ANNEXURE B

STATEMENT OF POSSIBLE SPECIAL INDIRECT TAX BENEFITS AVAILABLE TO THE COMPANY AND ITS SHAREHOLDERS

Under the Central Goods and Services Tax Act, 2017/the Integrated Goods and Services Tax Act, 2017/the relevant State Goods and Services Tax Act (“GST law”), the Customs Act, 1962 and the Customs Tariff Act, 1975 (“Customs law”), and the Foreign Trade Policy (“FTP”) (collectively, “indirect tax laws”):

SPECIAL INDIRECT TAX BENEFITS AVAILABLE TO THE COMPANY

- A. GST law provides for refund of accumulated input tax credit arising on account of exports without payment of tax, i.e. under a Letter of Undertaking (“LUT”). our Company has an active export order book, including orders from South Africa aggregating approximately ₹48.50 crore, and expects further export orders of approximately ₹50.00 crore over the following six months, primarily for female condoms; whether the Company has furnished an LUT and is availing zero-rated export supply/refund of accumulated input tax credit should be confirmed with the Company.
- B. Exporters may be eligible for benefits under the RoDTEP (Remission of Duties and Taxes on Exported Products) scheme, which remits certain otherwise non-creditable duties and taxes embedded in export products.
- C. Our Company may be eligible to avail benefits under the Advance Authorisation Scheme and/or the Export Promotion Capital Goods (“EPCG”) Scheme under the FTP, which allow duty-free or concessional import of raw materials and capital goods respectively, linked to a corresponding export obligation. Given our Company's proposed capital expenditure for its female condom manufacturing facility (including certain imported components) and its export operations, the Company may explore availing these schemes, subject to fulfilment of prescribed conditions.
- D. Our Company is engaged in import transactions for certain raw materials and capital goods and may accordingly be eligible to obtain Authorized Economic Operator (“AEO”) status. The AEO programme, administered in India by the Central Board of Indirect Taxes and Customs under the World Customs Organization's SAFE Framework of Standards, is a voluntary programme available to business entities participating in the global supply chain, offering tangible benefits such as faster customs clearances, simplified customs procedures and deferred payment of customs duty to operators providing a high degree of supply chain security, subject to prescribed conditions.
- E. Our Company may be eligible to avail benefits under Manufacturing and Other Operations in a Warehouse (“MOOWR”). The scheme allows importers to import raw materials and capital goods and deposit them in a private bonded warehouse, by filing a bill of entry for warehousing without payment of customs duty and IGST at the time of import, subject to payment of applicable interest if goods are warehoused beyond a specified time limit. Our Company may explore the option of MOOWR, to the extent applicable, to avail the benefit of duty deferment on imported raw materials and capital goods used in its manufacturing operations

SPECIAL INDIRECT TAX BENEFITS AVAILABLE TO THE SHAREHOLDERS

There are no special indirect tax benefits available to the shareholders of the Company under indirect tax regulations in India.

NOTES:

- i. The above statement of special tax benefits is based on the best understanding of the Company's business landscape and the tax benefits available to the Company and its shareholders under the current tax laws presently in force in India.
- ii. This statement is only intended to provide general information to investors and is neither designed nor intended to be a substitute for professional tax advice. In view of the individual nature of the tax consequences and the changing tax laws, each investor is advised to consult his or her own tax consultant with respect to the specific tax implications arising out of their participation in the Issue.
- iii. This statement does not discuss any tax consequences, in a country outside India, of an investment in the shares of the Company. Subscribers of the shares in a country other than India are urged to consult their own professional advisers regarding possible indirect tax consequences that apply to them.
- iv. The above statement covers only the above-mentioned indirect tax law benefits and does not cover any income tax law benefit or benefit under any other law.

No assurance is given that the revenue authorities/courts will concur with the views expressed herein. Our views are based on the existing provisions of law and their interpretations, which are subject to changes from time to time. We do not assume responsibility to update the views consequent to such changes.

SECTION IV - OUR MANAGEMENT

A. Board of Directors

As per the Articles of Association, unless otherwise determined by our Company in a general meeting vide a special resolution, our Company is required to have not less than 3 (Three) directors and not more than 15 (Fifteen) Directors. As on the date of this Letter of Offer, we have five (5) Directors on our Board, which includes, one (1) Managing Director, one (1) Whole-Time Director (1) Non-Executive Director and two (2) Independent Directors including one (1) Women Independent director. The present composition of our Board of Directors is in conformity with the Companies Act, 2013 and SEBI Listing Regulations, to the extent applicable.

Set forth below are details regarding our Board as on the date of this Letter of Offer:

Sr. No.	Particulars	Details
1.	Name of the Director	Anupam Ghosh
	Residential Address	C-6, Near D M Residence, Sector-27, Gautam Budhha Nagar, Uttar Pradesh-201301
	Date of Birth	March 10, 1969
	Age	57 years
	Designation	Managing Director
	DIN	02675517
	Occupation	Business
	Date of expiration of current term	May 14, 2029 (being the expiry of the 5-year current term)

Sr. No.	Particulars	Details
2.	Name of the Director	Reshant Ghosh
	Residential Address	C-6, Sector-27, Near D M Residence, Gautam Budhha Nagar, Uttar Pradesh-201301
	Date of Birth	May 23, 1996
	Age	30 years
	Designation	Whole-Time Director
	DIN	8632812
	Occupation	Business
	Date of expiration of current term	May 14, 2029 (being the expiry of the 5-year current term)

Sr. No.	Particulars	Details
3.	Name of the Director	Lakhinder Singh
	Residential Address	8/203, East End Apartments, Mayur Vihar Phase-1 Extn, Vasundhara Enclave, East Delhi-110096
	Date of Birth	January 05, 1949
	Age	77 years
	Designation	Non-Executive Director
	DIN	7703780
	Occupation	Retired
	Date of expiration of current term	NA

Sr. No.	Particulars	Details
4.	Name of the Director	Gaurav Kumar
	Residential Address	House No. 567, Ward No. 2, Jain Moholla, Panipat, Haryana-132103
	Date of Birth	August 19, 1989
	Age	37 years
	Designation	Non-Executive Independent Director
	DIN	08062315
	Occupation	Self Employed
	Date of expiration of current term	June 28 2029 (being the expiry of the 5-year current term)

Sr. No.	Particulars	Details
5.	Name of the Director	Nishi Goel
	Residential Address	F 83, 2 nd Floor, Mansarovar Garden, Ramesh Nagar, New Delhi-110015
	Date of Birth	June 07, 1982
	Age	44 years
	Designation	Non-Executive Independent Director
	DIN	08164136
	Occupation	Self Employed
	Date of expiration of current term	May 14, 2029 (being the expiry of the 5-year current term)

B. Confirmations

Neither any of our directors are debarred from accessing the capital markets by the SEBI nor any of our directors are directors of any company that is debarred from accessing the capital markets by the SEBI as on the date of filing of this Letter of Offer.

None of our Directors have been identified as Wilful Defaulters or Fraudulent Borrowers as defined under the SEBI ICDR Regulations. Further, none of the directors have been declared a fugitive economic offender in accordance with the Fugitive Economic Offenders Act, 2018.

None of our Directors is or was a director of any listed company which has been or was delisted from any stock exchange, during the term of their directorship in such company, in the last ten years immediately preceding the date of filing of this Letter of Offer.

Details of Key Managerial Personnel and Senior Management

S.No	Particulars	Designation
1.	Anupam Ghosh	Managing Director
2.	Reshant Ghosh	Whole-time director
3.	Sunita Naithani	Chief Financial Officer
4.	Bhawna Bisht	Company Secretary and Compliance Officer
Senior Management (excluding Key Managerial Personnel) – NA		

SECTION V - FINANCIAL INFORMATION**FINANCIAL STATEMENTS**

Sr. No.	Particulars	Website Link
1	Audited Standalone financial results for the quarter and financial year ended March 31, 2026	https://anonditamedicare.com/march/Submission%20of%20Financial%20Results.pdf
2	Audited Consolidated financial results for the quarter and financial year ended March 31, 2026	https://anonditamedicare.com/march/Resubmission%20of%20%20Audited%20Consolidated%20Financial%20Result%20March%202026.pdf

Financial Information

Extract of the Financial Year 2026 Audited Standalone Financial Statements prepared in accordance with applicable accounting standards for the last financial year (with the comparative prior full year period), disclosed to the Stock Exchange:

(Amount in Lakhs)

Sr. No.	Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
1	Revenue from operations	11,169.62	6,051.52
2	Other income	175.91	36.38
3	Total income	11,345.53	6,087.90
4	Net profit/loss before tax and extraordinary items	3,651.37	1,460.73
5	Net profit/loss after tax and extraordinary items	2,682.01	1,091.01
6	Equity share capital	1,808.66	1,329.36
7	Reserves and surplus	9494.38	1430.40
8	Net-worth	11,303.04	2,834.76
9	Earnings per Share (Basic) (in ₹)	16.65	9.70
10	Earnings per Share (Diluted) (in ₹)	16.65	9.70
11	Return on Net Worth (%)*	23.73	39.53
12	Net Asset Value per Share (in ₹)**	62.49	20.77

Notes:

*Return on Equity / Net-worth is calculated as Profit for the year divided by Average Total Equity (Average of total equity at the beginning of the year and total equity at the end of the year)

**Net assets value per equity share (₹): Total Equity at the end of the year/period divided by outstanding number of equity shares at the end of the year.

The audited Standalone financial results for the quarter and financial year ended March 31, 2026, and the audited Standalone financial results for the quarter and financial year ended March 31, 2025, of our Company are uploaded on the website of our Company at <https://www.anonditamedicare.com/march/Submission>.

The above figures are derived from the Financial Year 2026 Audited Standalone Financial Statements of our Company for the purpose of disclosure in this Letter of Offer, in accordance with the SEBI ICDR Regulations.

The Financial Year 2026 Audited Standalone Financial Statements of our Company have been prepared in accordance with the Indian Accounting Standards as notified by the Ministry of Corporate Affairs and as amended from time to time.

Detailed rationale for the Issue Price

The Issue Price of ₹950 per Equity Share has been determined by our Company after considering various qualitative and quantitative factors, including the Company's operating track record, business strengths, financial performance, asset base, earnings profile and prevailing market price of its Equity Shares.

The key factors considered in determining the Issue Price are set forth below:

Qualitative factors:

Some of the qualitative factors which form the basis for computing the Issue Price are set forth below:

1. Established manufacturer of male condoms under the flagship brand "COBRA," with a certified installed manufacturing capacity of 869 million pieces per annum following the capacity enhancement commissioned in February 2026, among the larger domestic manufacturers in this segment;
2. Promoted by Mr. Anupam Ghosh, the Managing Director of the company with over 25 years of experience in the condom manufacturing industry, supported by an experienced management team with relevant domain expertise.
3. A diversified and evolving customer base comprising Government institutional customers and own-brand consumer customers, with the Company progressively expanding its focus towards higher-margin own-brand and export business.
4. Patent holder for the process and technology of manufacturing advanced latex and non-latex female condom production systems, positioning our Company among a limited number of manufacturers globally with this capability;

5. Long-standing and established relationships with Government procurement agencies, including the Central Medical Services Society, since 2016, supported by a confirmed existing order book aggregating approximately ₹229.84 crore as on date, of which approximately ₹92.61 crore is from Government institutional customers;
6. Integrated in-house manufacturing capability, including self-fabricated dipping machinery, in-house foil printing, and 100% electronic pinhole testing, reducing dependence on third-party job-work arrangements and external vendors;
7. Demonstrated track record of margin improvement through in-house R&D-led cost efficiencies, including optimisation of raw material composition and integration of biofuel in the manufacturing process;
8. Consistent and significant growth in revenue and profitability, with revenue from operations increasing by approximately 84.58% and profit after tax increasing by approximately 145.82% in Fiscal 2025-26 over the previous year;
9. Established international presence with confirmed export orders from customers in South Africa and Nepal, along with ongoing efforts to expand the Company's presence across additional international markets.

Quantitative factors:

The following quantitative factors have also been considered in determining the Issue Price:

1. The Basic and diluted earnings per Equity Share ("EPS") (face value of each Equity Share is ₹10):

Fiscal	Basic EPS (₹)	Diluted EPS (₹)
March 31, 2026	16.65	16.65
March 31, 2025	9.70	9.70

The Company's EPS increased from ₹9.70 in Fiscal 2024-25 to ₹16.65 in Fiscal 2025-26, reflecting the significant improvement in profitability during the period.

2. Net Asset Value ("NAV") per Equity Share:

Fiscal	NAV (₹)
March 31, 2026	62.49
March 31, 2025	20.76

The NAV per Equity Share increased from ₹20.76 as at March 31, 2025 to ₹62.49 as at March 31, 2026, reflecting the increase in the Company's net worth during the period.

3. Return on Net Worth ("RONW"):

Fiscal	RONW (%)
March 31, 2026	23.73%
March 31, 2025	39.53%

While the RONW declined during Fiscal 2025-26 primarily due to the significant increase in the Company's net worth during the period, the Company continued to generate a healthy return on its shareholders' funds.

4. Volume-Weighted Average Market Price ("VWAMP") of the Equity Shares on the NSE for the 90 trading days, 60 trading days, and 10 trading days ended August 26, 2026, being the last trading day immediately preceding the date of the meeting of the Board of Directors held on Thursday, August 27, 2026, at which the Issue Price was approved:

Period	VWAMP (₹)	Discount of Issue Price to VWAMP (%)
90 trading days	1,117.10	14.96%
60 trading days	1,142.49	16.85%
10 trading days	1,077.66	11.85%

The Issue Price of ₹950 represents a discount of 14.96%, 16.85%, and 11.85% to the volume-weighted average market price of our Equity Shares on NSE for the 90 trading days, 60 trading days, and 10 trading days, respectively, ended August 26, 2026.

Accordingly, the Issue Price of has been determined after considering, among other factors, the Company's operating performance, growth in revenue and profitability, improvement in net worth, earnings per Equity Share, return on net worth, business prospects, order visibility, manufacturing capabilities and the prevailing market price of the Equity Shares.

The discount to the prevailing market price is intended to provide the existing shareholders with an opportunity to subscribe to the Equity Shares offered pursuant to the Issue at a price below the recent market prices of the Equity Shares, while enabling eligible shareholders to participate in the Company's future growth prospects and maintain their proportionate ownership, subject to the terms and conditions of the Issue.

SECTION VI: REGULATORY APPROVALS AND STATUTORY DISCLOSURES

GOVERNMENT AND OTHER APPROVALS

We are not required to obtain any licenses or approvals from any government or regulatory authority for the objects of this Issue. For further details, refer to the chapter titled “Objects of the Issue” beginning at page 40.

Authority for the Issue

The Issue has been authorised by a resolution of our Board of Directors passed at its meeting held on August 01, 2026, pursuant to Section 62(1)(a) and other applicable provisions of the Companies Act, 2013.

This Draft Letter of Offer has been approved by our Board of Directors pursuant to its resolution dated August 01, 2026. The terms and conditions of the Issue including the Rights Entitlement, Issue Price, Record Date, timing of the Issue and other related matters, have been approved by a resolution passed by the Board of Directors at its meeting held on August 27, 2026.

The Board of Directors, at its meeting held on August 27, 2026, has resolved to issue the Rights Equity Shares to the Eligible Equity Shareholders at ₹950/- per Rights Equity Share of face value ₹10/- each (including a premium of ₹940/- per Rights Equity Share), aggregating up to ₹9,101.00 lakhs, in the Rights Entitlement ratio of 97:1,831, i.e., 97 Rights Equity Shares for every 1,831 fully paid-up Equity Shares of face value ₹10/- each held as on the Record Date.

** Assuming full subscription in the Issue and subject to finalisation of the basis of allotment.*

Our Company has received in-principle approval from NSE in accordance with Regulation 28(1) of the SEBI LODR Regulations for listing of the Rights Equity Shares to be Allotted in this Issue pursuant to their letter dated August 25, 2026. Our Company will also make application to NSE to obtain their trading approval for the Rights Entitlements as required under the SEBI ICDR Master Circular.

Our Company has been allotted the ISIN: INE0VTV20012 for the Rights Entitlements to be credited to the respective demat accounts of Allottees. For details, please see "Terms of the Issue" beginning on page 67.

Prohibition by SEBI or Other Governmental Authorities

Our Company, our Promoters, the members of our Promoter Group and our Directors have not been and are not prohibited or debarred from accessing or operating in the capital market so restrained from buying, selling or dealing in securities under any order or direction passed by SEBI or any securities market regulator in any other jurisdiction or any other authority/court.

Further, our Promoter and our Directors are not promoter(s) or director(s) of any other company which is debarred from accessing or operating in the capital markets or restrained from buying, selling or dealing in securities under any order or direction passed by SEBI.

None of our Directors are associated with the securities market in any manner. Further, there is no outstanding action initiated by SEBI against any of our directors, who have been associated with the securities market.

Neither our Individual Promoter nor any of our Directors are declared as fugitive economic offenders under Section 12 of the Fugitive Economic Offenders Act, 2018.

Previous Public and Rights Issues

Our Company completed its initial public offering of Equity Shares (the "IPO") pursuant to a Prospectus dated August 28, 2025, raising gross proceeds of ₹69,49,85,000 and net proceeds of ₹61,15,87,000.

At the Extraordinary General Meeting of our members held on February 12, 2026, our Company ratified the utilisation of the IPO Proceeds up to December 31, 2025 and approved a variation in the objects and terms of utilisation of the unutilised portion thereof, including a change in the source of procurement of equipment under the capital expenditure object of the IPO, from an overseas vendor to domestic vendors, without any change in the amount allocated to that object. For further details, see "Objects of the Issue – Details of Variation in Objects of Previous Issue" on page 50.

Prohibition by RBI

Neither our Company nor our Promoters or any of our Directors have been or are identified as Wilful Defaulters or Fraudulent Borrowers.

Association with Entities Prohibited By SEBI

Our directors are not associated with any other entity which is debarred from accessing or operating in the capital markets or restrained from buying, selling or dealing in securities under any order or direction passed by SEBI.

Eligibility for the Issue

Our Company is a listed company and has been incorporated under the Companies Act, 2013. Our Equity Shares are presently listed on the SME Platform of NSE Limited ("**NSE SME**"). Our Company is eligible to offer Equity Shares pursuant to this Issue in terms of Chapter III and other applicable provisions of the SEBI ICDR Regulations. Further, our Company is undertaking this Issue in compliance with Part B of Schedule VI of the SEBI ICDR Regulations.

Compliance with Regulations 61 and 62 of the SEBI ICDR Regulations

Our Company is in compliance with the conditions specified in Regulations 61 and 62 of the SEBI ICDR Regulations, to the extent applicable. Further, in relation to compliance with Regulation 62(1)(a) of the SEBI ICDR Regulations, our Company will make applications to the Stock Exchange for in-principle approvals for listing of the Rights Equity Shares to be issued pursuant to the Issue.

Compliance with Part B of Schedule VI of SEBI ICDR Regulations

Company has paid the outstanding SOP and ALF dues, however as on date of the filing Letter of offer there is no dues pending and Company is in compliance with the equity listing agreement entered into with the Stock Exchange and the SEBI LODR Regulations.

As on the date of filing of this Letter of Offer, neither any show-cause notices nor proceedings for imposition of penalty, have been issued by SEBI and are pending against our Company, our Promoters or Whole-time Directors.

Further, no show cause notices have been issued by the SEBI or an Adjudicating Officer in a proceeding for imposition of penalty and/or no prosecution proceedings have been initiated by SEBI, against our Company, our Promoters or Whole-time Directors.

Our Equity Shares have not been suspended from trading as a disciplinary measure during the three years immediately preceding the date of filing of this Letter of Offer.

Caution

Our Company shall make all information available to the Eligible Equity Shareholders in accordance with the SEBI ICDR Regulations and no selective or additional information would be available for a section of the Eligible Equity Shareholders in any manner whatsoever including at presentations, in research or sales reports etc. after filing of this Letter of Offer.

No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this Letter of Offer and the Letter of Offer. You must not rely on any unauthorized information or representations. This Letter of Offer is an offer to sell only the Rights Equity Shares and rights to purchase the Rights Equity Shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this Letter of Offer is current only as of its date.

Our Company, its officers, agents, affiliates and representatives accept no responsibility or liability for advising any Applicant on whether such Applicant is eligible to acquire any Rights Equity Shares.

Disclaimer with respect to jurisdiction

This Letter of Offer has been prepared under the provisions of Indian laws and the applicable rules and regulations thereunder. Any disputes arising out of the Issue will be subject to the jurisdiction of the appropriate court(s) in Delhi only.

Designated Stock Exchange

The Designated Stock Exchange for the purpose of the Issue is NSE.

Disclaimer Clause of the NSE

As required, a copy of this Letter of Offer has been submitted to National Stock Exchange of India Limited. The disclaimer clause as intimated by NSE to us, post scrutiny of this Letter of Offer, is reproduced below:

“As required, a copy of this letter of offer has been submitted to National Stock Exchange of India Limited (hereinafter referred to as NSE). NSE has given vide its letter Ref. No. NSE/LIST/C/2026/0866 dated August 25, 2026, permission to the Issuer to use the Exchange's name in this letter of offer as one of the stock exchanges on which this Issuer's securities are proposed to be listed. The Exchange has scrutinized this letter of offer for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Issuer.

It is to be distinctly understood that the aforesaid permission given by NSE should not in any way be deemed or construed that the letter of offer has been cleared or approved by NSE; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of this letter of offer; nor does it warrant that this Issuer's securities will be listed or will continue to be listed on the Exchange; nor does it take any responsibility for the financial or other soundness of this Issuer, its promoters, its management or any scheme or project of this Issuer.

Every person who desires to apply for or otherwise acquire any securities of this Issuer may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything stated or omitted to be stated herein or any other reason whatsoever.”

No Offer in the United States

THE RIGHTS ENTITLEMENTS AND THE EQUITY SHARES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT, OR ANY U.S. STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD, RESOLD OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES, EXCEPT IN A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE U.S. STATE SECURITIES LAWS. ACCORDINGLY, THE EQUITY SHARES AND THE RIGHTS ENTITLEMENTS REFERRED TO IN THIS LETTER OF OFFER ARE BEING OFFERED AND SOLD ONLY OUTSIDE THE UNITED STATES IN “OFFSHORE TRANSACTIONS” IN RELIANCE ON REGULATION S TO EXISTING SHAREHOLDERS LOCATED IN JURISDICTIONS WHERE SUCH OFFER AND SALE OF THE EQUITY SHARES AND/ OR RIGHTS ENTITLEMENTS IS PERMITTED UNDER LAWS OF SUCH JURISDICTIONS AND IN COMPLIANCE WITH THE APPLICABLE LAWS OF SUCH JURISDICTIONS. THE OFFERING TO WHICH THIS LETTER OF OFFER RELATES IS NOT, AND UNDER NO CIRCUMSTANCES IS TO BE CONSTRUED AS, AN OFFERING OF ANY EQUITY SHARES OR RIGHTS ENTITLEMENTS FOR SALE IN THE UNITED STATES OR AS A SOLICITATION THEREIN OF AN OFFER TO BUY OR TRANSFER ANY OF THE SAID SECURITIES.

Neither our Company, nor any person acting on behalf of our Company, will accept a subscription or renunciation or purchase of the Equity Shares and/ or Rights Entitlements from any person, or the agent of any person, who appears to be, or who our Company, or any person acting on behalf of our Company, has reason to believe is, in the United States when the buy order is made. No Application Form should be postmarked in the United States, electronically transmitted from the United States or otherwise dispatched from the United States or from any other jurisdiction where it would be illegal to make an offer of securities under the Letter of Offer. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders and will dispatch, only through email, the Letter of Offer, the Application Form and other applicable Issue materials only to Eligible Equity Shareholders who have provided an Indian address to our Company.

Any person who acquires Rights Entitlements or Equity Shares will be deemed to have declared, warranted and agreed, by accepting the delivery of this Letter of Offer, that it is not and that at the time of subscribing for the Equity Shares or the Rights Entitlements, it will not be, in the United States, and is authorized to acquire the Rights Entitlements and the Equity Shares in compliance with all applicable laws and regulations.

Our Company reserves the right to treat as invalid any Application Form which: (i) appears to our Company or its agents to have been executed in, electronically transmitted from or dispatched from the United States or other jurisdictions where the offer and sale of the Equity Shares and/ or the Rights Entitlements is not permitted under laws of such jurisdictions; (ii) does not include the relevant certifications set out in the Application Form, including to the effect that the person submitting and/or renouncing the Application Form is not in the United States and is eligible to subscribe for the Equity Shares and/ or the Rights Entitlements under applicable securities laws, and such person is complying with laws of jurisdictions applicable to such person in connection with this Issue and have obtained requisite approvals before applying in this Issue; or (iii) where either a registered Indian address is not provided or our Company believes acceptance of such Application Form may infringe applicable legal or regulatory requirements. Our Company shall not be bound to issue or allot any Equity Shares and/ or the Rights Entitlements in respect of any such Application Form.

Selling Restrictions

This Letter of Offer is solely for the use of the person who has received it from our Company or from the Registrar to the Issue. This Letter of Offer is not to be reproduced or distributed to any other person.

The distribution of this Letter of Offer/ Draft Letter of Offer, Application Form and the Rights Entitlement Letter and the issue of Rights Entitlements and Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession this Letter of Offer/ Draft Letter of Offer, Application Form and the Rights Entitlement Letter may come are required to inform themselves about and observe such restrictions. Our Company is making this Issue on a rights basis to the Eligible Equity Shareholders of our Company and will dispatch the Letter of Offer, Application Form and the Rights Entitlement Letter only to Eligible Equity Shareholders who have provided an Indian address to our Company.

No action has been or will be taken to permit the Issue in any jurisdiction, or the possession, circulation, or distribution of the Letter of Offer /Draft Letter of Offer or any other material relating to our Company, the Equity Shares or Rights Entitlement in any jurisdiction, where action would be required for that purpose, except that this Letter of Offer has been filed with the Stock Exchange.

Accordingly, the Rights Entitlement or Equity Shares may not be offered or sold, directly or indirectly, and this Letter of Offer or Draft Letter of Offer or any offering materials or advertisements in connection with the Issue or Rights Entitlement may not be distributed or published in any jurisdiction, except in accordance with legal requirements applicable in such jurisdiction. Receipt of this Letter of Offer will not constitute an offer in those jurisdictions in which it would be illegal to make such an offer.

This Letter of Offer/ Draft Letter of Offer and its accompanying documents being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose. If this Letter of Offer is received by any person in any jurisdiction where to do so would or might contravene local securities laws or regulation, or by their agent or nominee, they must not seek to subscribe to the Equity Shares or the Rights Entitlement referred to in this Letter of Offer. Investors are advised to consult their legal counsel prior to applying for the Rights Entitlement and Equity Shares or accepting any provisional allotment of Equity Shares, or making any offer, sale, resale, pledge or other transfer of the Equity Shares or Rights Entitlement.

Filing

This Letter of Offer has been filed with the National Stock Exchange of India Limited, being the Designated Stock Exchange, pursuant to receipt of the In-Principle Approval from the said Exchange, and has also been filed with the Securities and Exchange Board of India for information and dissemination on its website, along with the fee specified in Schedule III, at its head office situated at **“SEBI Bhavan, Plot No. C4-A, “G” Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051”**, in each case as required under Regulation 71 of the SEBI ICDR Regulations, the SEBI ICDR Master Circular, and other applicable circulars issued by SEBI from time to time.

Disclaimer with respect to Redressal of Investor Grievances

Our Company has an investor grievance-handling mechanism which includes meeting of the Stakeholders' Relationship Committee at frequent intervals, appropriate delegation of power by our Board as regards share transfer and clearly laid down systems and procedures for timely and satisfactory redressal of investor grievances. All investor grievances received by us have been handled by the Registrar and Share Transfer Agent in consultation with the Company Secretary and Compliance Officer within 15 days from the receipt of the complaint.

Mechanism for Redressal of Investor Grievances

Our Company has adequate arrangements for the redressal of investor complaints in compliance with the corporate governance requirements in compliance with the Listing Agreements and the SEBI Listing Regulations. We have been registered with the SEBI Complaints Redress System (SCORES) as required by the SEBI Circular No. SEBI/HO/OIAE/IGRD/CIR/P/2020/152 dated August 13, 2020 and shall comply with the SEBI circular bearing reference number SEBI/HO/OIAE/CIR/P/2023/156 dated September 20, 2023 and any other circulars issued in this regard. Consequently, investor grievances are also tracked online by our Company through the SCORES mechanism.

Investor complaints received by our Company are typically disposed of within 30 days from the receipt of the complaint.

Investors may contact the Registrar to the Issue or our Company Secretary for any pre- Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process), ASBA Account number and the Designated Branch of the SCSBs where the Application Form or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process). For details on the ASBA process, see "Process of making an application through ASBA Process" at page 69 of this Letter of Offer.

The contact details of our Registrar to the Issue and our Company Secretary and Compliance Officer are as follows:

Registrar to the Issue

SKYLINE FINANCIAL SERVICES PRIVATE LIMITED

D-153A, 1st Floor, Okhla Industrial Area, Phase – I, New Delhi - 110020

Tel: 011-40450193-197

E-mail: ipo@skylinerta.com

Investor grievance ID: grievances@skylinerta.com

Contact person: Mr. Anuj Rana

Website: www.skylinerta.com

SEBI Registration No.: INR000003241

CIN: U74899DL1995PTC071324

Company Secretary and Compliance Officer of the Company

Ms. Bhawna Bisht is the Company Secretary and Compliance Officer of our Company. Her details are as follows:

Bhawna Bisht

D-001, Sector 80, Noida, Gautam Buddha

Nagar, Noida, Uttar Pradesh-201301

Tel: + 9220322218

E-mail: secretarial@anonditamedicare.com

Other Confirmations

Our Company, in accordance with Regulation 79 of the SEBI ICDR Regulations, shall not offer any incentive, whether direct or indirect, in any manner, whether in cash or kind or services or otherwise, to any person for making an Application, and shall not make any payment, whether direct or indirect, whether in the nature of discounts, commission, allowance or otherwise, to any person for making an Application.

SECTION VII: ISSUE INFORMATION

TERM OF THE ISSUE

This section is for the information of the Investors proposing to apply in this Issue. Investors should carefully read the provisions contained in this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter and the Application Form, before submitting the Application Form. Our Company is not liable for any amendments or modifications or changes in applicable laws or regulations, which may occur after the date of this Letter of Offer. Investors are advised to make their independent investigation and ensure that the Application Form is accurately filled up in accordance with instructions provided therein and the Letter of Offer. Unless otherwise permitted under the SEBI ICDR Regulations read with the SEBI ICDR Master Circular, Investors proposing to apply in this Issue can apply only through ASBA or by any other mode which may be notified by SEBI.

For guidance on the application process through ASBA and resolution of difficulties faced by investors, you are advised to read the frequently asked question on the website of the Registrar of the issue at <https://www.skylinerta.com/>.

The Rights Entitlement on the Equity Shares, the ownership of which is currently under dispute and including any court proceedings or are currently under transmission or are held in a demat suspense account and for which our Company has withheld the dividend, shall be held in abeyance and the Application Form along with the Rights Entitlement Letter in relation to these Rights Entitlements shall not be dispatched pending resolution of the dispute or court proceedings or completion of the transmission or pending their release from the demat suspense account. On submission of such documents/records confirming the legal and beneficial ownership of the Equity Shares with regard to these cases, at least two clear Working Days prior to the Issue Closing Date, to the satisfaction of our Company, our Company shall make available the Rights Entitlement on such Equity Shares to the identified Eligible Equity Shareholder at least on day before the Issue Closing Date. The identified Eligible Equity Shareholder shall be entitled to subscribe to the Rights Equity Shares pursuant to the Issue during the Issue Period with respect to these Rights Entitlement and subject to the same terms and conditions as the Eligible Equity Shareholder.

Overview

This Issue is proposed to be undertaken on a rights basis and is subject to the terms and conditions contained in this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter, the Application Form, and the Memorandum of Association and the Articles of Association of our Company, the provisions of the Companies Act, 2013, the FEMA, the FEMA Rules, the SEBI ICDR Regulations, the SEBI LODR Regulations, the SEBI ICDR Master Circular and the guidelines, notifications, circulars and regulations issued by SEBI, the Government of India and other statutory and regulatory authorities from time to time, approvals, if any, from RBI or other regulatory authorities, the terms of the Listing Agreements entered into by our Company with Stock Exchange and the terms and conditions as stipulated in the Allotment Advice.

I. DISPATCH AND AVAILABILITY OF ISSUE MATERIALS

Pursuant to the requirements of the SEBI ICDR Regulations and other applicable laws, the Rights Entitlements will be credited to the demat account of the Eligible Equity Shareholders who are Equity Shareholders as on the Record Date, however, the Issue Materials will be sent/ dispatched only to such Eligible Equity Shareholders who have provided an Indian address to our Company and only such Eligible Equity Shareholders are permitted to participate in the Issue. The credit of Rights Entitlement does not constitute an offer, invitation to offer or solicitation for participation in the Issue, whether directly or indirectly, and only dispatch of the Issue Material shall constitute an offer, invitation or solicitation for participation in the Issue in accordance with the terms of the Issue Material. Further, receipt of the Issue Materials (including by way of electronic means) will not constitute an offer, invitation to or solicitation by anyone in (i) the United States or (ii) any jurisdiction or in any circumstances in which such an offer, invitation or solicitation is unlawful or not authorized or to any person to whom it is unlawful to make such an offer, invitation or solicitation. In those circumstances, the Letter of Offer and any other Issue Materials must be treated as sent for information only and should not be acted upon for subscription to Rights Equity Shares and should not be copied or re-distributed, in part or full. Accordingly, persons receiving a copy of the Issue Materials should not distribute or send the Issue Materials in or into any jurisdiction where to do so, would or might contravene local securities laws or regulations, or would subject our Company or its affiliates to any filing or registration requirement (other than in India). If Issue Material is received by any person in any such jurisdiction or the United States, they must not seek to subscribe to the Rights Equity Shares. For more details, see “*Restrictions on Purchases and Resales*” beginning on page 92.

The Application Form, the Rights Entitlement Letter and other Issue material will be sent/ dispatched only to the Eligible Equity Shareholders who have provided an Indian address to our Company. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such

Eligible Equity Shareholders have not provided their valid e-mail address, then the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Further, the Letter of Offer will be sent/dispatched to the Eligible Equity Shareholders who have provided their Indian address and who have made a request in this regard.

Investors can access the Letter of Offer, Draft Letter of Offer and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe to the Rights Equity Shares under applicable laws) on the websites of:

- i. our Company at <https://www.anonditamedicare.com/>;
- ii. the Registrar at <https://www.skylinerta.com/>
- iii. the Stock Exchange at <https://www.nseindia.com/>

To update the respective Indian addresses/e-mail addresses/phone or mobile numbers in the records maintained by the Registrar or by our Company, Eligible Equity Shareholders should visit <https://www.skylinerta.com/>.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., <https://www.skylinerta.com/>) by entering their DP ID and Client ID or folio number (for Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date) and PAN. The link for the same shall also be available on the website of our Company at <https://www.anonditamedicare.com/>;

Please note that neither our Company nor the Registrar shall be responsible for not sending the physical copies of Issue materials, including this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter and the Application Form or delay in the receipt of this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter or the Application Form attributable to non-availability of the e-mail addresses of Eligible Equity Shareholders or electronic transmission delays or failures, or if the Application Forms or the Rights Entitlement Letters are delayed or misplaced in the transit.

The distribution of this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter and the issue of Rights Equity Shares on a rights basis to persons in certain jurisdictions outside India is restricted by legal requirements prevailing in those jurisdictions. No action has been, or will be, taken to permit the Issue in any jurisdiction where action would be required for that purpose, except that this Letter of Offer is being filed with SEBI and the Stock Exchange. Accordingly, the Rights Entitlements and Rights Equity Shares may not be offered or sold, directly or indirectly, and this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter, the Application Form or any Issue related materials or advertisements in connection with the Issue may not be distributed, in any jurisdiction, except in accordance with and as permitted under the legal requirements applicable in such jurisdiction. Receipt of this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter or the Application Form (including by way of electronic means) will not constitute an offer, invitation to or solicitation by anyone in any jurisdiction or in any circumstances in which such an offer, invitation or solicitation is unlawful or not authorised or to any person to whom it is unlawful to make such an offer, invitation or solicitation. In those circumstances, this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter or the Application Form must be treated as sent for information only and should not be acted upon for making an Application and should not be copied or re-distributed.

Accordingly, persons receiving a copy of this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter or the Application Form should not, in connection with the issue of the Rights Equity Shares or the Rights Entitlements, distribute or send this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter or the Application Form in or into any jurisdiction where to do so, would, or might, contravene local securities laws or regulations or would subject our Company or its affiliates to any filing or registration requirement (other than in India). If this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter or the Application Form is received by any person in any such jurisdiction, or by their agent or nominee, they must not seek to make an application or acquire the Rights Entitlements referred to in this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter or the Application Form. Any person who makes an application to acquire Rights Entitlements and the Rights Equity Shares offered in the Issue will be deemed to have declared, represented and warranted that such person is authorized to acquire the Rights Entitlements and the Rights Equity Shares in compliance with all applicable laws and regulations prevailing in such person's jurisdiction and India, without requirement for our Company or our affiliates to make any filing or registration (other than in India).

The Letter of Offer will be provided, primarily through e-mail, by the Registrar on behalf of our Company to the Eligible Equity Shareholders and in case such Eligible Equity Shareholders have not provided their valid e-mail address, then the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Eligible Equity Shareholders who have provided their Indian addresses to our Company and who make a request in this regard.

II. PROCESS OF MAKING AN APPLICATION IN THE ISSUE

- **In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI ICDR Master Circular and the ASBA Circulars, all Investors desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA.**

The Application Form can be used by the Eligible Equity Shareholders as well as the Renouncees to make Applications in this Issue basis the Rights Entitlement credited in their respective demat accounts.

Please note that one single Application Form shall be used by Investors to make Applications for all Rights Entitlements available in a particular demat account. In case of Investors who have provided details of demat account in accordance with the SEBI ICDR Regulations, such Investors will have to apply for the Rights Equity Shares from the same demat account in which they are holding the Rights Entitlements and in case of multiple demat accounts, the Investors are required to submit a separate Application Form for each demat account.

Investors may apply for the Rights Equity Shares by submitting the Application Form to the Designated Branch of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts. Investors are also advised to ensure that the Application Form is correctly filled up stating therein that the ASBA Account in which an amount equivalent to the amount payable on Application as stated in the Application Form will be blocked by the SCSB.

Applicants should carefully fill-in their depository account details and PAN in the Application Form or while submitting application through online/electronic Application through the website of the SCSBs (if made available by such SCSB). Please note that incorrect depository account details or PAN or Application Forms without depository account details shall be treated as incomplete and shall be rejected. For details, see “*Grounds for Technical Rejection*” on page 74. Our Company, the Registrar and the SCSBs shall not be liable for any incomplete or incorrect demat details provided by the Applicants.

Additionally, in terms of Regulation 78 of the SEBI ICDR Regulations, Investors may choose to accept the offer to participate in this Issue by making plain paper Applications. Please note that SCSBs shall accept such applications only if all details required for making the application as per the SEBI ICDR Regulations are specified in the plain paper application and that Eligible Equity Shareholders making an application in this Issue by way of plain paper applications shall not be permitted to renounce any portion of their Rights Entitlements. For details, see “*Making of an Application by Eligible Equity Shareholders on Plain Paper under ASBA process*” on page 71.

- ***Options available to the Eligible Equity Shareholders***

The Rights Entitlement Letter will clearly indicate the number of Rights Equity Shares that the Eligible Equity Shareholder is entitled to in the Issue.

If the Eligible Equity Shareholder applies in this Issue, then such Eligible Equity Shareholder can:

- (i) apply for its Rights Equity Shares to the full extent of its Rights Entitlements; or
- (ii) apply for its Rights Equity Shares to the extent of part of its Rights Entitlements (without renouncing the other part); or
- (iii) apply for Rights Equity Shares to the extent of part of its Rights Entitlements and renounce the other part of its Rights Entitlements; or
- (iv) apply for its Rights Equity Shares to the full extent of its Rights Entitlements and apply for Additional Rights Equity Shares; or
- (v) renounce its Rights Entitlements in full.

- ***Making of an Application through the ASBA process***

An Investor, wishing to participate in this Issue through the ASBA facility, is required to have an ASBA enabled bank account with SCSBs, prior to making the Application. Investors desiring to make an Application in this Issue through ASBA process, may submit the Application Form in physical mode to the Designated Branches of the SCSB or online/ electronic Application through the website of the SCSBs (if made available by such SCSB)

for authorizing such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Investors should ensure that they have correctly submitted the Application Form and have provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34.

Please note that subject to SCSBs complying with the requirements of the SEBI ICDR Master Circular, within the periods stipulated therein, applications may be submitted at the Designated Branches of the SCSBs. Further, in terms of the SEBI ICDR Master Circular, it is clarified that for making Applications by SCSBs on their own account using ASBA facility, each such SCSB should have a separate account in its own name with any other SEBI registered SCSB(s). Such account shall be used solely for the purpose of making an Application in this Issue and clear demarcated funds should be available in such account for such an Application.

Our Company, their directors, their employees, affiliates, associates and their respective directors and officers and the Registrar shall not take any responsibility for acts, mistakes, errors, omissions and commissions etc., in relation to Applications accepted by SCSBs, Applications uploaded by SCSBs, Applications accepted but not uploaded by SCSBs or Applications accepted and uploaded without blocking funds in the ASBA Accounts.

Investors applying through the ASBA facility should carefully read the provisions applicable to such Applications before making their Application through the ASBA process.

Do's for Investors applying through ASBA:

- (a) Ensure that the necessary details are filled in the Application Form including the details of the ASBA Account.
- (b) Ensure that the details about your Depository Participant, PAN and beneficiary account are correct and the beneficiary account is activated as the Rights Equity Shares will be Allotted in the dematerialized form only.
- (c) Ensure that the Applications are submitted with the Designated Branch of the SCSBs and details of the correct bank account have been provided in the Application.
- (d) Ensure that there are sufficient funds (equal to {number of Rights Equity Shares (including Additional Rights Equity Shares) applied for} X {Application Money of Equity Shares}) available in ASBA Account mentioned in the Application Form before submitting the Application to the respective Designated Branch of the SCSB.
- (e) Ensure that you have authorised the SCSB for blocking funds equivalent to the total amount payable on application mentioned in the Application Form, in the ASBA Account, of which details are provided in the Application Form and have signed the same.
- (f) Ensure that you have a bank account with SCSBs providing ASBA facility in your location and the Application is made through that SCSB providing ASBA facility in such location.
- (g) Ensure that you receive an acknowledgement from the Designated Branch of the SCSB for your submission of the Application Form in physical form or plain paper Application.
- (h) Ensure that the name(s) given in the Application Form is exactly the same as the name(s) in which the beneficiary account is held with the Depository Participant. In case the Application Form is submitted in joint names, ensure that the beneficiary account is also held in same joint names and such names are in the same sequence in which they appear in the Application Form and the Rights Entitlement Letter.
- (i) Ensure that your PAN is linked with Aadhaar and you are in compliance with CBDT notification dated Feb 13, 2020 read with press release dated June 25, 2021 and September 17, 2021.

Don'ts for Investors applying through ASBA:

- (a) Do not apply if you are not eligible to participate in the Issue under the securities laws applicable to your jurisdiction.

- (b) Do not apply if you have not provided an Indian address.
- (c) Do not submit the Application Form after you have submitted a plain paper Application to a Designated Branch of the SCSB or vice versa.
- (d) Do not send your physical Application to the Registrar, the Bankers to the Issue (assuming that such Bankers to the Issue are not SCSB's), a branch of the SCSB which is not a Designated Branch of the SCSB or our Company; instead submit the same to a Designated Branch of the SCSB only.
- (e) Do not instruct the SCSBs to unblock the funds blocked under the ASBA process upon making the Application.
- (f) Do not submit Application Form using third party ASBA account.
- (g) Avoiding applying on the Issue Closing Date due to risk of delay/restriction in making any physical Application.
- (h) Do not submit Multiple Application Forms.

- ***Making of an Application by Eligible Equity Shareholders on Plain Paper under ASBA process***

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to this Issue on plain paper in terms of Regulation 78 of SEBI ICDR Regulations in case of non-receipt of Application Form as detailed above. In such cases of non-receipt of the Application Form through physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application Form that is available on the website of the Company, Registrar of the Issue or Stock Exchange. An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that in terms of Regulation 78 of SEBI ICDR Regulations, the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilize the Application Form for any purpose including renunciation even if it is received subsequently.

The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

1. Name of our Company, being **Anondita Medicare Limited**;
2. Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);
3. Folio number (in case of Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date)/DP and Client ID;
4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to this Issue;
5. Number of Equity Shares held as on Record Date;
6. Allotment option – only dematerialised form;
7. Number of Rights Equity Shares entitled to;
8. Number of Rights Equity Shares applied for within the Rights Entitlements;
9. Number of Additional Rights Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
10. Total number of Rights Equity Shares applied for;

11. Total Application amount paid at the rate of Rs 950/- (Rupees Nine Hundred and Fifty only) per Rights Equity Share;
12. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE / FCNR/ NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and
16. All such Eligible Equity Shareholders shall be deemed to have made the representations, warranties and agreements set forth in "Restrictions on Purchases and Resales - Representations, Warranties and Agreements by Purchasers" on page 92, and shall include the following:

"I/We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States (including its territories and possessions thereof, any State of the United States and the District of Columbia) (the "United States"), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable securities laws of any State of the United States. I/we understand the Rights Equity Shares and Rights Entitlements referred to in this application are being offered and sold only outside the United States in "offshore transactions" in reliance on Regulation S under the U.S. Securities Act ("Regulation S") to existing shareholders and located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions and in compliance with the applicable laws of such jurisdictions. I/we understand that the Issue is not, and under no circumstances is to be construed as, an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of the said Rights Equity Shares or Rights Entitlements in the United States. I/we confirm that I/we (a) am/are not in the United States and am/are eligible to subscribe for the Rights Equity Shares under applicable securities laws, (b) am/are complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar to the Issue, nor any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar to the Issue or any other person acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction.

I/We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation. I/We satisfy, and each account for which I/we are acting satisfies, (a) all suitability standards for investors in investments of the type subscribed for herein imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.

I/we hereby make the representations, warranties, acknowledgments and agreements set forth in the section of the Letter of Offer titled "Restrictions on Purchases and Resales" on page 92.

I/ We acknowledge that the Company, its affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account including cases where an Investor submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar (i.e. <https://www.skylinerta.com/>) and the Stock Exchange (i.e. www.nseindia.com)

Our Company and the Registrar of the Issue shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Investors' ASBA Accounts on or before the Issue Closing Date.

- ***Making of an Application by Eligible Equity Shareholders holding Equity Shares in physical form***

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialised form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Rights Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two clear Working Days prior to the Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shares in physical form, and/or whose demat account details are not available with our Company or the Registrar, shall be credited in the Demat Suspense Account.

Eligible Equity Shareholders, who hold Equity Shares in physical form as on Record Date and who have opened their demat accounts after the Record Date, shall adhere to following procedure for participating in this Issue:

- (a) The Eligible Equity Shareholders shall visit <https://www.skylinerta.com/>, to upload their client master sheet and also provide the other details as required, no later than two Clear Working Days prior to the Issue Closing Date;
- (b) The Registrar shall, after verifying the details of such demat account, transfer the Rights Entitlements of such Eligible Equity Shareholders to their demat accounts at least one day before the Issue Closing Date; and
- (c) The remaining procedure for Application shall be same as set out in the section entitled “- Making of an Application by Eligible Equity Shareholders on Plain Paper under ASBA process” on page 69.

Resident Eligible Equity Shareholders who hold Equity Shares in physical form as on the Record Date will not be allowed to renounce their Rights Entitlements in the Issue. However, such Eligible Equity Shareholders, where the dematerialized Rights Entitlements are transferred from the demat suspense escrow account to the respective demat accounts within prescribed timelines, can apply for Additional Rights Equity Shares while submitting the Application through ASBA process.

- ***Application for Additional Rights Equity Shares***

Investors are eligible to apply for Additional Rights Equity Shares over and above their Rights Entitlements, provided that they are eligible to apply for Equity Shares under applicable law and they have applied for all the Rights Equity Shares forming part of their Rights Entitlements without renouncing them in whole or in part. Where the number of Additional Rights Equity Shares applied for exceeds the number available for Allotment, the Allotment would be made as per the Basis of Allotment finalised in consultation with the Designated Stock Exchange. Applications for Additional Rights Equity Shares shall be considered and Allotment shall be made in accordance with the SEBI ICDR Regulations and in the manner as set out in the section entitled “- Basis of Allotment” on page 85.

- ***Additional general instructions for Investors in relation to making of an Application***

- a) Please read the Letter of Offer carefully to understand the Application process and applicable settlement process.
- b) Please read the instructions on the Application Form sent to you. Application should be complete in all respects. The Application Form found incomplete with regard to any of the particulars required to be given therein, and/or which are not completed in conformity with the terms of this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter and the Application Form are liable to be rejected. The Application Form must be filled in English.
- c) In case of non-receipt of Application Form, Application can be made on plain paper mentioning all necessary details as mentioned under the section entitled “Making of an Application by Eligible Equity Shareholders on Plain Paper under ASBA process” on page 69.
- d) Applications should be submitted to the Designated Branch of the SCSB or made online/electronic through the website of the SCSBs (if made available by such SCSB) for authorising such SCSB to block Application Money payable on the Application in their respective ASBA Accounts. Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchange.
- e) Applications should not be submitted to the Bankers to the Issue (assuming that such Bankers to the Issue are not SCSBs), our Company or the Registrar.
- f) All Applicants, and in the case of Application in joint names, each of the joint Applicants, should mention their PAN allotted under the Income-Tax Act, irrespective of the amount of the Application. Except for Applications on behalf of the Central or the State Government, the residents of Sikkim and the officials

appointed by the courts, Applications without PAN will be considered incomplete and are liable to be rejected. With effect from August 16, 2010, the demat accounts for Investors for which PAN details have not been verified shall be “suspended for credit” and no Allotment and credit of Rights Equity Shares pursuant to this Issue shall be made into the accounts of such Investors.

- g) Ensure that the demographic details such as address, PAN, DP ID, Client ID, bank account details and occupation (“Demographic Details”) are updated, true and correct, in all respects. Investors applying under this Issue should note that on the basis of name of the Investors, DP ID and Client ID provided by them in the Application Form or the plain paper Applications, as the case may be, the Registrar will obtain Demographic Details from the Depository. Therefore, Investors applying under this Issue should carefully fill in their Depository Account details in the Application. These Demographic Details would be used for all correspondence with such Investors including mailing of the letters intimating unblocking of bank account of the respective Investor and/or refund. The Demographic Details given by the Investors in the Application Form would not be used for any other purposes by the Registrar. Hence, Investors are advised to update their Demographic Details as provided to their Depository Participant The Allotment Advice and the intimation on unblocking of ASBA Account or refund (if any) would be mailed to the address of the Investor as per the Indian address provided to our Company or the Registrar or Demographic Details received from the Depositories. The Registrar will give instructions to the SCSBs for unblocking funds in the ASBA Account to the extent Rights Equity Shares are not Allotted to such Investor. Please note that any such delay shall be at the sole risk of the Investors and none of our Company, the SCSBs or the Registrar shall be liable to compensate the Investor for any losses caused due to any such delay or be liable to pay any interest for such delay. In case no corresponding record is available with the Depositories that match three parameters, (a) names of the Investors (including the order of names of joint holders), (b) DP ID, and (c) Client ID, then such Application Forms are liable to be rejected.
- h) By signing the Application Forms, Investors would be deemed to have authorised the Depositories to provide, upon request, to the Registrar, the required Demographic Details as available on its records.
- i) For physical Applications through ASBA at Designated Branches of SCSB, signatures should be either in English or Hindi or in any other language specified in the Eighth Schedule to the Constitution of India. Signatures other than in any such language or thumb impression must be attested by a Notary Public or a Special Executive Magistrate under his/her official seal. The Investors must sign the Application as per the specimen signature recorded with the SCSB.
- j) Investors should provide correct DP ID and Client ID/ folio number (for Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date) while submitting the Application. Such DP ID and Client ID/ folio number should match the demat account details in the records available with Company and/or Registrar of the Issue, failing which such Application is liable to be rejected. Investor will be solely responsible for any error or inaccurate detail provided in the Application. Our Company, SCSBs or the Registrar will not be liable for any such rejections.
- k) In case of joint holders and physical Applications through ASBA process, all joint holders must sign the relevant part of the Application Form in the same order and as per the specimen signature(s) recorded with the SCSB. In case of joint Applicants, reference, if any, will be made in the first Applicant’s name and all communication will be addressed to the first Applicant.
- l) All communication in connection with Application for the Rights Equity Shares, including any change in contact details of the Eligible Equity Shareholders should be addressed to the Registrar prior to the date of Allotment in this Issue quoting the name of the first/sole Applicant, folio number (for Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date)/DP ID and Client ID and Application Form number, as applicable. In case of any change in contact details of the Eligible Equity Shareholders, the Eligible Equity Shareholders should also send the intimation for such change to the respective depository participant, or to our Company or the Registrar in case of Eligible Equity Shareholders holding Equity Shares in physical form.
- m) Investors are required to ensure that the number of Rights Equity Shares applied for by them does not exceed the prescribed limits under the applicable law.
- n) Do not apply if you are ineligible to participate in this Issue under the securities laws applicable to your jurisdiction.
- o) Do not submit the GIR number instead of the PAN as the application is liable to be rejected on this ground.
- p) Avoid applying on the Issue Closing Date due to risk of delay/ restrictions in making any physical Application.
- q) Do not pay the Application Money in cash, by money order, pay order or postal order.
- r) Do not submit Multiple Applications.
- s) An Applicant being an OCB is required not to be under the adverse notice of RBI and in order to apply in this Issue as an incorporated non-resident must do so in accordance with the FDI Policy and the FEMA Rules, as amended.
- t) Ensure that your PAN is linked with Aadhaar and you are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021 and September 17, 2021.

- ***Grounds for Technical Rejection***

Applications made in this Issue are liable to be rejected on the following grounds:

- a) DP ID and Client ID mentioned in Application does not match with the DP ID and Client ID records available with the Registrar.
- b) Details of PAN mentioned in the Application does not match with the PAN records available with the Registrar.
- c) Sending an Application to our Company, the Registrar of the Issue, Bankers to the Issue (assuming that such Bankers to the Issue are not SCSBs), to a branch of a SCSB which is not a Designated Branch of the SCSB.
- d) Insufficient funds are available in the ASBA Account with the SCSB for blocking the Application Money.
- e) Funds in the ASBA Account whose details are mentioned in the Application Form having been frozen pursuant to regulatory orders.
- f) Account holder not signing the Application or declaration mentioned therein.
- g) Submission of more than one Application Form for Rights Entitlements available in a particular demat account.
- h) Multiple Application Forms, including cases where an Investor submits Application Forms along with a plain paper Application.
- i) Submitting the GIR number instead of the PAN (except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts).
- j) Applications by persons not competent to contract under the Indian Contract Act, 1872, except Applications by minors having valid demat accounts as per the Demographic Details provided by the Depositories.
- k) Applications by SCSB on own account, other than through an ASBA Account in its own name with any other SCSB.
- l) Application Forms which are not submitted by the Investors within the time periods prescribed in the Application Form and the Letter of Offer.
- m) Physical Application Forms not duly signed by the sole or joint Investors, as applicable.
- n) order, postal order or outstation demand drafts.
- o) If an Investor is (a) debarred by SEBI; or (b) if SEBI has revoked the order or has provided any interim relief then failure to attach a copy of such SEBI order allowing the Investor to subscribe to their Rights Entitlements.
- p) Applications which: (i) appears to our Company or its agents to have been executed in, electronically transmitted from or dispatched from jurisdictions where the offer and sale of the Rights Equity Shares is not permitted under laws of such jurisdictions; (ii) does not include the relevant certifications set out in the Application Form, including to the effect that the person submitting and/or renouncing the Application Form is outside the United States, and is eligible to subscribe for the Rights Equity Shares under applicable securities laws and is complying with laws of jurisdictions applicable to such person in connection with this Issue; and our Company shall not be bound to issue or allot any Rights Equity Shares in respect of any such Application Form.
- q) Applications which have evidence of being executed or made in contravention of applicable securities laws.
- r) Application from Investors that are residing in U.S. address as per the depository records [(unless the Application Form is submitted by a person who is both an U.S. QIB and U.S. Qualified Purchaser in the United States)].
- s) Applicants not having the requisite approvals to make Application in the Issue.

- ***Multiple Applications***

In case where multiple Applications are made using same demat account in respect of the same set of Rights Entitlement, such Applications shall be liable to be rejected. A separate Application can be made in respect of Rights Entitlements in each demat account of the Investors, and such Applications shall not be treated as multiple applications. Similarly, a separate Application can be made against Equity Shares held in dematerialized form and Equity Shares held in physical form, and such Applications shall not be treated as multiple applications. Further supplementary Applications in relation to further Rights Equity Shares with/without using additional Rights Entitlement will not be treated as multiple application. A separate Application can be made in respect of each scheme of a mutual fund registered with SEBI and such Applications shall not be treated as multiple applications. For details, please see “- Procedure for Applications by Mutual Funds” on page 77.

In cases where Multiple Application Forms are submitted, including cases where (a) an Investor submits Application Forms along with a plain paper Application or (b) multiple plain paper Applications (c) or multiple applications through ASBA, such Applications may be treated as multiple applications and are liable to be rejected or all the balance shares other than Rights Entitlement will be considered as additional shares applied for, other than multiple applications submitted by any of our Promoter or members of our Promoter Group to meet the minimum subscription requirements, if applicable, to this Issue as described in the section entitled “Summary of this Letter of Offer – Intention and extent of participation by our Promoters and Promoter Group” on page 15.

- **Procedure for Applications by certain categories of Investors**

- ***Procedure for Applications by FPIs***

In terms of applicable FEMA Rules and the SEBI FPI Regulations, investments by FPIs in the Equity Shares is subject to certain limits, i.e., the individual holding of an FPI (including its investor group (which means multiple entities registered as foreign portfolio investors and directly and indirectly having common ownership of more than 50% of common control)) shall be below 10% of our post-Issue Equity Share capital. In case the total holding of an FPI or investor group increases beyond 10% of the total paid-up Equity Share capital of our Company, on a fully diluted basis or 10% or more of the paid-up value of any series of debentures or preference shares or share warrants that may be issued by our Company, the total investment made by the FPI or investor group will be re-classified as FDI subject to the conditions as specified by SEBI and RBI in this regard. Further, the aggregate limit of all FPIs investments is up to the sectoral cap applicable to the sector in which our Company operates.

FPIs are permitted to participate in this Issue subject to compliance with conditions and restrictions which may be specified by the Government from time to time. FPIs who wish to participate in the Issue are advised to use the Application Form for non-residents. Subject to compliance with all applicable Indian laws, rules, regulations, guidelines and approvals in terms of Regulation 21 of the SEBI FPI Regulations, an FPI may issue, subscribe to or otherwise deal in offshore derivative instruments (as defined under the SEBI FPI Regulations as any instrument, by whatever name called, which is issued overseas by an FPI against securities held by it that are listed or proposed to be listed on any recognised stock exchange in India, as its underlying) directly or indirectly, only in the event (i) such offshore derivative instruments are issued only to persons registered as Category I FPI under the SEBI FPI Regulations; (ii) such offshore derivative instruments are issued only to persons who are eligible for registration as Category I FPIs (where an entity has an investment manager who is from the Financial Action Task Force member country, the investment manager shall not be required to be registered as a Category I FPI); (iii) such offshore derivative instruments are issued after compliance with 'know your client' norms; and (iv) compliance with other conditions as may be prescribed by SEBI.

An FPI issuing offshore derivative instruments is also required to ensure that any transfer of offshore derivative instruments issued by or on its behalf, is carried out subject to, inter-alia, the following conditions:

- a. such offshore derivative instruments are transferred only to persons in accordance with the SEBI FPI Regulations; and
- b. prior consent of the FPI is obtained for such transfer, except when the persons to whom the offshore derivative instruments are to be transferred to are pre-approved by the FPI.

Procedure for Applications by AIFs, FVCIs, VCFs and FDI route

The SEBI VCF Regulations and the SEBI FVCI Regulations prescribe, among other things, the investment restrictions on VCFs and FVCIs registered with SEBI. Further, the SEBI AIF Regulations prescribe, among other things, the investment restrictions on AIFs.

As per the SEBI VCF Regulations and SEBI FVCI Regulations, VCFs and FVCIs are not permitted to invest in listed companies pursuant to rights issues. Accordingly, applications by VCFs or FVCIs will not be accepted in this Issue. Further, venture capital funds registered as Category I AIFs, as defined in the SEBI AIF Regulations, are not permitted to invest in listed companies pursuant to rights issues. Accordingly, applications by venture capital funds registered as category I AIFs, as defined in the SEBI AIF Regulations, will not be accepted in this Issue. Other categories of AIFs are permitted to apply in this Issue subject to compliance with the SEBI AIF Regulations. Such AIFs having bank accounts with SCSBs that are providing ASBA in cities / centres where such AIFs are located are mandatorily required to make use of the ASBA facility. Otherwise, applications of such AIFs are liable for rejection.

Procedure for Applications by NRIs

Investments by NRIs are governed by the FEMA Rules. Applications will not be accepted from NRIs that are ineligible to participate in this Issue under applicable securities laws.

As per the FEMA Rules, an NRI or Overseas Citizen of India ("OCI") may purchase or sell capital instruments of a listed Indian company on repatriation basis, on a recognised stock exchange in India, subject to the conditions, inter alia, that the total holding by any individual NRI or OCI will not exceed 5% of the total paid-up equity capital on a fully diluted basis or should not exceed 5% of the paid-up value of each series of debentures or preference shares or share warrants issued by an Indian company and the total holdings of all NRIs and OCIs put together will not exceed 10% of the total paid-up equity capital on a fully diluted basis or shall not exceed 10% of the paid-up value of each series of debentures or preference shares or share warrants. The aggregate ceiling of 10% may be raised to 24%, if a special resolution to that effect is passed by the general body of the Indian company.

Further, in accordance with press note 3 of 2020, the FDI Policy has been amended to state that all investments by entities incorporated in a country which shares land border with India or where the beneficial owner of an investment into India is situated in or is a citizen of any such country ("Restricted Investors"), will require prior

approval of the Government of India. It is not clear from the press note whether or not an issue of the Rights Equity Shares to Restricted Investors will also require prior approval of the Government of India and each Investor should seek independent legal advice about its ability to participate in the Issue. In the event such prior approval has been obtained, the Investor shall intimate our Company and the Registrar about such approval within the Issue Period.

- ***Procedure for Applications by Mutual Funds***

A separate application can be made in respect of each scheme of an Indian mutual fund registered with SEBI and such applications shall not be treated as multiple applications. The applications made by asset management companies or custodians of a mutual fund should clearly indicate the name of the concerned scheme for which the application is being made.

No Mutual Fund scheme shall invest more than 10% of its net asset value in equity shares or equity related instruments of any single company provided that the limit of 10% shall not be applicable for investments in case of index funds or exchange traded funded or sector or industry specific schemes. No Mutual Fund under all its schemes should own more than 10% of any company's paid-up share capital carrying voting rights.

- ***Procedure for Applications by Systemically Important Non-Banking Financial Companies ("NBFC-SI")***

In case of an application made by NBFC-SI registered with RBI, (a) the certificate of registration issued by RBI under Section 45IA of RBI Act, 1934 and (b) net worth certificates from its statutory auditors or any independent chartered accountant based on the last audited financial statements is required to be attached to the application.

- ***Application by Specific Investor***

In case of renunciation of Rights Entitlement to Specific Investor by Our Promoter or members of our Promoter Group

Our Promoter or members of our Promoter Group may renounce any portion of their Rights Entitlement to one of more Specific Investor(s) subject to disclosure of the same in terms of the SEBI ICDR Regulations. The name of the Specific Investor(s) (i.e. the Renouncee), the name of our Promoter or members of our Promoter Group (i.e. renouncer) and the number of Rights Entitlements renounced in favour of such Specific Investor(s) shall be disclosed by our Company in the public advertisement at least two days prior to the Issue Opening Date.

In case of such renunciation of Rights Entitlement by our Promoter or members of our Promoter Group to any Specific Investor, all rights and obligations of the Eligible Equity Shareholders in relation to Applications and refunds pertaining to this Issue shall apply to the Specific Investor(s) (i.e. the Renouncee) as well.

The Application by such Specific Investor(s) shall be made on the Issue Opening Date before 11:00 a.m. (Indian Standard Time) and no withdrawal of such Application by the Specific Investor(s) shall be permitted. Our Company undertakes to disclose to the Stock Exchange(s) whether such Specific Investor(s) have made the Application or not, for dissemination on the Issue Opening Date by 11:30 a.m. (Indian Standard Time).

In case of allotment of any undersubscribed portion of the Rights Issue to Specific Investor

Our Company may allot any undersubscribed portion (if any) of the Rights Issue to one of more Specific Investor(s) and the names of such Specific Investor(s) shall be disclosed by our Company in the public advertisement at least two days prior to the Issue Opening Date. The Application by such Specific Investor(s) shall be made along with their Application Money before the finalisation of Basis of Allotment for undersubscribed portion of the Rights Issue in co-ordination with our Company and Registrar.

- ***Last date for Application***

The last date for submission of the duly filled in the Application Form or a plain paper Application is Tuesday, September 22, 2026, i.e., Issue Closing Date. Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application Form is not submitted with an SCSB, uploaded with the Stock Exchange and the Application Money is not blocked with the SCSB, on or before the Issue Closing Date or such date as may be extended by our Board or any committee thereof, the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby

offered, as set out in the section entitled “- Basis of Allotment” on page 85.

Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5.00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchange.

Please ensure that the Application Form and necessary details are filled in. In place of Application number, Investors can mention the reference number of the e-mail received from Registrar informing about their Rights Entitlement or last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of application number.

- ***Withdrawal of Application***

An Investor who has applied in this Issue may withdraw their Application at any time during Issue Period by approaching the SCSB where application is submitted. However, no Investor applying through ASBA facility may withdraw their Application post 5.00 P.M. (Indian Standard Time) on the Issue Closing Date.

No withdrawal of the Application by Specific Investor(s) shall be permitted, if such application is made pursuant to renunciation of Rights Entitlement by Our Promoter or members of our Promoter Group in favour of such Specific Investor.

- ***Disposal of Application and Application Money***

No acknowledgment will be issued for the Application Money received by our Company. However, the Designated Branches of the SCSBs receiving the Application Form will acknowledge its receipt by stamping and returning the acknowledgment slip at the bottom of each Application Form.

Our Board or a committee thereof reserves its full, unqualified and absolute right to accept or reject any Application, in whole or in part, and in either case without assigning any reason thereto.

In case an Application is rejected in full, the whole of the Application Money will be unblocked in the respective ASBA Accounts, in case of Applications through ASBA. Wherever an Application is rejected in part, the balance of Application Money, if any, after adjusting any money due on Rights Equity Shares Allotted, will be refunded / unblocked in the respective bank accounts from which Application Money was received/ASBA Accounts of the Investor within one Working Day from the Issue Closing Date. In case of failure to do so, our Company shall pay interest at such rate and within such time as specified under applicable law.

For further instructions, please read the Application Form carefully.

III. CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS

As your name appears as a beneficial owner in respect of the issued and paid-up Equity Shares held in dematerialised form or appears in the register of members of our Company as an Eligible Equity Shareholder in respect of our Equity Shares held in physical form, as on the Record Date, you may be entitled to subscribe to the number of Rights Equity Shares as set out in the Rights Entitlement Letter.

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar of the issue (i.e. <https://www.skylinerta.com/>) by entering their DP ID and Client ID or folio number (for Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date) and PAN. The link for the same shall also be available on the website of our Company (i.e. <https://www.anonditamedicare.com/>).

In this regard, our Company has made necessary arrangements with NSDL and CDSL for crediting of the Rights Entitlements to the demat accounts of the Eligible Equity Shareholders in a dematerialized form. A separate ISIN for the Rights Entitlements has also been generated which is ISIN: INE0VTV20012 . The said ISIN shall remain frozen (for debit) until the Issue Opening Date. The said ISIN shall be suspended for transfer by the Depositories post the Issue Closing Date.

Additionally, our Company will submit the details of the total Rights Entitlements credited to the demat accounts of the Eligible Equity Shareholders and the demat suspense escrow account to the Stock Exchange after completing the corporate action. The details of the Rights Entitlements with respect to each Eligible Equity Shareholders can be accessed by such respective Eligible Equity Shareholders on the website of the Registrar after keying in their respective details along with other security control measures implemented thereat.

Rights Entitlements shall be credited to the respective demat accounts of Eligible Equity Shareholders before the Issue Opening Date only in dematerialised form. Further, if no Application is made by the Eligible Equity Shareholders of Rights Entitlements on or before Issue Closing Date, such Rights Entitlements shall lapse and

shall be extinguished after the Issue Closing Date. No Rights Equity Shares for such lapsed Rights Entitlements will be credited, even if such Rights Entitlements were purchased from market and purchaser will lose the premium paid to acquire the Rights Entitlements. Persons who are credited the Rights Entitlements are required to make an Application to apply for Rights Equity Shares offered under the Issue for subscribing to the Rights Equity Shares offered under the Issue.

If Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date, have not provided the details of their demat accounts to our Company or to the Registrar, they are required to provide their demat account details to our Company or the Registrar no later than two clear Working Days prior to the Issue Closing Date, to enable the credit of the Rights Entitlements by way of transfer from the demat suspense escrow account to their respective demat accounts, at least one day before the Issue Closing Date. Such Eligible Equity Shareholders holding shares in physical form can update the details of their respective demat accounts on the website of the Registrar of the issue (i.e. <https://www.skylinerta.com/>). Such Eligible Equity Shareholders can make an Application only after the Rights Entitlements is credited to their respective demat accounts.

In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Master Circular, the credit of Rights Entitlements and Allotment of Rights Equity Shares shall be made in dematerialized form only.

Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, “ANONDITA MEDICARE LIMITED RIGHTS ISSUE SUSPENSE ESCROW DEMAT ACCOUNT”) opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI LODR Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non- institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two clear Working Days prior to the Issue Closing Date, i.e., by Tuesday, September 15, 2026 to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in the Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar account is active to facilitate the aforementioned transfer.

IV. RENUNCIATION AND TRADING OF RIGHTS ENTITLEMENT

- ***Renouncees***

All rights and obligations of the Eligible Equity Shareholders in relation to Applications and refunds pertaining to this Issue shall apply to the Renouncee(s) as well.

- ***Renunciation of Rights Entitlements***

This Issue includes a right exercisable by Eligible Equity Shareholders to renounce the Rights Entitlements credited to their respective demat account either in full or in part.

The renunciation from non-resident Eligible Equity Shareholder(s) to resident Indian(s) and vice versa shall be subject to provisions of FEMA Rules and other circular, directions, or guidelines issued by RBI or the Ministry of Finance from time to time. However, the facility of renunciation shall not be available to or operate in favour of an Eligible Equity Shareholders being an erstwhile OCB unless the same is in compliance with the FEMA Rules and other circular, directions, or guidelines issued by RBI or the Ministry of Finance from time to time.

The renunciation of Rights Entitlements credited in your demat account can be made either by sale of such Rights Entitlements, using the secondary market platform of the Stock Exchange or through an off-market transfer.

- ***Procedure for Renunciation of Rights Entitlements***

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market platform of the Stock Exchange (the “**On Market Renunciation**”); or (b) through an off-market transfer (the “**Off Market Renunciation**”), during the Renunciation Period. The Investors should have the demat Rights Entitlements credited / lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation and Off Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism.

Investors may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Investors who intend to trade in the Rights Entitlements should consult their tax advisor or stock-broker regarding any cost, applicable taxes, charges and expenses (including brokerage) that may be levied for trading in Rights Entitlements.

Please note that the Rights Entitlements which are neither renounced nor subscribed by the Investors on or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

a) *On Market Renunciation*

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchange through a registered stock-broker in the same manner as the existing Equity Shares of our Company.

In this regard, in terms of provisions of the SEBI ICDR Regulations and the SEBI ICDR Master Circular, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchange under ISIN: INE0VTV20012 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from the Stock Exchange for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will trade. The details for trading in Rights Entitlements will be as specified by the Stock Exchange from time to time.

The Rights Entitlements are tradable in dematerialized form only. As our Company is listed on the SME Platform of NSE Limited, the market lot for trading of Rights Entitlements shall be the same as applicable to the Equity Shares of our Company on the SME Platform, i.e., 200 Rights Entitlements per lot.

The On Market Renunciation shall take place only during the Renunciation Period for On Market Renunciation, i.e., from Wednesday, September 09, 2026 to Friday, September 11, 2026 (both days inclusive).

The Investors holding the Rights Entitlements who desire to sell their Rights Entitlements will have to do so through their registered stock-brokers by quoting the ISIN: INE0VTV20012 and indicating the details of the Rights Entitlements they intend to trade. The Investors can place order for sale of Rights Entitlements only to the extent of Rights Entitlements available in their demat account.

The On Market Renunciation shall take place electronically on secondary market platform of NSE under automatic order matching mechanism and on ‘T+2 rolling settlement basis’, where ‘T’ refers to the date of trading. The transactions will be settled on trade-for-trade basis. Upon execution of the order, the stock-broker will issue a contract note in accordance with the requirements of the Stock Exchange and the SEBI.

b) *Off Market Renunciation*

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off-market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only.

Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date to enable Renouncees to subscribe to the Rights Equity Shares in the Issue.

The Investors holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the ISIN: INE0VTV20012, the details of the buyer and the details of the Rights Entitlements they intend to transfer. The buyer of the Rights Entitlements (unless already having given a standing receipt instruction) has to issue a receipt instruction slip to their depository participant. The Investors can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demat account.

The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants.

The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL

and CDSL from time to time.

V. MODE OF PAYMENT

All payments against the Application Forms shall be made only through ASBA facility. The Registrar will not accept any payments against the Application Forms, if such payments are not made through ASBA facility.

Under the ASBA facility, the Investor agrees to block the entire amount payable on Application with the submission of the Application Form, by authorizing the SCSB to block an amount, equivalent to the amount payable on Application, in the Investor's ASBA Account. The SCSB may reject the application at the time of acceptance of Application Form if the ASBA Account, details of which have been provided by the Investor in the Application Form does not have sufficient funds equivalent to the amount payable on Application mentioned in the Application Form. Subsequent to the acceptance of the Application by the SCSB, our Company would have a right to reject the Application on technical grounds as set forth in this Letter of Offer and the Draft Letter of Offer.

After verifying that sufficient funds are available in the ASBA Account details of which are provided in the Application Form, the SCSB shall block an amount equivalent to the Application Money mentioned in the Application Form until the Transfer Date. On the Transfer Date, upon receipt of intimation from the Registrar, of the receipt of minimum subscription and pursuant to the finalization of the Basis of Allotment as approved by the Designated Stock Exchange, the SCSBs shall transfer such amount as per the Registrar's instruction from the ASBA Account into the Allotment Account(s) which shall be a separate bank account maintained by our Company, other than the bank account referred to in sub-section (3) of Section 40 of the Companies Act, 2013. The balance amount remaining after the finalisation of the Basis of Allotment on the Transfer Date shall be unblocked by the SCSBs on the basis of the instructions issued in this regard by the Registrar to the respective SCSB.

In terms of RBI Circular DBOD No. FSC BC 42/24.47.00/2003- 04 dated November 5, 2003, the stock invest scheme has been withdrawn. Hence, payment through stock invest would not be accepted in this Issue.

Mode of payment for Resident Investors

All payments on the Application Forms shall be made only through ASBA facility. Applicants are requested to strictly adhere to these instructions.

Mode of payment for Non-Resident Investors

As regards the Application by non-resident Investors, payment must be made only through ASBA facility and using permissible accounts in accordance with FEMA, FEMA Rules and requirements prescribed by RBI and subject to the following:

1. In case where repatriation benefit is available, interest, dividend, sales proceeds derived from the investment in Rights Equity Shares can be remitted outside India, subject to tax, as applicable according to the Income- Tax Act. However, please note that conditions applicable at the time of original investment in our Company by the Eligible Equity Shareholder including repatriation shall not change and remain the same for subscription in the Issue or subscription pursuant to renunciation in the Issue.
2. Subject to the above, in case Rights Equity Shares are Allotted on a non-repatriation basis, the dividend and sale proceeds of the Rights Equity Shares cannot be remitted outside India.
3. In case of an Application Form received from non-residents, Allotment, refunds and other distribution, if any, will be made in accordance with the guidelines and rules prescribed by RBI as applicable at the time of making such Allotment, remittance and subject to necessary approvals.
4. Application Forms received from non-residents/ NRIs, or persons of Indian origin residing abroad for Allotment of Rights Equity Shares shall, amongst other things, be subject to conditions, as may be imposed from time to time by RBI under FEMA, in respect of matters including Refund of Application Money and Allotment.
5. In the case of NRIs who remit their Application Money from funds held in FCNR/NRE Accounts, refunds and other disbursements, if any shall be credited to such account.

Non-resident Renouncees who are not Eligible Equity Shareholders must submit regulatory approval for applying for Additional Rights Equity Shares.

Payment Schedule of Rights Equity Shares

Particulars	Amount payable per Rights Equity Shares
On the Issue application (i.e. along with the Application Form)	Rs 950/-

The Rights Equity Shares allotted pursuant to the Issue, shall be fully paid up.

Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Investors.

VI. BASIS FOR THIS ISSUE AND TERMS OF THIS ISSUE

The Rights Equity Shares are being offered for subscription to the Eligible Equity Shareholders whose names appear as beneficial owners as per the list to be furnished by the Depositories in respect of our Equity Shares held in dematerialised form and on the register of members of our Company in respect of our Equity Shares held in physical form at the close of business hours on the Record Date.

For principal terms of Issue such as face value, Issue Price, Rights Entitlement, please see “The Issue” beginning on page 33.

- ***Fractional Entitlements***

For Equity Shares being offered on a rights basis under the Issue, if the shareholding of any of the Eligible Equity Shareholders is less than 19 (Nineteen) Equity Shares or is not in multiples, the fractional entitlement of such Eligible Equity Shareholders shall be ignored for computation of the Rights Entitlement. However, Eligible Equity Shareholders whose fractional entitlements are being ignored as above will be given preference in the Allotment of one additional Equity Share each, if such Eligible Equity Shareholders have applied for additional Equity Shares over and above their Rights Entitlement, if any.

As our Company is listed on the SME Platform of NSE, Rights Entitlements can be sold on the online mechanism of the Stock Exchange only in the market lot of 200 (Two Hundred) Rights Entitlements. Eligible Equity Shareholders holding Rights Entitlements less than the said market lot, or in a quantity that is not in multiples thereof, will accordingly be unable to sell such Rights Entitlements through the online mechanism, and may, at their discretion, renounce the same through off-market transfer in accordance with the applicable provisions of the SEBI ICDR Regulations.

- ***Ranking***

The Rights Equity Shares to be issued and Allotted pursuant to this Issue shall be subject to the provisions of this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter, the Application Form, and the Memorandum of Association and the Articles of Association, the provisions of the Companies Act, 2013, FEMA, the SEBI ICDR Regulations, the SEBI Listing Regulations, and the guidelines, notifications and regulations issued by SEBI, the Government of India and other statutory and regulatory authorities from time to time, the terms of the Listing Agreement entered into by our Company with the Stock Exchange and the terms and conditions as stipulated in the Allotment advice. The Rights Equity Shares to be issued and Allotted under this Issue, shall rank *pari passu* with the existing Equity Shares, in all respects including dividends.

- ***Listing and trading of the Rights Equity Shares to be issued pursuant to this Issue***

Subject to receipt of the listing and trading approvals, the Rights Equity Shares proposed to be issued on a rights basis shall be listed and admitted for trading on the Stock Exchange. Unless otherwise permitted by the SEBI ICDR Regulations, the Rights Equity Shares Allotted pursuant to this Issue will be listed as soon as practicable and all steps for completion of necessary formalities for listing and commencement of trading in the Rights Equity Shares will be taken within such period prescribed under the SEBI ICDR Regulations. Our Company has received in-principal approval from the NSE through letter bearing reference number NSE/LIST/C/2026/0866, dated August 25, 2026. Our Company will apply to the Stock Exchange for final approvals for the listing and trading of the Rights Equity Shares subsequent to their Allotment. No assurance can be given regarding the active or sustained trading in the Rights Equity Shares or the price at which the Rights Equity Shares offered under this Issue will trade after the listing thereof.

The existing Equity Shares are listed and traded on NSE (Symbol: ANONDITA) under the ISIN: INE0VTV01012. The Rights Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of the final listing/trading approvals from the Stock Exchange. Upon receipt of such listing and trading approvals, the Rights Equity Shares shall be debited from such temporary ISIN and credited to the new ISIN for

the Rights Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL.

The listing and trading of the Rights Equity Shares issued pursuant to this Issue shall be based on the current regulatory framework then applicable. Accordingly, any change in the regulatory regime would affect the listing and trading schedule.

In case our Company fails to obtain listing or trading permission from the Stock Exchange, our Company shall refund through verifiable means/unblock the respective ASBA Accounts, the entire monies received/blocked within four days of receipt of intimation from the Stock Exchange, rejecting the application for listing of the Rights Equity Shares, and if any such money is not refunded/ unblocked within fifteen days after our Company becomes liable to repay it, our Company and every director of our Company who is an officer-in-default shall, on and from the expiry of the fourth day, be jointly and severally liable to repay that money with interest at rates prescribed under applicable law.

- ***Subscription to this Issue by our Promoter and members of our Promoter Group***

For details of the intent and extent of subscription by our Promoter and members of our Promoter Group, please see “Summary of this Letter of Offer – Intention and extent of participation by our Promoters and Promoter Group” on page 15.

- ***Rights of Holders of Equity Shares of our Company***

Subject to applicable laws, Equity Shareholders who have been Allotted Rights Equity Shares pursuant to the Issue shall have the following rights:

The right to receive dividend, if declared;

- a. The right to receive surplus on liquidation;
- b. The right to receive offers for rights shares and be allotted bonus shares, if announced;
- c. The right to free transferability of Rights Equity Shares;
- d. The right to attend general meetings of our Company and exercise voting powers in accordance with law, unless prohibited / restricted by law and as disclosed in this Letter of Offer; and
- e. Such other rights as may be available to a shareholder of a listed public company under the Companies Act, 2013, the Memorandum of Association and the Articles of Association.

VII. GENERAL TERMS OF THE ISSUE

- ***Market Lot***

The Equity Shares of our Company shall be tradable only in dematerialized form. The market lot for Equity Shares in dematerialised mode is 200 Equity Share.

- ***Joint Holders***

Where two or more persons are registered as the holders of any Equity Shares, they shall be deemed to hold the same as the joint holders with the benefit of survivorship subject to the provisions contained in our Articles of Association. In case of Equity Shares held by joint holders, the Application submitted in physical mode to the Designated Branch of the SCSBs would be required to be signed by all the joint holders (in the same order as appearing in the records of the Depository) to be considered as valid for allotment of Equity Shares offered in this Issue.

- ***Nomination***

Nomination facility is available in respect of the Equity Shares in accordance with the provisions of the Section 72 of the Companies Act, 2013 read with Rule 19 of the Companies (Share Capital and Debenture) Rules, 2014.

Since the Allotment is in dematerialised form, there is no need to make a separate nomination for the Equity Shares to be Allotted in this Issue. Nominations registered with the respective DPs of the Investors would prevail. Any Investor holding Equity Shares in dematerialised form and desirous of changing the existing nomination is requested to inform its Depository Participant.

- ***Arrangements for Disposal of Odd Lots***

Our Company's Equity Shares are traded in dematerialised form only, and the marketable lot for trading of Equity Shares on the SME Platform of NSE Limited is 200 Equity Shares. The Issue Size has accordingly been structured such that the total number of Rights Equity Shares to be issued is a whole multiple of 200, and Eligible Equity Shareholders shall apply for Rights Equity Shares only in multiples of the market lot.

At the Rights Entitlement ratio of 97:1,831 applied to our Company's existing 1,80,86,618 Equity Shares, the theoretical entitlement works out to 9,58,166 Equity Shares, equivalent to 4,790.83 lots of 200 Equity Shares each. As a fractional lot cannot be issued or traded, our Company has structured the Issue to comprise 4,790 complete lots, aggregating 9,58,000 Rights Equity Shares ($4,790 \times 200$), which is exactly divisible by the market lot of 200. Accordingly, at the Issue Price of ₹950 per Equity Share, the Issue Size aggregates ₹91,01,00,000 (₹9,101.00 lakhs).

As the Issue itself has been structured to issue only whole lots, and Eligible Equity Shareholders are permitted to apply only in multiples of 200 Equity Shares, no odd lots shall arise pursuant to the Issue, and accordingly no arrangements for disposal of odd lots are required.

- ***Restrictions on transfer and transmission of shares and on their consolidation/splitting***

There are no restrictions on transfer and transmission and on their consolidation/splitting of shares issued pursuant this Issue. However, the Investors should note that pursuant to the provisions of the SEBI Listing Regulations, with effect from April 1, 2019, except in case of transmission or transposition of securities, the request for transfer of securities shall not be affected unless the securities are held in the dematerialized form with a depository.

- ***Notices***

Our Company will send through e-mail and speed post, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

Further, the Letter of Offer will be sent/dispatched to the Eligible Equity Shareholders who have provided their Indian address and who have made a request in this regard.

All notices to the Eligible Equity Shareholders required to be given by our Company shall be published in one English language national daily newspaper with wide circulation and one Hindi language national daily newspaper with wide circulation, Hindi being the regional language of Delhi, where our Company's Registered Office is situated.

This Letter of Offer, Draft Letter of Offer, and the Application Form shall also be submitted with the Stock Exchange for making the same available on their websites.

- ***Offer to Non-Resident Eligible Equity Shareholders/Investors***

As per Rule 7 of the FEMA Rules, RBI has given general permission to Indian companies to issue rights equity shares to non-resident equity shareholders including additional rights equity shares. Further, as per the Master Direction on Foreign Investment in India dated January 4, 2018 issued by RBI, non-residents may, amongst other things, (i) subscribe for additional shares over and above their rights entitlements; (ii) renounce the shares offered to them either in full or part thereof in favour of a person named by them; or (iii) apply for the shares renounced in their favour. Applications received from NRIs and non-residents for allotment of Rights Equity Shares shall be, amongst other things, subject to the conditions imposed from time to time by RBI under FEMA in the matter of Application, refund of Application Money, Allotment of Rights Equity Shares and issue of Rights Entitlement Letters/ letters of Allotment/Allotment advice. If a non-resident or NRI Investor has specific approval from RBI or any other governmental authority, in connection with his shareholding in our Company, such person should enclose a copy of such approval with the Application details and send it to the Registrar. It will be the sole responsibility of the Investors to ensure that the necessary approval from the RBI or the governmental authority is valid in order to make any investment in the Issue and our Company will not be responsible for any such allotments made by relying on such approvals.

The Letter of Offer, the Rights Entitlement Letter and Application Form shall be sent only to the Indian addresses of the non-resident Eligible Equity Shareholders on a reasonable efforts basis, who have provided an Indian address to our Company and located in jurisdictions where the offer and sale of the Rights Equity Shares may be permitted under laws of such jurisdictions. Eligible Equity Shareholders can access this

Letter of Offer, Draft Letter of Offer, and the Application Form (provided that the Eligible Equity Shareholder is eligible to subscribe for the Rights Equity Shares under applicable securities laws) from the websites of the Registrar, our Company, and the Stock Exchange. Further, Application Forms will be made available at Registered and Corporate Office of our Company for the non-resident Indian Applicants. Our Board may at its absolute discretion, agree to such terms and conditions as may be stipulated by RBI while approving the Allotment. The Rights Equity Shares purchased by non-residents shall be subject to the same conditions including restrictions in regard to the repatriation as are applicable to the original Equity Shares against which Rights Equity Shares are issued on rights basis.

In case of change of status of holders, i.e., from resident to non-resident, a new demat account must be opened. Any Application from a demat account which does not reflect the accurate status of the Applicant is liable to be rejected at the sole discretion of our Company.

The non-resident Eligible Equity Shareholders can update their Indian address in the records maintained by the Registrar of the Issue and our Company by submitting their respective copies of self-attested proof of address, passport, etc. at <https://www.skylinerta.com/>

VIII. ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, PLEASE SEE “ALLOTMENT ADVICE OR REFUND/ UNBLOCKING OF ASBA ACCOUNTS” ON PAGE 86.

IX. ISSUE SCHEDULE

LAST DATE FOR CREDIT OF RIGHTS ENTITLEMENTS	Friday, September 04, 2026
ISSUE OPENING DATE	Wednesday, September 09, 2026
LAST DATE FOR ON MARKET RENUNCIATION OF RIGHTS ENTITLEMENTS#	Friday, September 11, 2026
ISSUE CLOSING DATE*	Tuesday, September 22, 2026
FINALISATION OF BASIS OF ALLOTMENT (ON OR ABOUT)	Wednesday, September 23, 2026
DATE OF ALLOTMENT (ON OR ABOUT)	Wednesday, September 23, 2026
DATE OF CREDIT OF RIGHTS EQUITY SHARES (ON OR ABOUT)	Thursday, September 24, 2026
DATE OF LISTING (ON OR ABOUT)	Friday, September 25, 2026

#Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.

** Our Board or the Rights Issue Committee will have the right to extend the Issue Period as it may determine from time to time but not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.*

Please note that if Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date, have not provided the details of their demat accounts to our Company or to the Registrar, they are required to provide their demat account details to our Company or the Registrar no later than two clear Working Days prior to the Issue Closing Date, i.e., Tuesday, September 15, 2026, to enable the credit of the Rights Entitlements by way of transfer from the demat suspense escrow account to their respective demat accounts, at least one day before the Issue Closing Date, i.e., Wednesday, September 16, 2026. If demat account details are not provided by the Eligible Equity Shareholders holding Equity Shares in physical form to the Registrar or our Company by the date mentioned above, such Shareholders will not be allotted any Rights Equity Shares, nor such Rights Equity Shares be kept in demat suspense escrow account on behalf of such shareholder in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar, is active to facilitate the aforementioned transfer. Eligible Equity Shareholders holding Equity Shares in physical form can update the details of their demat accounts on the website of the Registrar of the Issue (i.e. <https://www.skylinerta.com/>).

Such Eligible Equity Shareholders can make an Application only after the Rights Entitlements is credited to their respective demat accounts. Eligible Equity Shareholders can obtain the details of their Rights Entitlements from the website of the Registrar of the Issue (i.e. <https://www.skylinerta.com/>) by entering their DP ID and Client ID or Folio Number (in case of Eligible Equity Shareholders holding Equity Shares in physical form) and PAN. The link for the same shall also be available on the website of our Company.

X. BASIS OF ALLOTMENT

Subject to the provisions contained in this Letter of Offer, Draft Letter of Offer, the Rights Entitlement Letter, the Application Form, the Articles of Association and the approval of the Designated Stock Exchange, our Board will proceed to allot the Rights Equity Shares in the following order of priority:

- a. Full Allotment to those Eligible Equity Shareholders who have applied for their Rights Entitlements of Rights Equity Shares either in full or in part and also to the Renouncee(s) who has or have applied for Rights Equity Shares renounced in their favour, in full or in part.
- b. Eligible Equity Shareholders whose fractional entitlements are being ignored and Eligible Equity Shareholders with zero entitlement, would be given preference in allotment of one Additional Rights Equity Share each if they apply for Additional Rights Equity Shares. Allotment under this head shall be considered if there are any unsubscribed Rights Equity Shares after allotment under (a) above. If number of Rights Equity Shares required for Allotment under this head are more than the number of Rights Equity Shares available after Allotment under (a) above, the Allotment would be made on a fair and equitable basis in consultation with the Designated Stock Exchange and will not be a preferential allotment.
- c. Allotment to the Eligible Equity Shareholders who having applied for all the Rights Equity Shares offered to them as part of this Issue, have also applied for Additional Rights Equity Shares. The Allotment of such Additional Rights Equity Shares will be made as far as possible on an equitable basis having due regard to the number of Equity Shares held by them on the Record Date, provided there are any unsubscribed Rights Equity Shares after making full Allotment in (a) and (b) above. The Allotment of such Rights Equity Shares will be at the sole discretion of our Board in consultation with the Designated Stock Exchange, as a part of this Issue and will not be a preferential allotment.
- d. Allotment to Renouncees who having applied for all the Rights Equity Shares renounced in their favour, have applied for Additional Rights Equity Shares provided there is surplus available after making full Allotment under (a), (b) and (c) above. The Allotment of such Rights Equity Shares will be made on a proportionate basis having due regard to the number of Rights Entitlement held by them as on Issue Closing Date and in consultation with the Designated Stock Exchange, as a part of this Issue and will not be a preferential allotment.
- e. Allotment to Specific Investor, if any, as disclosed by our Company before opening of the Issue, or to any other person, as deem fit by our Board, provided there is surplus available after making Allotment under (a), (b), (c) and (d) above, and the decision of our Board in this regard shall be final and binding. After taking into account Allotment to be made under (a) to (e) above, if there is any unsubscribed portion, the same shall be deemed to be 'unsubscribed'.

Upon approval of the Basis of Allotment by the Designated Stock Exchange, the Registrar shall send to the Controlling Branches, a list of the Investors who have been allocated Rights Equity Shares in this Issue, along with:

1. The amount to be transferred from the ASBA Account to the separate bank account opened by our Company for this Issue, for each successful Application;
2. The date by which the funds referred to above, shall be transferred to the aforesaid bank account; and
3. The details of rejected ASBA applications, if any, to enable the SCSBs to unblock the respective ASBA Accounts.

Further, the list of Applicants eligible for refund with corresponding amount will also be shared with Banker to the Issue to refund such Applicants.

XI. ALLOTMENT ADVICE OR REFUND/ UNBLOCKING OF ASBA ACCOUNTS

Our Company will send/dispatch Allotment advice, refund intimations, if applicable, or demat credit of securities and/or letters of regret, only to the Eligible Equity Shareholders who have provided Indian address; along with crediting the Allotted Rights Equity Shares to the respective beneficiary accounts (only in dematerialised mode) or in demat suspense escrow account (in respect of Eligible Equity Shareholders holding Equity Shares in physical form on the Allotment Date) or issue instructions for unblocking the funds in the respective ASBA Accounts, if any, within one Working Day from the Issue Closing Date. In case of failure to do so, our Company and our Directors who are "officers in default" shall pay interest at such other rate as specified under applicable law from the expiry of such 15 days' period.

The Rights Entitlements will be credited in the dematerialized form using electronic credit under the depository system and the Allotment advice shall be sent, through a mail, to the Indian mail address provided to our Company or at the address recorded with the Depository.

In the case of non-resident Investors who remit their Application Money from funds held in the NRE or the FCNR Accounts, unblocking refunds and/or payment of interest or dividend and other disbursements, if any, shall be

credited to such accounts. Where an Applicant has applied for Additional Rights Equity Shares in the Issue and is allotted a lesser number of Rights Equity Shares than applied for, the excess Application Money paid/blocked shall

be refunded/unblocked. The unblocking of ASBA funds/refund of monies shall be completed within such period as prescribed under the SEBI ICDR Regulations. In the event that there is a delay in making refunds beyond such period as prescribed under applicable law, our Company shall pay the requisite interest at such rate as prescribed under applicable law.

XII. PAYMENT OF REFUND

Mode of making refunds

The payment of refund, if any, including in the event of oversubscription or failure to list or otherwise would be done through any of the following modes.

- a. Unblocking amounts blocked using ASBA facility.
- b. NACH – National Automated Clearing House is a consolidated system of electronic clearing service. Payment of refund would be done through NACH for Applicants having an account at one of the centres specified by RBI, where such facility has been made available. This would be subject to availability of complete bank account details including a Magnetic Ink Character Recognition (“MICR”) code wherever applicable from the depository. The payment of refund through NACH is mandatory for Applicants having a bank account at any of the centres where NACH facility has been made available by RBI (subject to availability of all information for crediting the refund through NACH including the MICR code as appearing on a cheque leaf, from the depositories), except where Applicant is otherwise disclosed as eligible to get refunds through NEFT or Direct Credit or RTGS.
- c. National Electronic Fund Transfer (“NEFT”) – Payment of refund shall be undertaken through NEFT wherever the Investors’ bank has been assigned the Indian Financial System Code (“IFSC Code”), which can be linked to a MICR, allotted to that particular bank branch. IFSC Code will be obtained from the website of RBI as on a date immediately prior to the date of payment of refund, duly mapped with MICR numbers. Wherever the Investors have registered their nine-digit MICR number and their bank account number with the Registrar to our Company or with the Depository Participant while opening and operating the demat account, the same will be duly mapped with the IFSC Code of that particular bank branch and the payment of refund will be made to the Investors through this method.
- d. Direct Credit – Investors having bank accounts with the Bankers to the Issue shall be eligible to receive refunds through direct credit. Charges, if any, levied by the relevant bank(s) for the same would be borne by our Company.
- e. RTGS – If the refund amount exceeds ₹2,00,000, the Investors have the option to receive refund through RTGS. Such eligible Investors who indicate their preference to receive refund through RTGS are required to provide the IFSC Code in the Application Form. In the event the same is not provided, refund shall be made through NACH or any other eligible mode. Charges, if any, levied by the Investor’s bank receiving the credit would be borne by the Investor.
- f. For all other Investors, the refund orders will be dispatched through speed post or registered post subject to applicable laws. Such refunds will be made by cheques, pay orders or demand drafts drawn in favour of the sole/first Investor and payable at par.

Credit of refunds to Investors in any other electronic manner, permissible by SEBI from time to time.

Refund payment to non-residents

The Application Money will be unblocked in the ASBA Account of the non-resident Applicants, details of which were provided in the Application Form.

XIII. ALLOTMENT ADVICE OR DEMAT CREDIT OF SECURITIES

The demat credit of securities to the respective beneficiary accounts will be credited within 2 working Days from the Issue Closing Date or such other timeline in accordance with applicable laws.

Receipt of the Rights Equity Shares in Dematerialized Form

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR UNDER THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO (A) THE SAME DEPOSITORY ACCOUNT/ CORRESPONDING PAN IN WHICH THE EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE, OR (B) THE DEPOSITORY ACCOUNT, DETAILS OF WHICH HAVE BEEN PROVIDED TO OUR COMPANY OR THE REGISTRAR AT LEAST TWO CLEAR WORKING DAYS PRIOR TO THE ISSUE CLOSING DATE BY THE ELIGIBLE EQUITY SHAREHOLDER HOLDING EQUITY SHARES IN PHYSICAL FORM AS ON THE RECORD DATE.

Investors shall be Allotted the Rights Equity Shares in dematerialized (electronic) form. Our Company has signed two agreements with the respective Depositories and the Registrar to the Issue, which enables the Investors to hold and trade in the securities issued by our Company in a dematerialized form, instead of holding the Equity Shares in the form of physical certificates:

- a. Tripartite agreement dated May 03, 2024, amongst our Company, NSDL and the Registrar to the Issue; and
- b. Tripartite agreement dated May 06, 2024, amongst our Company, CDSL and the Registrar to the Issue.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGE ONLY IN DEMATERIALIZED FORM.

The procedure for availing the facility for Allotment of Rights Equity Shares in this Issue in the dematerialised form is as under:

1. Open a beneficiary account with any depository participant (care should be taken that the beneficiary account should carry the name of the holder in the same manner as is registered in the records of our Company. In the case of joint holding, the beneficiary account should be opened carrying the names of the holders in the same order as registered in the records of our Company). In case of Investors having various folios in our Company with different joint holders, the Investors will have to open separate accounts for such holdings. Those Investors who have already opened such beneficiary account(s) need not adhere to this step.
2. It should be ensured that the depository account is in the name(s) of the Investors and the names are in the same order as in the records of our Company or the Depositories.
3. The responsibility for correctness of information filled in the Application Form vis-a-vis such information with the Investor's depository participant, would rest with the Investor. Investors should ensure that the names of the Investors and the order in which they appear in Application Form should be the same as registered with the Investor's depository participant.
4. If incomplete or incorrect beneficiary account details are given in the Application Form, the Investor will not get any Rights Equity Shares and the Application Form will be rejected.
5. The Rights Equity Shares will be allotted to Applicants only in dematerialized form and would be directly credited to the beneficiary account as given in the Application Form after verification. Allotment advice, refund order (if any) would be sent through physical dispatch, by the Registrar but the Applicant's depository participant will provide to him the confirmation of the credit of such Rights Equity Shares to the Applicant's depository account.
6. Non-transferable Allotment advice/refund intimation will be directly sent to the Investors by the Registrar, on their registered e-mail address or through physical dispatch.
7. Renouncees will also have to provide the necessary details about their beneficiary account for Allotment of Rights Equity Shares in this Issue. In case these details are incomplete or incorrect, the Application is liable to be rejected.
8. Dividend or other benefits with respect to the Equity Shares held in dematerialized form would be paid to those Equity Shareholders whose names appear in the list of beneficial owners given by the Depository Participant to our Company as on the date of the book closure.
9. Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date, and who have not provided the details of their demat accounts to our Company or to the Registrar at least two Working Days prior to the Issue Closing Date, shall not be able to apply in this Issue.

XIV. IMPERSONATION

Attention of the Investors is specifically drawn to the provisions of sub-section (1) of Section 38 of the Companies Act, 2013 which is reproduced below:

“Any person who –

1. makes or abets making of an application in a fictitious name to a company for acquiring, or subscribing for, its securities; or
2. makes or abets making of multiple applications to a company in different names or in different combinations of his name or surname for acquiring or subscribing for its securities; or
3. otherwise induces directly or indirectly a company to allot, or register any transfer of, securities to him, or to any other person in a fictitious name, shall be liable for action under Section 447.”

The liability prescribed under Section 447 of the Companies Act, 2013 for fraud involving an amount of at least ₹10 lakh or 1% of the turnover of the company, whichever is lower, includes imprisonment for a term which shall not be less than six months extending up to ten years and fine of an amount not less than the amount involved in the fraud, extending up to three times such amount (provided that where the fraud involves public interest, such term shall not be less than three years.) Further, where the fraud involves an amount less than ₹10 lakh or one per cent of the turnover of the company, whichever is lower, and does not involve public interest, any person guilty of

such fraud shall be punishable with imprisonment for a term which may extend to five years or with fine which may extend to ₹50 lakh or with both.

XV. UTILISATION OF ISSUE PROCEEDS

Our Board declares that:

All monies received out of this Issue shall be transferred to a separate bank account;

- a. Details of all monies utilized out of this Issue referred to under (A) above shall be disclosed, and continue to be disclosed till the time any part of the Issue Proceeds remains unutilised, under an appropriate separate head in the balance sheet of our Company indicating the purpose for which such monies have been utilised; and
- b. Details of all unutilized monies out of this Issue referred to under (A) above, if any, shall be disclosed under an appropriate separate head in the balance sheet of our Company indicating the form in which such unutilized monies have been invested.

XVI. UNDERTAKINGS BY OUR COMPANY

Our Company undertakes the following:

1. The complaints received in respect of this Issue shall be attended to by our Company expeditiously and satisfactorily.
2. All steps for completion of the necessary formalities for listing and commencement of trading at all Stock Exchange where the Equity Shares are to be listed will be taken by our Board within the time limit specified by SEBI.
3. The funds required for making refunds / unblocking to unsuccessful Applicants as per the mode(s) disclosed shall be made available to the Registrar by our Company.
4. Where refunds are made through electronic transfer of funds, a suitable communication shall be sent to the Investor within 2 Working Days of the Issue Closing Date, giving details of the banks where refunds shall be credited along with amount and expected date of electronic credit of refund.
5. In case of refund/unblocking of the Application Money for unsuccessful Applicants or part of the Application Money in case of proportionate Allotment, a suitable communication shall be sent to the Applicants.
6. No further issue of securities shall be made from the date of filing the Letter of offer with Stock Exchange till the securities offered through the Letter of Offer are listed or till the application monies are refunded on account of non-listing, under subscription, etc. other than as disclosed in accordance with Regulation 97 of SEBI ICDR Regulations.
7. Adequate arrangements shall be made to collect all ASBA Applications.
8. As on date, our Company does not have any convertible debt instruments.
9. Our Company shall comply with such disclosure and accounting norms specified by SEBI from time to time.

XVII. INVESTOR GRIEVANCES, COMMUNICATION AND IMPORTANT LINKS

1. Please read the Letter of Offer carefully before taking any action. The instructions contained in the Application Form, and the Rights Entitlement Letter are an integral part of the conditions of this Letter of Offer and must be carefully followed; otherwise, the Application is liable to be rejected.
2. All enquiries in connection with this Letter of Offer must be addressed (quoting the registered folio number in case of Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date or the DP ID and Client ID number, the Application Form number and the name of the first Eligible Equity Shareholder as mentioned on the Application Form and superscribed “Anondita Medicare Limited– Rights Issue” on the envelope and postmarked in India) to the Registrar of the Issue at the following address:

Registrar to the Issue

SKYLINE FINANCIAL SERVICES PRIVATE LIMITED

D-153A, Ist Floor, Okhla Industrial Area, Phase – I, New Delhi - 110020

Tel: 011-40450193-197

E-mail: ipo@skylinerta.com

Investor grievance ID: grievances@skylinerta.com

Contact person: Mr. Anuj Rana

Website: www.skylinerta.com

SEBI Registration No.: INR000003241

CIN: U74899DL1995PTC071324

3. In accordance with SEBI ICDR Master Circular, frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors will be available on the website of the Registrar of the Issue (www.skylinerta.com). Further, helpline number provided by the Registrar of the Issue for guidance on the Application process and resolution of difficulties is 011-40450193-197
4. The Investors can visit following links for the below-mentioned purposes:
 - a. Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: www.skylinerta.com;
 - b. Updation of Indian address/ e-mail address/ phone or mobile number in the records maintained by the Registrar of the Issue or our Company: www.skylinerta.com;
 - c. Updation of demat account details by Eligible Equity Shareholders holding shares in physical form: www.skylinerta.com;
 - d. Submission of self-attested PAN, client master sheet and demat account details by non- resident Eligible Equity Shareholders: www.skylinerta.com.

This Issue will remain open for a minimum 10 (Ten days). However, our Board or the Rights Issue Committee will have the right to extend the Issue Period as it may determine from time to time but not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date and Issue Closing Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES

Foreign investment in Indian securities is regulated through the Industrial Policy, 1991, of the Government of India and FEMA. While the Industrial Policy, 1991, of the Government of India prescribes the limits and the conditions subject to which foreign investment can be made in different sectors of the Indian economy, FEMA regulates the precise manner in which such investment may be made. The Union Cabinet, as provided in the Cabinet Press Release dated May 24, 2017, has given its approval for phasing out the Foreign Investment Promotion Board. Under the Industrial Policy, 1991, unless specifically restricted, foreign investment is freely permitted in all sectors of the Indian economy up to any extent and without any prior approvals, but the foreign investor is required to follow certain prescribed procedures for making such investment. Accordingly, the process for foreign direct investment ("FDI") and approval from the Government of India will now be handled by the concerned ministries or departments, in consultation with the Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry, Government of India (formerly known as the Department of Industrial Policy and Promotion) ("DPIIT"), Ministry of Finance, Department of Economic Affairs through the FDI Policy (defined below). The Government has, from time to time, made policy pronouncements on FDI through press notes and press releases. The DPIIT issued the Consolidated FDI Policy Circular of 2020 ("FDI Policy"), which, with effect from October 15, 2020, consolidated and superseded all previous press notes, press releases and clarifications on FDI issued by the DPIIT that were in force and effect as on October 15, 2020. The Government proposes to update the consolidated circular on FDI policy once every year and therefore, FDI Policy will be valid until the DPIIT issues an updated circular. Further, the sectoral cap applicable to the sector in which our Company operates is 100% which is permitted under the automatic route. The Government has from time to time made policy pronouncements on FDI through press notes and press releases which are notified by RBI as amendments to FEMA. In case of any conflict, the relevant notification under Foreign Exchange Management (Non-Debt Instruments) Rules, 2019 will prevail. The payment of inward remittance and reporting requirements are stipulated under the Foreign Exchange Management (Mode of Payment and Reporting of Non-Debt Instruments) Regulations, 2019 issued by RBI. The FDI Policy, issued by the DPIIT, consolidates the policy framework in place as on October 15, 2020, and supersedes all previous press notes, press releases and clarifications on FDI issued by the DPIIT that were in force and effect as on October 15, 2020. The transfer of shares between an Indian resident and a non-resident does not require the prior approval of RBI, provided that (i) the activities of the investee company falls under the automatic route as provided in the FDI Policy and FEMA and transfer does not attract the provisions of the SEBI Takeover Regulations; (ii) the non-resident shareholding is within the sectoral limits under the FDI Policy; and (iii) the pricing is in accordance with the guidelines prescribed by SEBI and RBI. Further, in accordance with Press Note No. 3 (2020 Series), dated April 17, 2020 issued by the DPIIT and the Foreign Exchange Management (Non-debt Instruments) Amendment Rules, 2020 which came into effect from April 22, 2020, any investment, subscription, purchase or sale of equity instruments by entities of a country which shares land border with India or where the beneficial owner of an investment into India is situated in or is a citizen of any such country ("Restricted Investors"), will require prior approval of the Government, as prescribed in the FDI Policy and the FEMA Rules. Further, in the event of transfer of ownership of any existing or future foreign direct investment in an entity in India, directly or indirectly, resulting in the beneficial ownership falling within the aforesaid restriction/ purview, such subsequent change in the beneficial ownership will also require approval of the Government. Furthermore, on April 22, 2020, the Ministry of Finance, Government of India has also made a similar amendment to the FEMA Rules. Pursuant to the Foreign Exchange Management (Non-debt Instruments) (Fourth Amendment) Rules, 2020, a multilateral bank or fund, of which India is a member, shall not be treated as an entity of a particular country nor shall any country be treated as the beneficial owner of the investments of such bank or fund in India. Please also note that pursuant to Circular no. 14 dated September 16, 2003 issued by RBI, Overseas Corporate Bodies ("OCBs") have been derecognized as an eligible class of investors and RBI has subsequently issued the Foreign Exchange Management (Withdrawal of General Permission to Overseas Corporate Bodies (OCBs)) Regulations, 2003. Any Investor being an OCB is required not to be under the adverse notice of RBI and in order to apply for the issue as an incorporated non-resident must do so in accordance with the FDI Policy and Foreign Exchange Management (Non-Debt Instrument) Rules, 2019. Further, while investing in the Issue, the Investors are deemed to have obtained the necessary approvals, as required, under applicable laws and the obligation to obtain such approvals shall be upon the Investors. Our Company shall not be under an obligation to obtain any approval under any of the applicable laws on behalf of the Investors and shall not be liable in case of failure on part of the Investors to obtain such approvals. The above information is given for the benefit of the Applicants / Investors. Our Company is not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Letter of Offer. Investors are advised to make their independent investigations and ensure that the number of Rights Equity Shares applied for do not exceed the applicable limits under laws or regulations.

RESTRICTIONS ON PURCHASES AND RESALES

Eligibility and Restrictions

General

No action has been taken or will be taken to permit an offering of the Rights Entitlements or the Rights Equity Shares to occur in any jurisdiction, or the possession, circulation, or distribution of this Letter of Offer or any other Issue Material in any jurisdiction where action for such purpose is required, except that this Letter of Offer will be filed with the Stock Exchange and with the SEBI only for record purposes.

The Rights Entitlement and the Rights Equity Shares may not be offered or sold, directly or indirectly, and this Letter of Offer and any other Issue Materials may not be distributed, in whole or in part, in or into in (i) the United States or (ii) or any jurisdiction other than India except in accordance with legal requirements applicable in such jurisdiction. Receipt of this Letter of Offer or any other Issue Materials (including by way of electronic means) will not constitute an offer, invitation to or solicitation by anyone (i) in the United States or (ii) any jurisdiction in any circumstances in which such an offer, invitation or solicitation is unlawful or not authorized or to any person to whom it is unlawful to make such an offer, invitation or solicitation. In those circumstances, this Letter of Offer and any other Issue Materials must be treated as sent for information only and should not be acted upon for subscription to Rights Equity Shares and should not be copied or re-distributed. Accordingly, persons receiving a copy of this Letter of Offer and any other Issue Materials should not distribute or send this Letter of Offer or any such documents in or into any jurisdiction where to do so, would or might contravene local securities laws or regulations, or would subject our Company or its affiliates to any filing or registration requirement (other than in India). If this Letter of Offer or any other Issue Material is received by any person in any such jurisdiction or the United States, they must not seek to subscribe to the Rights Equity Shares.

Investors are advised to consult their legal counsel prior to accepting any provisional allotment of Rights Equity Shares, applying for excess Rights Equity Shares or making any offer, sale, resale, pledge or other transfer of the Rights Entitlements or the Rights Equity Shares.

This Letter of Offer and its accompanying documents are supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

Each person who exercises the Rights Entitlements and subscribes for the Rights Equity Shares, or who purchases the Rights Entitlements or the Rights Equity Shares shall do so in accordance with the restrictions set out above and below.

No offer in the United States

The Rights Entitlements and the Rights Equity Shares have not been, and will not be, registered under the U.S. Securities Act and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Rights Entitlements (including their credit) and the Rights Equity Shares are only being offered and sold outside the United States in “offshore transactions” as defined in and in reliance on Regulation S under the U.S. Securities Act to Eligible Equity Shareholders located in jurisdictions where such offer and sale is permitted under the laws of such jurisdictions. The offering to which this Letter of Offer relates is not, and under no circumstances is to be construed as, an offering of any Rights Entitlements or Rights Equity Shares for sale in the United States or as solicitation therein of an offer to buy any of the said securities. Accordingly, you should not forward or transmit this Letter of Offer into the United States at any time.

Representations, Warranties and Agreements by Purchasers

The Rights Entitlements and the Rights Equity Shares offered outside the United States are being offered in “offshore transactions” in reliance on Regulations. In addition to the applicable representations, warranties and agreements set forth above, each purchaser outside the United States by accepting the delivery of this Letter of Offer and its accompanying documents, submitting an Application Form for the exercise of any Rights Entitlements and subscription for any Rights Equity Shares and accepting delivery of any Rights Entitlements or any Rights Equity Shares, will be deemed to have represented, warranted and agreed as follows on behalf of itself and, if it is acquiring the Rights Entitlements or the Rights Equity Shares as a fiduciary or agent for one or more investor accounts, on behalf of each owner of such account (such person being the “purchaser”, which term shall include the owners of the investor accounts on whose behalf the person acts as fiduciary or agent):

The purchaser (i) is aware that the Rights Entitlements and the Rights Equity Shares have not been and will not be registered under the U.S. Securities Act and are being distributed and offered outside the United States in reliance on Regulation S, (ii) is, and the persons, if any, for whose account it is acquiring such Rights Entitlements and/or

the Rights Equity Shares are, outside the United States and eligible to subscribe for Rights Entitlements and Rights Equity Shares in compliance with applicable securities laws, and (iii) is acquiring the Rights Entitlements and/or the Rights Equity Shares in an “offshore transaction” meeting the requirements of Regulation S.

1. No offer or sale of the Rights Entitlements or the Rights Equity Shares to the purchaser is the result of any “directed selling efforts” in the United States (as such term is defined in Regulation S under the U.S. Securities Act).
2. The purchaser is, and the persons, if any, for whose account it is acquiring the Rights Entitlements and the Rights Equity Shares are, entitled to subscribe for the Rights Equity Shares, and the sale of the Rights Equity Shares to it will not require any filing or registration by, or qualification of, our Company with any court or administrative, governmental or regulatory agency or body, under the laws of any jurisdiction which apply to the purchaser or such persons.
3. The purchaser, and each account for which it is acting, satisfies (i) all suitability standards for investors in investments in the Rights Entitlements and the Rights Equity Shares imposed by the jurisdiction of its residence, and (ii) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.
4. The purchaser has the full power and authority to make the acknowledgements, representations, warranties and agreements contained herein and to exercise the Rights Entitlements and subscribe for the Rights Equity Shares, and, if the purchaser is exercising the Rights Entitlements and acquiring the Rights Equity Shares as a fiduciary or agent for one or more investor accounts, the purchaser has the full power and authority to make the acknowledgements, representations, warranties and agreements contained herein and to exercise the Rights Entitlements and subscribe for the Rights Equity Shares on behalf of each owner of such account.
5. If any Rights Entitlements were bought by the purchaser or otherwise transferred to the purchaser by a third party (other than our Company), the purchaser was in India at the time of such purchase or transfer.
6. The purchaser is aware and understands (and each account for which it is acting has been advised and understands) that an investment in the Rights Entitlements and the Rights Equity Shares involves a considerable degree of risk and that the Rights Entitlements and the Rights Equity Shares are a speculative investment.
7. The purchaser understands (and each account for which it is acting has been advised and understands) that no action has been or will be taken to permit an offering of the Rights Entitlements or the Rights Equity Shares in any jurisdiction (other than the filing of this Letter of Offer with the Stock Exchange); and it will not offer, resell, pledge or otherwise transfer any of the Rights Entitlements except in India or the Rights Equity Shares which it may acquire, or any beneficial interests therein, in any jurisdiction or in any circumstances in which such offer or sale is not authorised or to any person to whom it is unlawful to make such offer, sale, solicitation or invitation except under circumstances that will result in compliance with any applicable laws and/or regulations.
8. The purchaser (or any account for which it is acting) is an Eligible Equity Shareholder and has received an invitation from our Company, addressed to it and inviting it to participate in this Issue.
9. None of the purchaser, any of its affiliates or any person acting on its or their behalf have taken or will take, directly or indirectly, any action designed to, or which might be expected to, cause or result in the stabilization or manipulation of the price of any security of our Company to facilitate the sale or resale of the Rights Entitlements or the Rights Equity Shares pursuant to the Issue.
10. Prior to making any investment decision to exercise the Rights Entitlements and subscribe for the Rights Equity Shares, the purchaser (i) will have consulted with its own legal, regulatory, tax, business, investment, financial and accounting advisers in each jurisdiction in connection herewith to the extent it has deemed necessary; (ii) will have carefully read and reviewed a copy of this Letter of Offer and its accompanying documents; (iii) will have possessed and carefully read and reviewed all information relating to our Company and our Group and the Rights Entitlements and the Rights Equity Shares which it believes is necessary or appropriate for the purpose of making its investment decision, including, without limitation, the Exchange Information (as defined below); (iv) will have conducted its own due diligence on our Company and this Issue, and will have made its own investment decisions based upon its own judgement, due diligence and advice from such advisers as it has deemed necessary and will not have relied upon any recommendation, promise, representation or warranty of or view expressed by or on behalf of our Company or its affiliates (including any research reports) (other than, with respect to our Company and any information contained in this Letter of Offer); and (vi) will have made its own determination that any investment decision to exercise the Rights Entitlements and subscribe for the Rights Equity Shares is suitable and appropriate, both in the nature and number of Rights Equity Shares being subscribed.
11. Without limiting the generality of the foregoing, (i) the purchaser acknowledges that the Equity Shares are listed on NSE and our Company is therefore required to publish certain business, financial and other information in accordance with the rules and practices of NSE (which includes, but is not limited to, a description of the nature of our Company’s business and our Company’s most recent balance sheet and profit and loss account, and similar statements for preceding years together with the information on its website and its press releases, announcements, investor education presentations, annual reports, collectively constitutes “Exchange Information”), and that it has had access to such information without undue difficulty and has reviewed such Exchange Information as it has deemed necessary; and (ii) none of

our Company, any of its affiliates, has made any representations or recommendations to it, express or implied, with respect to our Company, the Rights Entitlements, the Rights Equity Shares or the accuracy, completeness or adequacy of the Exchange Information.

12. The purchaser acknowledges that any information that it has received or will receive relating to or in connection with this Issue, and the Rights Entitlements or the Rights Equity Shares, including this Letter of Offer and the Exchange Information (collectively, the "Information"), has been prepared solely by our Company.
13. The purchaser will not hold our Company or its affiliates responsible for any misstatements in or omissions to the Information or in any other written or oral information provided by our Company to it.
14. The purchaser understands that its receipt of the Rights Entitlements and any subscription it may make for the Rights Equity Shares will be subject to and based upon all the terms, conditions, representations, warranties, acknowledgements, agreements and undertakings and other information contained in this Letter of Offer and the Application Form. The purchaser understands that none of our Company, the Registrar, or any other person acting on behalf of us will accept subscriptions from any person, or the agent of any person, who appears to be, or who we, the Registrar, or any other person acting on behalf of us have reason to believe is in the United States, or is ineligible to participate in this Issue under applicable securities laws.
15. The purchaser subscribed to the Rights Equity Shares for investment purposes and not with a view to the distribution or resale thereof. If in the future the purchaser decides to offer, sell, pledge or otherwise transfer any of the Rights Equity Shares, the purchaser shall only offer, sell, pledge or otherwise transfer such Rights Equity Shares outside the United States in a transaction complying with Rule 903 or Rule 904 of Regulation S and in accordance with all applicable laws of any other jurisdiction, including India.
16. The purchaser is, and the persons, if any, for whose account it is acquiring the Rights Entitlements and the Rights Equity Shares are, entitled to subscribe for the Rights Equity Shares.

If the purchaser is outside India, the sale of the Rights Equity Shares to it will not require any filing or Registration by, or qualification of, our Company with any court or administrative, governmental or regulatory agency or body, under the laws of any jurisdiction which apply to the purchaser or such persons.

17. If the purchaser is outside India, the purchaser, and each account for which it is acting, satisfies (i) all suitability standards for investors in investments in the Rights Entitlements and the Rights Equity Shares imposed by all jurisdictions applicable to it, and (ii) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of all jurisdictions of residence.
18. The purchaser is authorized to consummate the purchase of the Rights Equity Shares sold pursuant to this Issue in compliance with all applicable laws and regulations.
19. Except for the sale of Rights Equity Shares on one or more of the Stock Exchange, the purchaser agrees, upon a proposed transfer of the Rights Equity Shares, to notify any purchaser of such Equity Shares or the executing broker, as applicable, of any transfer restrictions that are applicable to the Rights Equity Shares being sold.
20. The purchaser shall hold our Company harmless from any and all costs, claims, liabilities and expenses (including legal fees and expenses) arising out of or in connection with any breach of its representations, warranties or agreements set forth above and elsewhere in this Letter of Offer. The indemnity set forth in this paragraph shall survive the resale of the Rights Equity Shares.
21. The purchaser acknowledges that our Company, their affiliates and others will rely upon the truth and accuracy of the foregoing acknowledgements, representations and agreements.

SECTION VIII: OTHER INFORMATION

MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION

The copies of the following contracts which have been entered or are to be entered into by our Company (not being contracts entered into in the ordinary course of business carried on by our Company or contracts entered into more than two years before the date of this Letter of Offer) which are or may be deemed material have been entered or are to be entered into by our Company. Copies of the abovementioned contracts and also the documents for inspection at the registered office of the Company till the issue closing date on working days and working hours between 11:00 A.M. to 5:00 P.M. and also shall be available on the website of the Company at <https://www.anonditamedicare.com/> from the date of this Letter of Offer until the Issue Closing Date.

I. Material Contracts for the Issue

- i. Registrar Agreement dated August 01, 2026 entered into amongst our Company and the Registrar to the Issue;
- ii. Monitoring Agency Agreement dated August 27, 2026, between our Company and the Monitoring Agency. Bank.
- iii. Banker(s) to the Issue Agreement dated August 27, 2026, between our Company, Registrar and the Bankers to the Issue.

II. Material Documents

1. Certified copies of the updated Memorandum of Association and Articles of Association of our Company as amended from time to time.
2. Resolution of the Board of Directors dated August 01, 2026, in relation to the approval of this Issue.
3. Resolution of the Board of Directors dated August 27, 2026 in relation to approving the quantum of issue, issue price and ratio of rights entitlement.
4. Resolution passed by our Board of directors dated August 27, 2026 finalizing the Offering Information including Record Date and the Rights Entitlement ratio
5. Resolution of the Board of directors dated August 01, 2026, approving and adopting the Letter of Offer.
6. Consent of our Directors, Company Secretary and Compliance Officer, Chief Financial Officer, Statutory and Peer Review Auditor, the Registrar to the Issue, Banker to the Issue/ Refund Bank for inclusion of their names in the Letter of Offer in their respective capacities.
7. Audit Reports dated May 22, 2026, for the year ended March 2026 of the Statutory Auditor, on our Company's Audited Financial Statements, included in this Letter of Offer.
8. Statement of Tax Benefits dated August 01, 2026, from the Statutory Auditor included in this Letter of Offer
9. Tripartite Agreement dated May 03, 2024 between our Company, NSDL and the Registrar to the Company.
10. Tripartite Agreement dated May 06, 2024, between our Company, CDSL and the Registrar to the Company.
11. In principle approval letter no. NSE/LIST/C/2026/0866 dated August 25, 2026 issued by NSE.

Any of the contracts or documents mentioned in this Letter of Offer may be amended or modified at any time if so, required in the interest of our Company or if required by the other parties, without reference to the shareholders subject to compliance of the provisions contained in the Companies Act and other relevant statutes.

DECLARATION

I hereby certify that no statement made in this Letter of Offer contravenes any of the provisions of the Companies Act, the SEBI Act, or the rules made thereunder or regulations issued thereunder, as the case may be. I further certify that all the legal requirements connected with the Issue as also the regulations, guidelines, instructions, etc., issued by SEBI, Government of India and any other competent authority in this behalf, have been duly complied with.

I further certify that all disclosures made in this Letter of Offer are true and correct.

SIGNED BY THE MANAGING DIRECTOR OF OUR COMPANY

(ANUPAM GOSH)
Managing Director
DIN: 02675517

Date: August 27, 2026
Place: Noida

DECLARATION

I hereby certify that no statement made in this Letter of Offer contravenes any of the provisions of the Companies Act, the SEBI Act, or the rules made thereunder or regulations issued thereunder, as the case may be. I further certify that all the legal requirements connected with the Issue as also the regulations, guidelines, instructions, etc., issued by SEBI, Government of India and any other competent authority in this behalf, have been duly complied with.

I further certify that all disclosures made in this Letter of Offer are true and correct.

SIGNED BY THE WHOLE TIME DIRECTOR OF OUR COMPANY

(RESHANT GHOSH)
Whole-time director
DIN: 08632812

Date: August 27, 2026
Place: Noida

DECLARATION

I hereby certify that no statement made in this Letter of Offer contravenes any of the provisions of the Companies Act, the SEBI Act, or the rules made thereunder or regulations issued thereunder, as the case may be. I further certify that all the legal requirements connected with the Issue as also the regulations, guidelines, instructions, etc., issued by SEBI, Government of India and any other competent authority in this behalf, have been duly complied with.

I further certify that all disclosures made in this Letter of Offer are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY

(LAKHINDER SINGH)
Non-Executive Director
DIN: 07703780

Date: August 27, 2026
Place: Noida

DECLARATION

I hereby certify that no statement made in this Letter of Offer contravenes any of the provisions of the Companies Act, the SEBI Act, or the rules made thereunder or regulations issued thereunder, as the case may be. I further certify that all the legal requirements connected with the Issue as also the regulations, guidelines, instructions, etc., issued by SEBI, Government of India and any other competent authority in this behalf, have been duly complied with.

I further certify that all disclosures made in this Letter of Offer are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY

(GAURAV KUMAR)
Independent Director
DIN: 08062315

Date: August 27, 2026
Place: Noida

DECLARATION

I hereby certify that no statement made in this Letter of Offer contravenes any of the provisions of the Companies Act, the SEBI Act, or the rules made thereunder or regulations issued thereunder, as the case may be. I further certify that all the legal requirements connected with the Issue as also the regulations, guidelines, instructions, etc., issued by SEBI, Government of India and any other competent authority in this behalf, have been duly complied with.

I further certify that all disclosures made in this Letter of Offer are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY

(NISHI GOEL)
Independent Director
DIN: 08164136

Date: August 27, 2026
Place: Noida